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Abstract 
 
In the present study, the function and the mechanism of action of RGS4, a member of a 
family of proteins called Regulators of G protein Signalling (RGS) was investigated.   
A C-terminal fluorescent tag on RGS4 confirmed that transiently transfected RGS4 was 
predominantly cytosolic and underwent translocation to the plasma membrane of 
HEK293T cells following co-expression of Gαi1, the α2A-adrenoceptor, or agonist activated 
α2A-adrenoceptor.  This translocation of RGS4 to the plasma membrane was most 
pronounced with the co-expression of the constitutively active GTPase deficient Gαi1
Q204L.   
 
High-affinity GTPase experiments indicated that RGS4
S30C had enhanced GAP activity 
towards Gαo1 compared to wild type RGS4.  This approach also demonstrated a 
simultaneous significant decrease in potency of both adrenaline and UK14304 to increase 
α2A-arenoceptor-activated high-affinity GTPase activity of Gαo1 in the presence of RGS4 
and a further significant decrease in potency of both ligands in the presence of RGS4
S30C.  
This enhanced GAP activity and observed decrease in agonist potency was also 
transferable to RGS16, an RGS protein closely related to RGS4.  The selectivity of the Gα 
subunit was also investigated.  The enhanced GAP activity and simultaneous significant 
decrease in potency of adrenaline and UK14304 to increase α2A-arenoceptor-activated 
high-affinity GTPase activity of RGS4
S30C and RGS16
S30C was selective for Gαo1 over 
Gαi1.  RGS4
S30K and RGS4
S30F also demonstrated higher GAP activity than wild type 
RGS4 but no consensus side chain could be identified that conferred a specific 
enhancement or loss of GAP activity. 
 
The ability to inhibit intracellular calcium release by an activated α1b-adrenoceptor-Gα11 
fusion protein was used in order to investigate the GAP activity of RGS4
N88S, RGS4
N128A 
and RGS4
N88S,N128A.  All three mutants had ablated GAP activity towards Gα11 and 
therefore failed to inhibit intracellular calcium release. 
 
A novel role for the RGS insensitive mutation G188S was also observed when despite 
similar expression, Gα11
G188S significantly reduced agonist-stimulated [
35S]GTPγS binding 
compared to wild type Gα11.  
 
RGS4 represents a novel target for pharmaceutical drug development and the study of its 
regulation of signal transduction is an important area of investigation.  These results 
highlight specific areas of RGS4 research with great pharmaceutical potential.     3 
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Definitions 
AC    adenylyl cyclase  
AH     amphipathic helix 
βCat    β-catenin interacting domain 
BCA    bicinhoninic acid  
[Ca
2+]i   intracellular calcium concentration 
CaM    calmodulin  
CHO    chinese hamster ovary  
CYS    polycysteine region  
DAG    diacylgylercol 
D-AKAP2  dual A kinase anchoring protein 2 
DEP    disheveled EGL-10 pleckstrin  
DH    dbl homology domain 
DIX    dishevelled-interacting domain 
eYFP    enhanced yellow fluorescent protein  
ERK2    extracellular signal-regulated kinase 2 
FOA    5-fluoro-orotic acid   
G protein  guanine nucleotide binding protein   
GAP    GTPase-activating protein 
GAIP    Gα-interacting protein   
GDI    guanine nucleotide dissociation inhibitor  
GDP    guanine 5-diphosphate    
GFP    green fluorescent protein  
GGL    G-protein γ subunit-like  
GIPC    GAIP-interacting protein C terminus   
GIRK    G protein-gated inwardly rectifying potassium  
GOF    gain-of-function  
GRK    G protein receptor kinase 
GoLoco  Gαi/o-loco-interacting domain 
GPCR   G protein coupled receptor 
GSK3β  glycogen synthase kinase 3β 
GST    glutathione S-transferase  
GTP    guanine 5-triphosphate  
HEK    human embyonic kidney  
IP3    inositol 1,4,5-trisphosphate      14 
LB    Luria-Bertani medium 
PCR     polymerase chain reaction 
PDEγ    phosphodiesterase γ  
PDZ    PSD-95 Disk-Large ZO-1 
PH    pleckstrin homology domain 
PIP3    phosphatidylinositol 3,4,5-trisphosphate   
PIP2    phosphatidylinositol 4,5-bisphosphate  
PKA    protein kinase A  
PKC    protein kinase C  
PLCβ    phospholipase C β  
PMCA   plasma membrane Ca
2+-ATPase 
PP2A    phosphatase 2A 
P. tox    pertussis toxin  
PBS    phosphate-buffered saline 
PTB    phospho-tyrosine binding domain 
PX    phosphatidylinositol binding domain 
PXA     phosphatidylinositol-associated domain 
RBD    rap1/2 - or ras binding domain 
RGS    regulator of G protein signalling  
SDS    sodium dodecyl sulphate 
SEM    standard error of the mean 
SERCA   sarco/endoplasmic reticulum ATPase 
SNPs    single nucleotide polymorphisms  
SRC    Src family kinases 
TM    transmembrane domain 
TNF-α   tumour necrosis factor-α 
TRH    thyrotropin-releasing hormone  
TRHR-1  thyrotropin-releasing hormone receptor 1 
Ura4    orotidine 5’-monophosphate decarboxylase 
WGA    wheat germ agglutinin   
1  Chapter 1  
1.1  GPCRs 
Cellular activity is regulated by a variety of receptors.  The largest of these receptor 
families is the G protein coupled receptors (GPCRs).  These are seven transmembrane 
domain receptors that serve to transduce signals from the extracellular to the intracellular 
environment.  GPCRs account for more than 30% of drug targets under investigation by 
the pharmaceutical industry (Klabunde and Hessler, 2002;Fredriksson et al., 2003).  
Ligands for these receptors are highly specific and include hormones, neurotransmitters, 
chemokines, calcium, odorants, taste and light (Pierce et al., 2002).  Over 800 GPCRs have 
been revealed to be encoded by the human genome and are found throughout the body.  As 
such, these receptors serve key regulatory functions for a large number of biological 
processes. 
1.2  G proteins  
GPCRs are associated with guanine nucleotide binding proteins (G proteins).  G proteins 
are heterotrimeric and consist of α, β and γ subunits. To date, there are over 20 different 
Gα proteins encoded by over 16 different genes that are divided into four families;  Gαs 
(Gαs and Gαolf), Gαi, (Gαi1, G αi2, Gαi3, Gαo, Gαz, Gαt-cone, Gαt-rod and Gαgust) Gαq, (Gαq, 
Gα11, Gα14, and Gα16) and Gα12 (Gα12 and Gα13) based on the sequence similarity of the α 
subunit (Cabrera-Vera et al., 2003). 5 different Gβ and 12 different Gγ subunits have also 
been discovered (Neer, 1995;Milligan and Kostenis, 2006).  It is generally accepted that 
ligand binding to the receptor produces G protein activation.  The resulting conformational 
change of the three ‘switch’ regions of the Gα subunit promote the exchange of guanine 
diphosphate (GDP) for guanine triphosphate (GTP) and the dissociation of the Gα subunit 
from the βγ subunits.   Alternatively, Bunemann et al., suggested that the Gα subunit and 
the Gβγ dimer do not physically dissociate during activation of the receptor (Bunemann et 
al., 2003).  Instead, a molecular rearrangement may take place after the GDP to GTP 
exchange, allowing the Gβγ to stay complexed to the Gα subunit.  Whichever 
physiological process takes place, both the Gα subunit and the Gβγ dimer are then active 
and can stimulate or inhibit effector proteins such as adenylyl cylcase, phospholipases and 
a variety of ion channels (Gudermann et al., 1997;McCudden et al., 2005).  Intrinsic 
GTPase activity of the Gα subunit hydrolyses the bound GTP to GDP, resulting in the     16 
reassociation of the G protein heterotrimer and prevention of further signalling (Figure 
1.1). 
The Gαi/o subfamily of G proteins are sensitive to treatment with pertussis toxin (P. tox).  
P.tox is one of the major virulence determinants produced by Bordetella pertussis, 
catalysing the transfer of an ADP-ribose group from NAD onto a cysteine residue four 
amino acids from the C-terminal of the Gαi/o subunit (cysteine
351) (Lochrie et al., 1985).  
The addition of a bulky side group to the Gαi/o subunit makes the Gα subunit unable to 
contact GPCRs, and renders it inactive. 
Mutating cysteine
351 of the P. tox sensitive Gα subunits can confer resistance to P. tox 
treatment.  A hydrophobic residue at position 351 of the Gα subunit is crucial to give 
optimal interactions between GPCRs and G proteins (Bahia et al., 1998).  Mutation to 
other residues, including isoleucine, offers P. tox resistance, and following expression of 
the α2A-adrenoceptor-Gαi1
C351I fusion protein, cells treated with P. tox have inactive 
endogenous Gαi/o proteins and agonist activation reflects only the G protein of interest in 
the experimental system. 
1.3  GPCR desensitisation and internalisation 
Following ligand binding to the GPCR, and G protein activation, GPCRs become 
desensitised and lose cellular activity (Ferguson, 2001).  Short-term desensitisation is 
mediated, in part, by the phosphorylation of residues within the C-terminal tail of GPCRs, 
or within the third extracellular loop of GPCRs with small C-termial tails without potential 
phosphorylation sites, by G protein receptor kinases (GRKs).  Long-term loss of cellular 
sensitivity can involve the down regulation of receptors by protein degradation and 
decreased receptor synthesis.  The C-terminal tail of many GPCRs contain several serine 
and theronine residues that can determine the intracellular trafficking and fate by providing 
phosphorylation sites for several protein kinases (Smith and Scott, 2002). 
There are currently seven GRK family members, and although no consensus site for GRK 
activity has been determined, the presence of acidic amino acids proximal to the 
phosphorylation site favours GRK2 mediated phosphorylation (Chen et al., 1993).  It is 
also known that GRKs preferentially phosphorylate receptors that are in the agonist-
occupied conformation (Luttrell and Lefkowitz, 2002).     17 
Phosphorylation of receptors by GRKs increase the affinity of the receptor for arrestins.  
Arrestin binding sterically hinders G protein coupling with the receptor, serving to 
uncouple the receptor from the G protein and target the receptor for endocytosis (Benovic 
et al., 1987).   
Receptor endocytosis is followed by the targeting of the receptor to either recycling 
pathways, for proteasomal degredation or to lysosomes for degradation (Kristiansen, 
2004).  Receptor resensitisation involves receptor dephosphorylation and dissociation from 
its ligand. The time frame over which these events occur for GPCR phosphorylation is 
minutes for receptor internalisation and hours for receptor down regulation. 
1.4  RGS proteins 
The intrinsic GTPase activity of the Gα subunit does not correlate to the physiological rate 
of G protein inactivation.  Discovery of the product of the yeast gene Ssst2 that could 
negatively regulate heterotrimeric G protein signalling indicated that extrinsic factors 
might also regulate the G protein cycle (Dietzel and Kurjan, 1987;Dohlman et al., 1996).  
This regulation of G proteins is not confined to Saccharomyces cerevisiae.  Similar genes 
were identified in the fungal organism Aspergillus nidulans (flbA) (Lee and Adams, 1994), 
and the nematode Caenorhabditis elegans (egl-10) (Koelle and Horvitz, 1996).  These 
regulatory proteins were recognised to share a novel conserved domain and mammalian 
genes have now also been isolated and termed regulators of G protein signalling (RGS) 
proteins.  To date, more than 37 mammalian RGS genes have been named, all containing 
the novel RGS domain (Siderovski and Willard, 2005).  
RGS proteins, termed GAPs due to their ability to enhance the intrinsic GTPase activity, 
regulate GPCR-mediated signalling through their interaction with Gα subunits.  
Biochemical and crystallography experiments revealed that RGS proteins preferentially 
bind to the transition state of the Gα protein that occurs immediately before the hydrolysis 
of GTP. The crystal structure of RGS4 complexed with Gαi1-GDP-AlF4
- (a stable mimic of 
Gα-GTP) revealed that the RGS domain forms a nine-alpha-helix bundle that contacts Gαi1 
at three distinct sites (Tesmer et al., 1997;Ross and Wilkie, 2000).  Two surface residues of 
Gαi1 (threonine
182 and glycine
183) appear essential for high-affinity Gα-RGS interaction, 
although other residues are also important (DiBello et al., 1998;Posner et al., 1999).       18 
RGS activity may therefore be used to recycle Gα to increase the concentration of inactive 
Gα that can be reactivated by GPCRs (Zhong et al., 2003).  Thus, RGS proteins increase 
the rate of GTP hydrolysis and consequently inhibit signalling. The discovery of RGS 
proteins shows the importance of model organisms in revealing complex signalling 
mechanisms which can be transferred to more complex mammalian systems. 
1.5  Structure and classification of RGS proteins 
Proteins containing the RGS domain or RGS-like domain have been classified into eight 
sub-families. A or RZ;  B or R4;  C or R7;  D or R12;  E or RA;  F or GEF;  G or GRK 
and H or SNX.  Additionally, D-AKAP2 (dual A kinase anchoring protein 2) and RGS22, 
which contain multiple RGS domains, have not been classified.  Most members of the 
A/RZ or B/R4 subfamily are small, 20-30 kDa proteins that contain short N- and C-
terminal regions flanking the RGS domain.  Members of the C/R7, D/R12, E/RA, F/GEF, 
G/GRK and H/SNX subfamilies (except RGS10) are much longer proteins, commonly up 
to 160 kDa, and contain multiple domains (Figure 1.2). 
RGS21 of the B/R4 sub-family is the smallest known RGS protein consisting of little more 
than an RGS domain (von Buchholtz et al., 2004).  In contrast, RET-RGS1 contains an N-
terminal cysteine rich region and a putative transmembrane region.  This region is likely to 
be involved in membrane targeting and attachment, protein-protein interaction and possible 
integration into the plasma membrane (Faurobert and Hurley, 1997;Jones, 2004).  RGS9-2, 
the longer splice variant of RGS9, has a long C-terminal which functions as an ‘affinity 
adapter’ increasing the affinity of the RGS proteins to Gαo (Martemyanov et al., 2003).  
The shorter splice variant (RGS9-1), does not contain this long C-terminal but instead the 
effector enzyme phosphodiesterase γ (PDEγ) increases the affinity between the RGS 
protein and its retinal-specific G protein target Gαt.   Only the RGS domain seems 
necessary and sufficient to confer GAP activity of RGS proteins but other domains can 
affect RGS proteins by altering the GAP activity, increasing receptor specificity, 
determining the cellular localisation, acting as effector antagonists or influence signal 
transduction mediated by GPCR activation.   
1.5.1  PDZ Domain 
Of the other domains in RGS proteins, the most frequently found is the PSD-95 disk-large 
ZO-1 (PDZ) domain.  This 90 amino acid domain facilitates protein-protein interactions     19 
through its highly conserved glycine-leucine-glycine-phenylalanine repeated motif.  Found 
in clusters of multiprotein signalling complexes, the PDZ domain of RGS12 has been 
found to selectively bind the chemokine receptor CXCR2 (Snow et al., 1998b).   
1.5.2  GGL Domain 
The G-protein γ subunit-like (GGL) domain is found in a number of RGS proteins, 
including RGS6, RGS7, RGS9 and RGS11.  It is a 64 amino acid domain with a high 
degree of similarity to the Gγ subunit.  Resembling a Gγ subunit allows this domain to 
form dimers with a number of other G protein subunits.   An RGS9-Gβ5 dimer is thought 
to be involved in the stabilising of the protein complex and subsequently the GAP activity 
of the RGS protein (Snow et al., 1998a). 
1.5.3  GoLoco Domain 
Comparable to RGS domain, the Gαi/o-loco-interacting (GoLoco) domain inhibits G 
protein signalling.  By binding directly to Gα subunits, the 19 amino acid domain stabilises 
the Gα-GDP form of the G protein and prevents GTP from binding.  Acting as a guanine 
nucleotide dissociation inhibitor (GDI), G protein signalling is decreased.  RGS14 contains 
this GoLoco domain, and signalling inhibition of Gαi was attained when this domain was 
present.  However, both the RGS domain and the GoLoco domain are necessary for 
maximum inhibition (Mittal and Linder, 2004). 
1.5.4  DEP Domain 
The importance of the disheveled EGL-10 pleckstrin (DEP) domain was exemplified in the 
discovery that this 70 amino acid domain in RGS7 can bind synaptin.  Synaptin in turn, 
interacts with synaptosomal-associated protein of 25 kDa, a component of 
the soluble N-ethylmaleimide–sensitive factor attachment protein receptor complex, 
suggesting a role for RGS7 in synaptic vesicle exocytosis (Riddle et al., 2005). Synaptin 
has also been discovered to bind to adenylyl cyclase (AC) and perhaps these complexes 
can come together allowing RGS7 to regulate cAMP levels (Chou et al., 2004).     20 
1.6  Regulation of RGS proteins 
The large number of RGS proteins and their multiple domains means that the activity of 
these proteins must be tightly regulated to maintain specificity within the cell.  The 
mechanisms for this regulation are complex and developments in this area of research are 
still ongoing.  Little is known about the functional consequences of this regulation but it is 
important that the direct protein-protein interactions within signalling components are 
elucidated for their potential as therapeutic targets. 
1.6.1  Expression of RGS proteins 
The transcripts of several RGS proteins have been shown to be dynamically regulated by 
various signals to offer feedback regulation to GPCR signalling (Ingi et al., 
1998;Kardestuncer et al., 1998;Pepperl et al., 1998).  Dopamine D1 receptor agonists 
increase RGS2 mRNA, whereas dopamine D2 receptor agonists result in a decrease in 
RGS2 mRNA but increase RGS4 mRNA (Taymans et al., 2003).  This suggests that RGS2 
and RGS4 must couple preferentially to D1 and D2 receptors respectively to exert distinct 
functions.  
The activation of the µ- or κ-opioid receptors expressed in PC12 cells can also increase the 
level of RGS4 mRNA.  This regulation of the opioid-signalling pathway could contribute 
to the desensitisation of opioid signalling and is perhaps a valuable area for future study in 
the combat of morphine and cocaine addiction (Nakagawa et al., 2001).  
Differences in expression patterns of RGS proteins in tissues add another layer of 
complexity to regulation of RGS proteins.  Some RGS proteins have ubiquitous 
expression, for example, RGS5 has been detected in heart, skeletal muscle, pericyte and a 
variety of sub-regions within the brain (Wieland and Mittmann, 2003;Li et al., 2004;Jean-
Baptiste et al., 2005a;Jean-Baptiste et al., 2005b). RGS8 however, seems only to be 
expressed in the brain (Moratz et al., 2004;Kurrasch et al., 2004).   
As mentioned previously, RGS9 has two splice variants.  RGS9-1 is expressed 
predominantly in the retina where it regulates rhodopsin signalling (Nagata et al., 2001).  
RGS9-2 is appropriately located in the brain to play its role in opioid signalling. Restricted 
tissue distribution and alternative splicing is therefore also a major factor in conferring     21 
specificity of RGS action and together with the regulation of RGS expression levels may 
have a major physiological relevance for future pharmaceutical development. 
1.6.2  RGS localisation 
Differences in expression patterns of RGS proteins may also take place at the subcellular 
level.  Some RGS proteins are compartmentalised with other signalling components to 
further regulate signalling.  Limited subcellular distribution of RGS proteins has been 
shown in a number of instances.  Surprisingly the nucleus of cells, although distant from 
other signalling components, has been reported to be a storage area for some RGS proteins. 
In fact, cytosolic localisation of RGS proteins may actually result from the competition 
between nuclear import and export signals located in the N-terminal of a number of RGS 
proteins (Chatterjee and Fisher, 2000;Heximer et al., 2001).  After PKA phosphorylation at 
its C-terminus, RGS10 translocates to the nucleus, making it unable to facilitate or impede 
signalling (Burgon et al., 2001).  RGS12TS-S is expressed in punctate nuclear foci.  The 
underlying mechanism for this seems unclear, but many tumour suppressor proteins also 
have this expression pattern and for that reason it has been suggested that RGS12 may 
have an important role in cell cycle events (Chatterjee and Fisher, 2000).  The translocation 
of RGS proteins from one cellular compartment to another has been suggested to very 
rapidly.  For RGS protein to have their desired effect, this process must be rapid, to allow 
the RGS protein to be translocated at the plasma membrane immediately after receptor 
activation.  Indeed, translocation of RGS4 from the cytoplasm to the plasma membrane is 
so fast that, to date, no researcher has been able to measure the speed of translocation.  No 
real time footage of translocation has ever been published, although it is widely accepted 
that such footage would be a break through in RGS research.   However, translocation 
from the nucleus to the cytoplasm has been reported to be slower.  RGS14, for example 
translocates from the nucleus to the cytoplasm in less than 30 minutes (Hepler et al., 2005).  
1.6.2.1  Interaction with Gα 
In some cases RGS proteins are preferentially located at the plasma membrane in an ideal 
location to allow interaction with Gα subunits and carry out their function as inhibitors of 
G protein signalling.  In particular, upon G protein activation RGS3 is translocated from 
the cytosol to the plasma membrane (Cheever et al., 2001).  RGS2 and RGS4 also follow 
this translocation pattern; however, the activation of G proteins seems irrelevant.  The G 
protein subtype seems particularly important in the cellular movement of RGS2 and RGS4     22 
(Roy et al., 2003).  In HEK293 cells transfected with RGS2, RGS2 translocated to the 
plasma membrane when cells were cotransfected with Gαq or Gαs but not Gαi1.  In contrast, 
RGS4 translocated to the plasma membrane when cotransfected with Gαi1 but not Gαq or 
Gαs (Roy et al., 2003). 
The large number of different RGS proteins quickly ruled out the possibility of one RGS 
protein interacting with only one Gα subtype.  Diverse RGS proteins such as RGS1, RGS4, 
RGS10 and RGS19 all act on both the Gαq and Gαi class of G proteins. However, some 
RGS proteins are only capable of acting as GAPs on very specific Gα subunits.  For 
example, RGSZ2 displays specificity for Gαz subunits (Mao et al., 2004) and RGS2 
appears to preferentially act on Gαq subunits.    
As mentioned previously, the threonine at position 182 in Gαi is particularly important for 
high-affinity Gα-RGS binding.  In fact, this residue is highly conserved among Gαi and 
Gαq but not Gαs.  This may explain the specificity of some RGS proteins.  
Some RGS proteins can discriminate between the two highly related Gαq family subunits, 
Gαq and Gα11.  Using a yeast based assay, Ladds et al., was the first to demonstrate RGS-
Gαq selectivity (Ladds et al., 2007). Despite similar Gα expression levels, RGS16 and 
RGS5 are unable to reduce signalling from Gα11 but are able to reduce signalling from Gαq.  
Gαq and Gα11 share 98% homology and future studies should identify the regions 
responsible for this selective inhibition. 
1.6.2.2  Interaction with GPCRs 
The selective binding and consequent recruitment of RGS proteins to the plasma 
membrane often seems to include the involvement of GPCRs.  Evidence suggests that 
interactions between GPCRs and all subfamilies of RGS proteins exist.  One noteworthy 
study used confocal microscopy to show that RGS2 was translocated to the plasma 
membrane of HEK293 cells in response to transient expression of the angiotensin II AT1 
receptor or the β2-adrenergic receptor.  Similarly, RGS4 was recruited to the plasma 
membrane when the M2 muscarinic receptor was also expressed (Roy et al., 2003).  
Subsequently, investigations have studied the direct binding of RGS proteins to receptors.  
Snow et al., demonstrated that the PDZ binding motif at the C-terminal of RGS12 interacts 
with CXCR2 (Snow et al., 1998b).  A model was proposed in which the RGS12 GAP     23 
activity was auto-inhibited.  However, the recruitment of the PDZ domain of RGS12 to the 
receptor stops this inhibition and allows the GAP activity of Gαi/o. As mentioned 
previously, a number of other RGS proteins contain this PDZ domain, and it is likely that 
this will show binding selectivity to other relevant receptors.  
Co-immunoprecipitation studies have also detailed some of the selectivity that exists 
between GPCRs and RGS proteins.  The N-terminus of RGS2 binds to the third 
intracellular loop of the M3 muscarinic receptors.  This binding was also seen for another 
member of the B/R4 family of RGS proteins, RGS16, but not for another member of this 
family, RGS1 (Bernstein et al., 2004).   
Receptor specific inhibition of signalling has also been shown for many RGS proteins.  
Studies in oocyte expression systems have suggested that the N-terminal of RGS8 is 
responsible for its ability to inhibit signalling by either the M1 muscarinic receptor or the 
substance P receptor but not the M3 muscarinic receptor (Saitoh et al., 2002).  In chinese 
hamster ovary (CHO) cells expressing RGS4, RGS10 or RGSZ1, there was effective 
inhibition in response to activation of the 5-HT1A receptor but less effective inhibition 
against the dopmaine D2 receptor despite both receptors coupling via Gαi (Ghavami et al., 
2004).   This phenomenon was also seen by Xu et al., when RGS1 was a 1000-fold more 
potent inhibitor of Gαq/11 intracellular calcium ([Ca
2+]i) mobilisation from the muscarinic 
receptors than the cholecystokinin receptors (Xu et al., 1999).  Indeed, this study also 
showed receptor selectivity of RGS4.  In permeabilized rat pancreatic acinar cells, 
cholinergic receptors
 showed 3- and 10-fold higher apparent affinity to RGS4 than 
bombesin
 and cholecystokinin receptors (Xu et al., 1999).  Localisation of RGS proteins in 
precise cellular compartments can increase the specificity of an RGS protein for G proteins 
or GPCRs.  The precise mechanisms for this specificity vary but tend to involve regions 
outwith the RGS domain and may often involve other auxiliary proteins. 
1.6.2.3  Oligomeric GPCRs 
It is now generally accepted that GPCRs form dimers or higher order oligomers (Hebert 
and Bouvier, 1998;Park et al., 2004).  Several studies have demonstrated GPCR 
oligomerisation using biochemical and biophysical techniques (Lavoie et al., 2002;Lee et 
al., 2003;Javitch, 2004;Milligan et al., 2004a;Milligan et al., 2004b). Atomic force 
microscopy of native mouse membranes has also observed rhodopsin receptors in an 
oligomeric array of closely packed dimers (Liang et al., 2003;Fotiadis et al., 2003).  This     24 
was the first conclusive evidence that receptor dimers exist in native membranes.  Four 
rhodopsin receptors seem to be complexed with two transducin proteins (Park et al., 2004).  
However, the physiological relevance of oligomeric GPCRs and multiple Gα subunits on 
RGS regulation is still unclear.   
RGS14 contains an RGS domain and a GoLoco domain, both of which inhibit G protein 
signalling by binding directly to Gα subunits, perhaps suggesting simultaneous regulation 
of multiple Gα subunits, and an involvement with oligomeric GPCRs.  Hepler et al., 
researched the activity of RGS4 when a truncated form of RGS14 containing the GoLoco 
domain but lacking the RGS domain was present (Hepler et al., 2005).  This mutant 
increased the GAP activity of RGS4 and it has been suggested that the binding of the 
truncated RGS14 to one G protein may increase the affinity of RGS4 to bind to another G 
protein within the signalling complex (Abramow-Newerly et al., 2006).  It could be 
implied that the recruitment of RGS proteins to the plasma membrane would be 
multiplicative unless the binding sites on RGS proteins for all interacting proteins were the 
same.   The main difficulty in this area is testing these hypotheses experimentally but 
suggests new functional implications for the regulation of RGS proteins. 
1.6.2.4  Interaction with effectors 
The interactions of RGS proteins with effectors can clearly influence regulation of signal 
transduction.  The RGS protein can act as an effector antagonist, preventing the interaction 
of Gα and the effector, to reduce signalling.  In contrast, signalling can also be increased 
by the RGS-effector interaction by creating a more stable complex to allow faster 
signalling. 
The effect of Gαs on AC is to increase the level of cyclic AMP. The observation that RGS2 
can physically interact with Gαs (Ko et al., 2001;Roy et al., 2006) but inhibit the rate of 
activation by AC in the absence of Gαs (Sinnarajah et al., 2001) suggested that RGS 
proteins may directly bind to AC.  Evidence now shows that RGS2 binds to the 
cytoplasmic domain of type V AC in cell extracts (Salim et al., 2003) and it has now also 
been demonstrated that RGS2 can translocate to the plasma membrane by expression of 
various AC isoforms (Roy et al., 2006).  The N-terminal domian of RGS2 seems 
particularly important for this interaction but the specific mechanism for this is still 
unclear.  AC type V is abundant in the heart and will undoubtedly prove to be an important 
area for further research (Salim et al., 2003).     25 
The rapid inhibition of [Ca
2+]i release by RGS proteins is mediated through the interaction 
of RGS proteins with the Gαq subfamily of G proteins. Gαq proteins, when triggered by a 
receptor, activate the plasma membrane bound enzyme phospholipase C β (PLCβ). This 
enzyme reacts on phosphitidylinositol 4,5-bisphosphate (PIP2) in the membrane to release 
inositol 1,4,5-trisphosphate (IP3).  The IP3 generated binds to specific receptors on the 
endoplasmic reticulum, which induce opening of calcium release channels. This quickly 
raises the concentration of Ca
2+ ions in the cytosol.  By increasing the GTPase activity of 
Gαq, RGS proteins decrease the inositol signalling of PLCβ and lower the amount of Ca
2+ 
ions released into the cytosol.   
However, RGS4 not only binds to activated Gαq, as predicted, but also to Gβγ and PLCβ.  
The affinity of RGS4 for Gβγ is much weaker than for Gαq, but this secondary interaction 
may serve to keep RGS4 localised in the signalling complex and possibly in the correct 
orientation for Gαq rebinding.  PLCβ, similarly to RGS4, has GAP activity for Gαq and the 
primary interaction of PLCβ has been suggested to be competitive with RGS4 interaction 
to Gαq.  Ternary complexes between Gα, Gβγ and PLCβ1 can form, but only at relatively 
high protein concentrations (Dowal et al., 2001).  These interactions may allow RGS4 to 
remain anchored to the signalling complex even in the inactive state and allow rapid 
cycling of activated Gαq. 
1.6.3  Cellular calcium 
As an important second messenger, the cellular concentration of Ca
2+ must be regulated for 
proper cell signalling.   There is a very large transmembrane electrochemical gradient of 
Ca
2+ driving the entry of the ion into cells and three calcium pumping ATPase systems 
operate to maintain cytosolic [Ca
2+] at a low level of about 10-7 M (Lytton et al., 1992).  
These ATPases include the sarco/endoplasmic reticulum ATPases (SERCAs) that 
sequester Ca
2+ into internal release compartments, and plasma membrane Ca
2+-ATPases 
(PMCAs) located in the surface membrane of cells that extrude Ca
2+ against a large 
concentration gradient (Dunham and Glynn, 1961). 
These pumps are powered by the hydrolysis of ATP, with a stoichiometry of two Ca
2+ ions 
removed for each molecule of ATP hydrolysed.  PMCAs tightly bind Ca
2+ ions (a high 
affinity, with a Km of 100 to 200 nM) but do not remove Ca
2+ at a very fast rate (Burette 
and Weinburg, 2006). Thus the PMCA is effective at binding Ca
2+ even when its 
concentrations within the cell are very low, thereby ideally suited for maintaining Ca
2+.     26 
Ca
2+/calmodulin binds and further activates the PMCA, increasing the affinity of the 
protein's Ca
2+ binding site twenty to thirty times.  Calmodulin also increases the rate at 
which the pump extrudes Ca
2+ from the cell, possibly up to ten fold (Carafoli, 1991). 
These PMCAs are in contrast to the sodium-calcium exchangers (NCX), which have a low 
affinity and a high capacity towards Ca
2+.  The NCX is an antiporter membrane protein 
which removes Ca
2+ from cells using the energy that is stored in the electrochemical 
gradient of Na
+ by allowing three Na
+ to flow down its gradient across the plasma 
membrane in exchange for the countertransport of  one Ca
2+ (Yu and Choi, 1997).   The 
NCX is considered one of the most important cellular mechanisms for removing Ca
2+ 
(Dipolo and Beauge, 2006), transporting up to five thousand Ca
2+ ions per second (Carafoli 
et al., 2001).   Therefore it requires large concentrations of Ca
2+ to be effective, but is 
useful for ridding the cell of large amounts of Ca
2+in a short time, as is needed in a neuron 
after an action potential. 
1.6.4  RGS proteins as scaffolding proteins 
The direct and specific binding of RGS proteins to other components of the cellular 
signalling complex also contributes to the regulation and function of RGS proteins.  
Preliminary research indicates that RGS proteins can act as scaffolds to assemble 
signalling complexes.  β-arrestins scaffold the signalling complex between GPCRs and 
related kinases to stabilise the MAPK signalling pathway (Miller and Lefkowitz, 2001).  In 
a similar way, a specific interaction between RGS2 and the α1b-adrenoceptor has been 
shown to include the scaffold, spinophillin (Wang et al., 2005).  A more direct 
involvement of RGS proteins to act as scaffolds for GPCRs came from the ability of Gα-
interacting protein (GAIP) to associate with the dopamine D2 receptor (Jeanneteau et al., 
2004).  This required the interaction of GAIP-interacting protein C terminus (GIPC), a 
protein with a history of acting as a scaffold to many signalling complexes, including TrkA 
nerve growth factor receptors  (De Vries and Farquhar, 2002;Abramow-Newerly et al., 
2006).  RGS19 also interacts with TrkA nerve growth factor receptor and a recent report 
indicated that in PC12 cells, GIPC interacts with the TrkA nerve growth factor receptor 
and RGS19.  All three proteins co-precipitate, indicating that a trimeric complex is 
possible (Lou et al., 2001).  However, to fully understand the stabilising contribution of 
RGS proteins, this area needs further investigation.     27 
1.6.5  Post translational modification of RGS proteins 
Direct regulation of RGS proteins can also be obtained by post-translational modifications 
on RGS proteins.  Phosphorylation and palymitoylation have both been shown to be 
powerful regulatory mechanisms of cellular signalling.  These modifications will only take 
place in living cells, stressing the importance of in vivo research to bring together all 
components of the signalling network. 
1.6.5.1  Phosphorylation 
Phosphorylation of RGS proteins can have the most impact on signalling.  The addition or 
removal of a phosphate from an RGS protein has diverse and complicated patterns of 
effect.  The phosphate group can sterically hinder or promote the interaction with other 
proteins in the signalling complex, increasing or decreasing GAP activity (Table 1.2). 
A number of different kinases are responsible for RGS protein phosphorylation.  Protein 
kinase C (PKC) phosphorylation of RGS7 is necessary for its interaction with the 
intracellular scaffold protein, 14-3-3 (Benzing et al., 2000).  The phosphorylation site on 
RGS7, serine
434, is within an important region for contact with Gαi.  Phosphorylation of 
this residue allows the RGS proteins to interact with 14-3-3 in place of Gαi, reducing GAP 
activity.  The complexity of the role of phosphorylation was increased when Benzing et al., 
found that this RGS7 phosphorylation is dynamically regulated by at least tumour necrosis 
factor-α (TNF-α), which reduces phosphorylation, allowing uncoupling from 14-3-3 
proteins and increased GAP activity (Benzing et al., 2000). 
Phosphorylation of RGS proteins can also influence positive feedback loops. Addition of 
phosphate to serine
53 on RGS16 occurs after α2A-adrenoceptor activation.  Phosphorylation 
reduces GAP activity and further increases α2A-adrenoceptor signalling (Chen et al., 2001).  
Transmembrane tyrosine kinases and second messenger tyrosine kinases have also been 
shown to phosphorylate RGS proteins (Derrien et al., 2003).  Recent studies have 
attempted to unravel this additional complexity for RGS regulation as GPCRs can 
themselves induce phosphorylation of tyrosine kinases (Ogier-Denis et al., 2000).  The 
network of signalling cascades is yet to be fully explored and there still seems to be no 
consistent effects of phosphorylation on RGS regulation.     28 
1.6.5.2  Palmitolyation 
The addition of palmitate to RGS proteins also influences regulation (Table 1.3).  
Palmitolyation of N-terminal cysteine residues occurs in a number of RGS proteins, 
including RGS3 (Castro-Fernandez et al., 2002), RGS4 (Srinivasa et al., 1998;Tu et al., 
1999;Bahia et al., 2003;Osterhout et al., 2003) RGS7 (Rose et al., 2000;Takida et al., 
2005), RGS10 (Tu et al., 1999;Castro-Fernandez et al., 2002) and RGS16 (Druey et al., 
1999a).  The post-translational, reversible addition of this fatty acid moiety occurs by thio-
ester bonds and serves to effect the membrane attachment and cellular localisation of the 
modified proteins.  RGS16 is palmitoylated at exposed cysteine residues 2 and 12, 
allowing RGS16 to become bound to the plasma membrane in close proximity to other 
signalling proteins. In this way, it has been suggested that RGS16 can properly regulate 
Gαi and Gαi-linked receptors (Druey et al., 1999b).  The closely related B/R4 RGS protein, 
RGS4, also has exposed cysteine residues at position 2 and 12.  However, RGS4 is also 
palmitolylated at reside 95 (Tu et al., 1999).  Cysteine
95 is in the RGS domain and addition 
of palmitate reduces RGS4 binding to G proteins.  Cysteine residues within the RGS 
domain are conserved among a number of RGS subfamilies and palmitoylation represents 
a common way in which post-translational modification can alter both localisation and 
GAP activity of RGS proteins. 
1.7  RGS proteins as therapeutic targets 
RGS proteins associate directly with proteins implicated in a number of diseases and 
consequently, RGS proteins are potential important drug targets of the future (Zhong and 
Neubig, 2001;Neubig and Siderovski, 2002).    
1.7.1  Polymorphisms  
A number of single nucleotide polymorphisms (SNPs) have been identified in RGS 
proteins.  SNPs are a single nucleotide variation in the genome between members of a 
species.  Non-synonymous SNPs in RGS proteins have been suggested to confer a 
protective genotype against tumourigenesis.  For example, a polymorphic variant of RGS6 
confers a reduction in the risk of bladder cancer (Berman et al., 2004).  Functional changes 
in transcript levels,
 alternative splicing events, and protein translation efficiency
 that may 
result from the presence of a variant cysteine to threonine allele were investigated.  This 
SNP appears to modulate protein translation
 and may contribute to the protective     29 
phenotype by increasing
 the level of RGS6 protein.  Further research by the same 
investigators has shown that replacement of a serine with a glycine in PDZ-RhoGEF is 
associated with a reduction in lung cancer among Mexican Americans.  Moreover, a 
combination of this SNP and the SNPs mentioned previously in RGS6 seems to have a 
synergistic interaction (Gu et al., 2006).  Patients with both SNPs had significant reduction 
in risk of lung cancer suggesting a dose-gene dependent effect.   
Many other RGS proteins have also been suggested as key regulators of tumorigenesis.  
For example, RGS14 binds to the Ras-related
 G proteins, Rap1/2 (Traver et al., 2000). 
RGS12 is a transcriptional repressor,
 and RGS12 overexpression in select cell lines inhibits 
DNA synthesis (Chatterjee and Fisher, 2002)
.  RGS3
 has been demonstrated to play a role 
in inducing apoptosis (Dulin et al., 2000). Advanced research into the genetic variation and 
ethnic differences of SNPs in this family of proteins may present new insights into 
therapeutic cancer treatments. 
1.7.2  Drug development 
Small molecules which modulate the RGS-Gα interaction have been proposed as novel 
drugs which could be used to treat numerous disease states.  Up to ten individual candidate 
regions that could serve as targets for drugs to alter RGS function exist on RGS proteins 
(Figure 1.2) 
One such drug has already been designed that could inhibit RGS4 from interacting with the 
Gα subunit (Jin et al., 2004;Riddle et al., 2005).  RGS4 over-expression reduced 
ventricular hypertrophy in response to pressure overload (Rogers et al., 1999).  A small 
molecule which blocks the interaction of RGS4 would suggest that despite up-regulation, 
RGS4 would have limited effects on the induction of ventricular hypertrophy.  
Novel drugs could also be designed for use in conjunction with existing drugs which are 
GPCR agonists, to maximise the signalling response.  Potentiating an exogenously 
administered GPCR agonist could suggest a smaller therapeutic dose of the agonist would 
be required, reducing unwanted side effects and tolerance. Specificity of the agonist may 
also be enhanced due to the precise regionalised localisation of RGS proteins.  This type of 
drug design was particularly important in a study which knocked down the levels of 
endogenous RGS2 and RGS9.  Lower levels of RGS2 were found to make morphine less 
potent.  However, reducing the level of RGS9 had the opposite effect, producing pain relief     30 
at lower concentrations of morphine thus reducing tolerance and allowing multiple 
treatments (Garzon et al., 2001).  Endogenous RGS9 therefore must facilitate tolerance and 
the potency of morphine.  A small molecule designed to inhibit RGS9 has great therapeutic 
potential in analgesic treatment. 
RGS9 has also been implicated in Parkinson’s disease (Tekumalla, 2001).  Significant 
increase in the levels of RGS9-2 was found in patients suffering from this disease. In 
Parkinson’s disease, dopamine neurons degenerate leading to defective circuitry within the 
brain.  Dopamine D1 and D2 receptors control movement and the equilibrium of these two 
receptors seems to dictate the signalling pathways.  Increasing levels of RGS9-2 
specifically inhibits D2 receptors, critically changing the balance of receptors (Tekumalla, 
2001).  Keeping the receptor signalling steady by use of a compound targeted towards 
RGS9-2 may prevent the progression of this disease. An RGS inhibitor might also be more 
specific than a D2 agonist due to the highly specific localisation of RGS9-2  in the caudate 
putamen (Gold et al., 1997).  The distinct subcellular localisation and expression pattern of 
RGS9-2 represent novel and
 potentially exciting targets for the development of new 
psychotropic
 medications.   
Further research is also required into the possibility of using compounds that would 
enhance RGS function, so called RGS agonists.   Blocking interactions with endogenous 
proteins that inhibit RGS function would stimulate GAP activity and inhibit G protein 
signalling.  This could be beneficial in a number of disease states, for example, stimulation 
of RGS1 would block Gαi1 signalling and reduce inflammatory responses.  Blocking Gαq 
signalling through stimulation of the GAP activity of RGS2 could be useful in treating 
hypertension and vascular restenosis.  
1.7.3  Transgenic animals 
Despite over ten years of research, only three RGS knock-out mice have been reported, 
RGS2
-/- (Tang et al., 2003), RGS4
-/- (Grillet et al., 2005)
 and RGS9
-/- (Chen et al., 2000).  
A novel method of studying the combined role of all endogenous RGS proteins has 
emerged instead. Fu et al., assessed the function of endogenous RGS proteins by using a 
knock-in strategy with a mutant Gα subunit that is unable to bind to RGS proteins (Fu et 
al., 2004).  The point mutation in switch I region of Gαo (
G184S) or Gαi1 (
G183S) blocks the 
interaction with RGS proteins but has been reported to have no effect on the G proteins 
ability to interact with other signalling components.  Introducing these mutant G proteins     31 
into embryonic stem cells by gene targeting allowed the function of endogenous RGS 
proteins in intact mice to be measured.  Loss of RGS protein function potently increased 
the heart rate and differential use of both Gαi and Gαo were observed, again suggesting 
novel therapeutic potential for RGS protein regulation in cardiovascular disease. 
Transgenic animals have been engineered with a double mutant approach.  In this way, a 
specific RGS-Gα subunit interaction can be rescued (Wieland et al., 2000).  This has been 
reported for both RGS16 and RGS4 where a lysine to glutamate mutation in both Gαi
 and 
Gαq renders the Gα subunit
 insensitive to endogenously expressed RGS proteins.  On the 
other hand, glutamate to lysine mutants of interacting RGS proteins were able to restore 
the original
 signalling.  These mutated proteins are selectively uncoupled from endogenous
 
signal transduction at the level of RGS-Gα subunit interaction
 but are otherwise 
functionally intact. Rescuing mutant pairs may be a helpful tool to analyse RGS-Gα 
subunit interaction in
 living cells or even transgenic
 animals.  In view of the fact that drugs 
targeted towards GPCRs can represent up to 30% of the portfolio of many pharmaceutical 
companies, RGS proteins are in a key position to become targeted for drug development. 
1.8  RGS4 
RGS4 is the most extensively researched RGS protein.  In resting cells, RGS4 is a soluble 
hydrophilic protein found in the cytosol.  It was one of the first RGS proteins to be 
discovered and the function of this RGS protein is best understood from yeast.  Early 
studies in S. cerevisiae found that removal of the gene Sst2 made the organism 
supersensitive to G protein directed pheromone responses (Chan and Otte, 1982;Weiner et 
al., 1993;Dohlman et al., 1995).  This discovery was instrumental in detecting the presence 
of mammalian RGS proteins and in fact, mammalian RGS4 has now been shown to be able 
to directly substitute for Sst2p, showing the high level of conservation between RGS 
proteins in yeast and mammals.   
1.8.1  N-terminal of RGS4 
RGS4 has a relatively simple protein architecture.  Apart from the RGS domain the only 
other recognisable domain is an amphipathic α helix at the N-terminal.  The 33 amino acid 
α helix is thought to be involved in the translocation of RGS4 to the cytosolic face of the 
plasma membrane.  In reconstituted systems using purified proteins, the N-terminus of 
RGS4 was found to interact with lipid vesicles (Tu et al., 2001). Conserved cysteine     32 
residues in the N-terminal of RGS4 are particularly important for correctly targeting the 
protein within the cell.  RGS4 is cytosolic, however post-translational addition of palmitate 
to cysteines within the N-terminus may target RGS4 to specialised lipid rafts in the plasma 
membrane (Druey et al., 1998;Moffett et al., 2000).  
The lipid raft microdomain in plasma membranes is constituted of many different protein-
lipid interactions thought to be involved in signal transduction.  RGS4 can penetrate the 
inner leaflet of the plasma membrane bilayer and growing evidence suggests that 
phosphatidic acid within the bilayer can also inhibit RGS4 GAP activity. Use of an N-
terminal truncation of RGS4 resulted in loss of both phosphatidic acid binding and lipid-
mediated functional inhibition.  Using single amino acid mutations, it was found that 
lysine
20 is responsible for these regulatory properties in reconstituted vesicles (Ouyang et 
al., 2003).  
The specificity of interaction between RGS4 and GPCRs also appears to be determined by 
the N-terminal of RGS4. As mentioned previously, signalling initiated by agonist
 binding 
to GPCRs bound to Gαq (Berridge, 1993), generates IP3 to trigger Ca
2+ release from 
internal stores.  In rat pancreatic acinar cells, RGS4 preferentially inhibits
 Gαq/11-mediated 
signalling induced by carbachol compared to bombesin
 and cholecystokinin regardless of 
the identity of the Gαq subunit (Zeng et al., 1998). Further use of an N-terminally truncated 
RGS4 exhibited no receptor selectivity but the ability to distinguish the carbachol activated 
muscarinic receptor was restored by re-addition of this N-terminal domain.  Such 
selectivity suggests intact RGS4 interacts directly or indirectly
 with receptors, most likely 
through the N-terminal domain (Zeng et al., 1998).   
Removal of the extreme N-terminal methionine of newly synthesized RGS4 can limit 
RGS4 availability.  The cysteine at position 2 is subsequently exposed and becomes the 
target for arginylation.  This allows for subsequent degradation of RGS4 by ubiquitination 
and the 26S proteasome (Davydov and Varshavsky, 2000). Redundant proteins that are 
damaged or no longer required are often targeted by ubiquinitation.  A mouse lacking the 
gene to encode the enzyme that adds arginine to the N-terminal of proteins (Arg-
transferase) died with cardiovascular defects, and the unmodified substrates of this enzyme 
were identified to be RGS proteins.  Given the ability of RGS4 to negatively regulate 
cardiovascular signalling pathways, RGS4 is an important target for consideration.  The 
ubiquitin-dependent N-end rule pathway relates to the half-life of the protein.  The half-life 
of RGS4 is approximately 1 hour but the amount of RGS4 degredaded by these means     33 
seems to be dependent on cell type (Davydov and Varshavsky, 2000).  Studies have 
concluded that the regulated degradation of RGS4, RGS5 and RGS16 by the N-end rule 
pathway is important for the correct functioning of the cardio vascular system (Lee et al., 
2005).  The ability of cysteine at postion 2 of RGS4 be a target for both palmitoylation and 
arginylation suggests a conflict between these two systems.  Perhaps palmitoylation not 
only helps target RGS4 to the plasma membrane but inhibits arginylation, promoting 
stability of the protein.   
Indeed, mutation of cysteine
2 to valine forms a degradation resistant RGS4.  An epitope-
tagged form of this mutant was used in co-immunoprecipitation studies in CHO cells 
transfected with the G protein-gated inwardly rectifying potassium (GIRK) channel (Jaen 
and Doupnik, 2006).  RGS4
C2V readily co-precipitated with GIRK channels.  This 
precipitation was shown to be RGS specific, as the short isofom of RGS3 did not interact 
with any of the GPCR-GIRK channel complexes.  Chimeric RGS4/RGS3 constructs 
indicated that the N-terminal domain of RGS4 is necessary for the GIRK interaction.  The 
N-terminus of RGS4 is therefore also important in the functional activity of the protein.  
The predominant expression of RGS4 is in the brain and heart so this activity may well be 
physiologically relevant in affecting neurotransmitter-mediated inhibitory events in the 
nervous and cardiovascular systems. 
RGS4 has also been found to directly associate with both the µ-opioid and δ-opioid 
receptors (Georgoussi et al., 2006). GST fusion proteins of the C-terminal of both 
receptors were found to associate with recombinant RGS4 in vitro.  Members of the RGS 
family are known to play an essential role in opioid signalling (Smrcka et al., 1991;Rhee, 
1991) but perhaps RGS4 has an undiscovered role in opiate action.  The specific contact 
sites on RGS4 and the dynamics of this interaction are also still unknown.  Perhaps the 
specificity of this interaction is also determined by the N-terminal of RGS4 and will further 
demonstrate that the relatively simple N-terminal of RGS4 is fundamental to the 
effectiveness of the protein to act as a negative regulator of G protein signalling. 
1.8.2  The RGS domain of RGS4  
The RGS domain of RGS4 (residues 58-177) had a normal GAP activity towards Gαo and 
appears to be able to work as a single functioning domain (Srinivasa et al., 1998).  
Forming a bundle of nine α-helices, the domain binds Gαi1 in a cleft consisting of 
conserved amino acids at the ends of helices 4, 7 and 8 and the loops between helices 3 and     34 
4 and helices 5 and 6.  Many other residues are important within the RGS domain of RGS4 
for the folding and/or the stability of the protein.  These include a pair of phenylalanine 
residues (phenylalanine
79 and phenylalanine
168), that when either is substituted with 
alanine, resulted in an insoluble protein when expressed in Escherichia coli. 
Previous studies on the role of RGS proteins on Ca
2+ signalling led to the discovery that 
calmodulin (CaM) and phosphatidylinositol (3,4,5)-trisphosphate  (PIP3) antagonise each 
others binding to the RGS domain of RGS4 (Popov et al., 2000). PIP3 binds RGS4 at a site 
within the RGS domain, distinct and opposite to the RGS/Gα contact face and inhibits the 
GAP activity of RGS4.  When complexed with Ca
2+, CaM competes with PIP3 for binding 
to RGS4 and removes GAP inhibition and restores activity of the RGS protein.  These data 
suggest a mechanism in which GPCR stimulation of Ca
2+ signalling is regulated by 
feedback inhibition (Sierra et al., 2000).  Interestingly, the pre-treatment of cells with the 
detergent methyl-β-cyclodextrin, which depletes the membrane of cholesterol and therefore 
disrupts the lipid rafts, and weakens the interaction of CaM with RGS4 (Ishii et al., 2005).  
Perhaps without lipid rafts, RGS4 and CaM cannot be brought into close proximity, 
reducing the strength and probability of their interaction. 
1.8.3  Endogenous functions of RGS4 
The engineering of Rgs4
-/- mutant mice allowed the endogenous role of RGS4 in 
developmental, behavioural and physiological tests to be explored (Grillet et al., 2005).  
Subtle symptoms recorded included lower weight and poorer sensory motor coordination.  
More serious defects were not displayed;  there was no alteration in neuronal 
differentiation or opioid signalling as mutant mice had normal tolerance to pain compared 
to wild type.    Perhaps future studies should compare these knock-out mice with knock-
down animal models. Compensation during development may take place in knock-out 
animals and these future experiments may reveal differences so far undiscovered. 
1.8.3.1  Heart 
It is increasingly clear that RGS4 acts as important negative regulator of both Gαi and Gαq 
signalling.  Little is known about the in vivo role of RGS4, but one study found the 
overexpression of RGS4 mRNA or protein is frequently seen in patients or animals with 
heart dysfunction (Mittmann et al., 2002).  In mouse cardiomyocytes increased levels of 
RGS4 are thought to be associated with a reduction of smooth muscle cells of the large     35 
vessels of the heart and coronaries activating a hypertrophic response and left ventricular 
dilation (Rogers et al., 1999).  However, the expression pattern of RGS4 in 
cardiomyocytes is contentious.  Grillet et al., could not detect any RGS4 in the heart 
muscle itself but instead found high levels in the endothelium (Grillet et al., 2005). 
Presumably the previous results seen in patients or animals with heart dysfunction could 
also have displayed this expression pattern (Mittmann et al., 2002).  Differences across 
species may account for these variations but the potential for cardiac therapeutics is low if, 
indeed, there is no expression of RGS4 in the heart itself.  
1.8.3.2  Central Nervous System 
RGS4 has also been speculated to perform physiological roles in the CNS (Gold et al., 
1997;Nomoto et al., 1997;Erdely et al., 2004).  Expression in the cerebral cortex suggested 
regulation of dopamine, serotonin, noradrenaline, glutamate and opioid receptors makes 
RGS4 a candidate gene for the functional modulation of neurotransmission.  Activation of 
opioid receptors by morphine altered the expression of RGS4 in distinct locations within 
the brain (Bishop et al., 2002;Gold et al., 2003).  Factors that control opioid signalling are 
likely to be important to the understanding of drug abuse.  Design of novel central nervous 
system drugs could prove useful in preventing the development of or treatment of drug 
dependence. 
1.8.3.3  Risk Factors for Schizophrenia 
The gene for RGS4 is located on chromosome 1q23 and many psychiatric genetic studies 
have suggested a linkage to schizophrenia (Brzustowicz et al., 2000;Gurling et al., 2001).  
The status of RGS4 as a susceptibility gene for schizophrenia first came from its high 
levels of expression in the cortex of the brain where it could potentially regulate dopamine 
and glutamate signalling.  
Controversy surrounding this linkage analysis still exists, a large scale study did not find 
any linkage between these RGS4 and schizophrenia (Levinson et al., 2002) but it is still 
generally accepted that RGS4 is
 an interesting candidate gene for schizophrenia. RGS4 is 
not only highly expressed in brain regions implicated in the pathophysiology
 of 
schizophrenia, but also modulates the function of multiple G protein coupled
 
neurotransmitter receptors and can exhibit robust transcriptional
 changes to stress (Levitt et 
al., 2006).  Expression of RGS4 has been demonstrated to decrease across the cerebral     36 
cortex
 in subjects with schizophrenia.  Importantly, expression of other RGS proteins or 
levels of RGS4 in patients with an alternative major depressive disorder are not altered.  A 
decrease in RGS4
 expression may enhance Gαi-mediated signalling, resulting
 in 
diminished AC activity as is associated with chronic stress.  However, the exact 
Gα subunit regulated by
 this RGS protein in the brain in vivo remains unclear.  Post-
mortem studies of schizophrenia patients detected no associated polymorphisms in RGS4 
suggesting that the principal explanation of any relationship is the decreased transcription 
level of RGS4 mRNA.  Indeed, in the previous research which confirmed linkage, it was 
the upstream sequence of RGS4 which controls transcription, that linked to the 
schizophrenia gene locus (Chowdari et al., 2002). 
1.9  RGS16 
RGS16, like RGS4 is a member of the B/R4 subfamily.  RGS16 also has an N-terminal 
amphipathic α helix which is a key determinant of membrane localisation of the protein.  
The current model of localisation suggests that RGS16 firsts finds a docking partner at the 
membrane and then undergoes palmitoylation that locks the protein in place (Dunphy and 
Linder, 1998;Wedegaertner, 1998). Mutagenesis of key cysteine residues therefore had 
little effect on overall localisation, but mutation of hydrophobic resides and basic resides 
had a much greater effect on decreasing plasma membrane localisation and activity of 
RGS16 (Chen et al., 1999;Bernstein et al., 2000).  Hiol et al., have suggested that cysteine
2 
and cysteine
12 of RGS16 are palmitoylated at the plasma membrane, stabilising the protein 
in to lipid rafts (Hiol et al., 2003).  These membrane microdomains, rich in protein 
acyltransferase serve to rotate RGS16 exposing cysteine
98, potentially leading to this 
residue being palmitoylated, and subsequently greatly enhancing the functionality of 
RGS16. 
RGS16 is expressed in several tissues including the liver, pituitary, retina and the pineal 
region of the brain (Chen et al., 1996;Chen et al., 1997).  The pineal gland is located deep 
in the midbrain area near many vital structures, including the aqueduct of Sylvius, which 
serves as a passage allowing cerebrospinal fluid to leave the centre of the brain where it is 
first produced.  Several types of tumours are known to originate from the pineal region and 
may often compress this aqueduct, causing the build-up of cerebrospinal fluid in the brain.  
Microarray analysis of differential gene expression patterns in tumours of the pineal region 
found high expression of many genes related to phototranduction in the retina, including 
RGS16 (Fevre-Montange et al., 2006).  The clinical significance of this expression needs     37 
further investigation but perhaps implies RGS16 could be a candidate gene for use as a 
molecular marker for identifying patients with pineal region tumours. 
Overexpression of RGS16 has also been found in megakaryocyte differentiation 
(Berthebaud et al., 2005).  In these cells RGS16 negatively regulates CXCR4 signalling, 
and subsequently reduces downstream effectors. RGS18 is also overexpressed in 
megakaryocyte differentiation (Yowe et al., 2001) but RGS16 and RGS18 affect CXCR4 
signalling differently seemingly due to RGS protein specificity of action on receptor and G 
protein subtypes. Experiments using RNAi interference saw reciprocal results (Airoldi et 
al., 2006) and perhaps studies on knock-out mice will further clarify the role of RGS16 in 
megakaryocytes. 
As mentioned previously, RGS16 is a phosphoprotein. Phosphorylation of RGS16 upon 
stimulation of the α2A-adrenoceptor by epinephrine significantly reduced its GAP function 
and consequently its attenuation of the MAPK pathway (Chen et al., 2001). RGS16 can 
also undergo epidermal
 growth factor receptor-mediated tyrosine phosphorylation
 on a 
conserved tyrosine residue in the RGS box, tyrosine
168, which enhances RGS16 GAP 
activity in single turnover assays
 (Derrien et al., 2003).  The authors also demonstrated that 
tyrosine
177, the only other tyrosine residue in RGS16, was also phosphorylated. 
Phosphorylation has been suggested to induce or prevent RGS16 localisation
 in lipid rafts 
or perhaps generate a docking site for interaction with novel proteins and regulate the GAP 
activity of RGS16. 
The high homology between RGS16 and RGS4, and the growing knowledge about the 
function of these proteins in vivo and in vitro, prompted the use of these RGS proteins in 
this study.  In particular, RGS16 was employed to deduce if a mutation in RGS4 was RGS 
specific or RGS subtype specific. 
1.10   Methods of studying RGS proteins 
A current challenge is to define the function of individual RGS proteins. Cellular 
mechanisms of RGS proteins are coordinated to regulate a diverse range of cellular 
functions and methods of studying individual endogenous RGS proteins demonstrate RGS 
functions not yet predicted by in vitro assays.       38 
1.10.1   Yeast as a model organism 
The presence of multiple RGS proteins and overlapping expression in mammalian cells 
makes investigating the activity of one RGS protein difficult.  Not every RGS protein is 
expressed in every cell, but various combinations are possible and create a multitude of 
signalling pathways (Bockaert and Pin, 1999).  Yeast has a similar signalling pathway to 
mammalian cells but has fewer components.  Yeast have therefore been previously 
characterised to express particular signalling components in isolation (Whiteway et al., 
1989;Cismowski et al., 1999)  
Since the identification of RGS proteins in S. cerevisiae, yeast has been continually used as 
a model organism to study the function of RGS proteins.  The pheromone response 
pathway in yeast is a GPCR mediated signalling pathway that allows signalling between 
the MATa and MATα cells.  The signalling components comprise of a single GPCR (Ste2p 
for MATa and Ste3p for MATα), a Gα protein (Gpa1p), a Gβ protein (Ste4p), a Gγ protein 
(Ste18p) and RGS protein (Sst2p).  Their mammalian counterparts have successfully 
replaced many components in S. cerevisiae.  However, the Gα subunit in S. cerevisiae is 
not equivalent Gα subunit in mammalian cells.  In S. cerevisiae the Gα subunit is a 
negative regulator of signalling and the Gβγ dimer propagates the signal.  Studies 
expressing functional mammalian Gα subunits in yeast have therefore been carried out in 
an alternative yeast, Schizosaccharomyces pombe.  The Gα subunit in this yeast is a 
positive regulator of signalling and the pheromone response pathway in fission yeast has 
been previously modified to provide assays with which to analyse individual GPCR 
signalling pathways (Watson et al., 1999;Didmon et al., 2002).  Sz. pombe mutants without 
Sst2p show a hyperresponsive GPCR response.  Endogenous levels of RGS proteins must 
therefore limit the pheromone response.  Overexpression of RGS proteins in this yeast 
strain show a reduction of this hyperresponsiveness and a reduced ability to desensitise in 
the continued presence of pheromone (Dohlman et al., 1996).  The basal level of RGS 
proteins in yeast is therefore the crucial rate-limiting factor in the yeast signalling pathway. 
1.10.2   Mutagenesis of RGS proteins 
Mutagenesis demonstrates the importance of certain amino acids in proteins.  As 
mentioned previously, the crystal structure of RGS4 complexed with Gαi-GDP-AlF4
-, 
highlighted important amino acids at the interface between the RGS protein and the Gα 
subunit.  Mutation of these specific residues within the Gα subunit can alter signalling.  A     39 
series of these mutations have been constructed, which are found either to be unable to 
release GDP (Carrillo et al., 2002) or have reduced interaction with RGS (DiBello et al., 
1998).  In addition, mutations of specific amino acids in RGS4, that directly contact the 
Gαi1 have been reported to completely abolish RGS4 GAP activity (Srinivasa et al., 1998).  
The identification and characterisation of a Gα subunit mutant that specifically disrupts the 
interaction with RGS proteins provided a new approach to study the endogenous function 
of RGS proteins (DiBello et al., 1998). As mentioned previously, a single amino acid 
change in the Gα subunit in switch region I can produce a G protein insensitive to RGS 
action.  These RGS-insensitive G proteins can also be used in vitro, to study the 
endogenous function of RGS proteins.  Following agonist activation, the µ-opioid increase 
in [Ca
2+]i was less affected when coupled through an RGS-insensitive
 Gαo as compared to a 
RGS-sensitive protein (Clark et al., 2004). This effect caused by the inability of the RGS-
insensitive protein to bind to Gαo suggests that the GAP activity of RGS
 proteins provides 
a control that regulates
 potency and maximal response of agonist activated signalling.  
1.10.3   Experimental methods used 
The complex and diverse structures of RGS proteins allow varied mechanisms of 
regulation and cellular functions.  In this regard, numerous experimental methods are 
commonly used to study this regulation and function.   
1.10.3.1 Adrenoceptors  
The adrenoceptors are the target of many therapeutic agents that regulate the peripheral 
and central nervous system.  The adrenoceptors are GPCRs by which the important 
neurotransmitters, noradrenaline and adrenaline function.  There are nine different 
subtypes of adrenoceptor, classified into two types α and β.  Both α- and β-adrenoceptors 
have now been further subdivided into two subtypes α1, and α2.  These subtypes were at 
first classified by their anatomical location; α1 is found mostly postsynaptically, whilst α2 
although typically sited presynaptically, can also occur postsynaptically. These initial 
subtypes were further divided into α1a, α 1b, and α 1d and α 2A, α 2B, α 2C, and α 2D. This 
knowledge has led to the development of selective agonists and antagonists for each 
subtype (Guimaraes and Moura, 2001).      40 
α2-adrenoceptors play a key role in regulating neurotransmitter release in the central and 
peripheral sympathetic
 nervous systems.  Activation of α2-adrenoceptors on sympathetic 
nerve terminals leads to a reduction in
 sympathetic tone, with a resultant decrease in heart 
rate and
 blood pressure. These presynaptic α2-adrenoceptors serve
 as autoreceptors 
regulating catecholamine release, inhibiting the release of noradrenaline and thus serving 
as an important receptor in the negative feedback control of noradrenaline release.  
Postsynaptic α2 receptors are located on liver cells, platelets, and the smooth muscle of 
blood vessels. Activation of these receptors causes platelet aggregation, and blood vessel 
constriction (Starke, 2001). 
Using genetically engineered mice, the α2A-adrenoceptors appears to be the subtype that 
plays the principal role in response to α2A agonists for the suppression of blood pressure, 
attenuation of pain perception, analgesia, anesthetic sparing, and suppression of 
neurotransmitter release (Limbird, 2003). 
The natural ligand for α2-adrenoceptors, adrenaline, shows no selectivity for the α2 subtype 
of receptors and so for the purpose of this study the α2 selective agonist UK14304 was also 
used to activate this receptor subtype.  The α2A-adrenoceptor couples preferentially to the 
Gαi subfamily of G proteins.  The high G protein cycling of this G protein subtype and 
good transient transfection efficiency makes the α2A-adrenoceptor ideal for using to study 
RGS regulation in the present study. 
α1-adrenoceptors mainly couple through the Gαq subfamily of G proteins (Zhong and 
Minneman, 1999).  Activation of Gαq/11 stimulates PLCβ and subsequently promotes the 
hydrolysis of PIP2 producing IP3 and diacylgylercol (DAG).  IP3 act as second 
messengers to release Ca
2+ from internal stores.  DAG synergises with calcium to activate 
PKC which phosphorylates specific target proteins in the cell to change their function.  The 
inhibitory action of RGS proteins on Gαq signalling has previously been investigated.  
Expression of functionally active RGS proteins reduced agonist-stimulated elevation of 
[Ca
2+]i and allowed the relative activity of individual RGS proteins on particular receptor 
systems to be investigated (Clark et al., 2004). The previous effectiveness of the α1b-
adrenoceptor to study [Ca
2+]i  promoted the use of this receptor subtype in the present study 
to investigate the inhibitory action of RGS proteins. 
α1-adrenoceptors are found in both the central and peripheral nervous system.  In the CNS 
they are found mostly postsynaptically and have an excitatory function.  Peripherally they     41 
are responsible for contraction and are situated on vascular and on non-vascular smooth 
muscle. α1-adrenoceptors on vascular smooth muscle are located intrasynaptically and 
function in response to neurotransmitter release.  For non-vascular smooth muscle they can 
be found on the liver, where they cause hepatic glycogenolysis and potassium release. On 
the heart they mediate a positive inotropic effect. Cause relaxation of gastrointestinal 
smooth muscle and decrease salivary secretion (Marshall et al., 1999).  
1.10.3.2 Fusion proteins 
The C-terminus of a GPCR directly fused to the N-terminal of a Gα subunit, has proved 
invaluable in a number of investigations.  In particular, the use of these fusion proteins in 
high-affinity GTPase assays has been invaluable to the understanding of RGS proteins.  A 
fusion protein defines the stoichiometry of 1:1 of receptor and Gα subunit expression and 
ensures the co-localisation of the two signalling proteins.  In addition, preservation of 
interactions between GPCRs, Gα subunits and Gβγ have also been demonstrated for these 
fusion proteins (Wise et al., 1997b;Cavalli et al., 2000;Bertaso et al., 2003).  A number of 
fusion proteins have been used in the present study as a proficient method of investigating 
RGS proteins. 
However, the use of fusion proteins creates an artificially constrained signalling cascade 
and is not physiological relevant.  Internalisation and desensitisation of fusion proteins 
may be different compared to native receptors (Loisel et al., 1999) and investigations using 
this system must be interpreted with caution. 
1.10.3.3 High-affinity GTPase assay 
The fusion of the α2A-adrenoceptor with a P. tox resistant Gαo has been used successfully 
to study the effect on the high-affinity GTPase activity of RGS proteins (Cavalli et al., 
2000). Indeed, fusion proteins allow the direct measurement of regulation of the agonist-
activation of a G protein, preloaded with [γ-
32P]GTP, by a GPCR.  Monitoring the release 
of [γ-
32P]Pi, the GTPase activity of Gαo
C351I and its regulation by RGS proteins can be 
analysed
 using basic enzyme kinetics. 
1.10.3.4 Measurement of [Ca
2+]i 
The α1b-adrenoceptor-Gα11 fusion protein has previously been used effectively to study 
single cell Ca
2+ mobilisation (Carrillo et al., 2002).  Activating cells expressing the α1b-    42 
adrenoceptor-Gα11 fusion protein with agonist causes a rise in [Ca
2+]i.  This effect is 
inhibited by the GAP activity of RGS proteins.  Using a Ca
2+ sensitive probe, RGS-
mediated inhibition of Gα11-mediated signalling in live cells in real time was assessed and 
the magnitude of signal inhibition by RGS4 was studied. 
 
1.10.3.5  [
35S]GTPγS 
The [
35S]GTPγS  binding assay measures the level of G protein activation following 
agonist occupation of a GPCR, by determining the binding of the non-hdrolyzable 
analogue [
35S]GTPγS  to the Gα subuit.  The non-hydrolysable γ thiophosphate bond 
allows the radiolabelled Gα to accumulate and be measured. To isolate and enrich the 
[
35S]GTPγS-bound
 α1b-adrenoreceptor-Gα11 fusion protein in the membrane fraction of 
transfected cells, Gα11 in the reactions was solubilised
 by detergents and 
immunoprecipitated using an anti-G protein antiserum, CQ and then
 counting the 
radioactivity.   The agonism of the α1b-adrenoceptor-Gα11 fusion protein has been well 
established (Carrillo et al., 2002) and this method was used to measure the G protein 
activation of a previously identified mutant of Gα11 
1.11   Objectives of this study 
The aim of this study was to investigate the role of RGS4 in signal transduction.  To focus 
this general aim, particular areas of current interest were investigated. The areas explored 
were set into three main objectives;   
1.  To investigate the cellular localisation of RGS4  
2.  To examine the effect of mutating selected residues on the subcellular localisation 
and functional activity of RGS4 
3.  To investigate a potential Gα11 RGS-insensitive mutant  
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Figure 1.1 The G protein cycle 
In the absence of stimulation, the Gα subunit is GDP bound and associated with the β and γ 
subunits.  The GPCR either via constitutive activity or in response to binding of an agonist, 
promotes the release of GDP and its replacement with GTP.  Conformational 
rearrangements may result in the dissociation of the Gβγ complex and these components 
can then interact with and regulate effectors.  Intrinsic GTPase activity of the Gα subunit 
hydrolyses the bound GTP to GDP, this activity is accelerated by the GTPase activity of 
RGS proteins.  The resulting reassociation of the G protein heterotrimer completes the 
cycle (taken from Milligan and Kostenis, 2006). 
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Family          Structure  Members 
A/RZ 
   
*RGS17 (RGSZ2), RGS19 
(GAIP), RGS20 (RGSZ1), 
RET-RGS 
 
B/R4 
 
RGS1, RGS2, RGS3, 
*RGS4, RGS5, RGS8, 
RSG13, RGS16, RGS18, 
RGS21 
 
C/R7 
 
RGS6, RGS7, RGS9, 
*RGS11 
D/R12 
 
RGS10, *RGS12, RGS14 
E/RA 
 
*Axin, Conductin 
F/GEF 
 
P115-RhoGEF, PDZ-
RhoGEF, *LARG 
G/GRK 
 
GRK1, * GRK2, GRK3, 
GRK4, GRK5, GRK6, 
GRK7 
H/SNX 
 
*SNX13, SNX14, SNX25 
Atypical 
 
*D-AKAP2 
 
*RGS22 
     
 
 
Table 1.1 Classification of RGS proteins 
The RGS families of proteins. A schematic diagram depicting the structural motifs present 
in a representative member (shown by ‘*’) of each of the RGS family is shown.  Individual 
members of each sub-family do not necessarily contain all the motifs of the represented 
member.  Abbreviations used to describe the different domains can be found in the 
Definitions (taken from Jean-Baptiste et al., 2006).     45 
RGS 
Protein 
Phosphorylated 
by 
Residue  Physiological 
Effect 
Reference 
RGS2  PKC         -  < GAP activity  (Cunningham et 
al., 2001)  
  PKGI-α  Serine 46/64  > GAP activity  (Tang et al., 
2003) 
RGS3/4  PKG        -  Induces 
translocation from 
cytosol to cell 
membrane 
(Pedram et al., 
2000) 
RGS7   PKCα  Serine 434  Promotes the 
binding of 14-3-3 
and decreases 
GAP activity 
(Benzing et al., 
2000) 
RGS9  PKA  Serine 427/428  < GAP activity  (Balasubramani
an et al., 2001) 
  PKCα/PKCθ  Serine 475  Alters subcellular 
localisation 
(Sokal et al., 
2003) 
RGS10  PKA  Serine 168  Induces nuclear 
translocation 
(Burgon et al., 
2001) 
RGS14  PKA  Serine 258/ 
Threonine 494 
> GDI activity  (Hollinger et 
al., 2003) 
RGS16  SRC  Tyrosine168  Promotes stability  (Derrien et al., 
2003) 
    -  Serine 194/53  < GAP activity  (Chen et al., 
2001) 
    -  Tyrosine 168/177  Tyrosine 168 > 
GAP activity 
(Derrien and 
Druey, 2001) 
RGS18    -  Serine 49    (Garcia et al., 
2004) 
RGS19  ERK2  Serine 151  > GAP activity  (Ogier-Denis et 
al., 2000) 
Table 1.2 Phosphorylation of RGS proteins 
RGS proteins and the kinase they are phosphorylated by.  If known, the amino acid 
phosphorylated together with the physiological effect of this post-translational 
modification are also shown (taken from Riddle et al., 2005).      46 
RGS 
Protein 
Residue  Subcellular 
Localisation 
RGS activity  Reference 
RGS3  -         -         -  (Castro-
Fernandez et al., 
2002) 
RGS4  Cysteine 2/12  No change  No change  (Srinivasa et al., 
1998) 
  Cysteine 2/12/95         -  > and < 
activity* 
(Tu et al., 1999) 
  Cysteine 95         -  > activity  (Osterhout et al., 
2003) 
RGS7  Cysteine 69  Targets to membrane  No change  (Rose et al., 
2000) 
  Cysteine 133  Targets to membrane  ND  (Takida et al., 
2005) 
RGS10  Cysteine 66         -  > and < activity  (Tu et al., 1999) 
  Cysteine 60         -  > activity  (Castro-
Fernandez et al., 
2002) 
RGS16  Cysteine 2/12  No change  > activity  (Druey et al., 
1999c) 
  Cysteine2/12/98  Targets to lipid rafts  > activity  (Hiol et al., 
2003) 
  Cysteine 98         -  > activity  (Osterhout et al., 
2003) 
RGS19         -  Targets to membrane         -  (De Vries et al., 
1996) 
 
Table 1.3 Palmitoylation of RGS proteins 
RGS proteins and the cysteine residues that they are palmitoylated by and the effect on 
RGS activity are shown. * dependent on assay (taken from Riddle et al., 2005). 
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1.  RGS/Gα contact site 1  2.  RGS/Gα contact site 2 
3.  RGS/Gα contact site 3  4.  Conserved APC binding groove 
5.  PIP3 and Ca
2+/CaM binding domains  6.  Palmitoylation 
7.  Palmitoylation  8.  Charged amphipathic helix 
9.  Undetermined regions  10. Multiple N- and C-terminal motifs 
 
Figure 1.2 Model of potential targets on RGS proteins for drug action 
Target sites 1-10 include amino acids that are essential for direct RGS/Gα binding  
(1, 2 and 3);  those that mediate RGS binding with other proteins/molecules to 
allosterically regulate RGS/Gα binding (4, 5 and 6);  amino acids required for RGS protein 
membrane attachment (7 and 8);  and those residues that mediate RGS binding to GPCR 
(9) and other regulatory and/or signalling proteins (10) (taken from Hollinger and Hepler, 
2002).  
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2  Materials and Methods 
2.1  Materials 
2.1.1  General reagents, enzymes and kits 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Full range Rainbow
TM molecular weight markers, protein G, Glutathione Sepharose 4B 
beads 
Amaxa, Gaithersburg, MD, USA 
Cell Line Nucleofector kit V 
BDH, Lutterworth, Leicestershire, UK 
22 mm coverslips, microscope slides 
Chemicon Europe Ltd., Chandlers Ford, UK 
ReBlot plus solution 
Eppendorf, Hamburg, Germany 
96 well deepwell plates 
Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK 
Glacial acetic acid, glycine, HEPES, sucrose, SDS, KH2PO4, Na2HPO4, orthophosphate, 
CaCl2, MnCl2, DTT, bactotryptone, yeast extract, bactoagar, ethylene glycol, methanol, 
isopropanol, ethanol, NaCl, Tris 
Flowgen Bioscience Ltd., Nottingham, UK 
Agarose 
Invitrogen Ltd., Paisley, UK 
NuPage pre-cast 8-12% (w/v) Bis-tris gels, MOPS running buffer, ProLong Gold antifade 
reagent, Image-iT™ LIVE Plasma Membrane labelling kit 
Konica Europe, Hohenbrunn, Germany      49 
X-ray film 
Merck Chemicals Ltd., Nottingham, UK 
Nonidet P-40, pansorbin 
New England Biolabs, MA, USA 
Restriction enzymes 
Perkin-Elmer Life Sciences Inc., Boston, MA, USA 
384 well black walled plates, Optiplate white 96 well plates 
Pierce, Perbio Science UK Ltd., Tattenhall, Cheshire, UK 
Supersignal West Pico chemiluminescent substrate 
Promega UK Ltd., Southhampton, UK 
All restriction endonucleases, DNA ligase, Pfu polymerase, Wizard™ Plus SV mini-preps 
Qiagen, Crawley, West Sussex, UK 
Qiaquick PCR purification kit, Qiaquick gel extraction kit, Qiafilter maxi-prep kit 
Roche Diagnostics Ltd., Lewes, East Sussex, UK 
Complete™ EDTA-free protease inhibitor tablets, AppNH 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
MgCl2, Tris, EDTA, bromophenol blue, Triton X-100, DMSO, glycerol, Tween 20, 
ethylene glycol, paraformaldehyde, ampicillin, ethidium bromide, ATP, Hoechst No. 
333442, BCA solution A, Pertussis toxin, GTPγS, GDP, Fura-2 AM, CuSO4, RbCl2 
Stratagene, Amsterdam, The Netherlands 
QuikChange site directed mutagenesis kit, XL-1 Blue competent cells 
Thermo Fisher Scientific, Ulm, Germany 
All oligonucleotides used for PCR reactions      50 
2.1.2  Tissue culture plasticware and reagents 
Costar, Cambridge, MA., USA 
5 mL, 10 mL and 25 mL pipettes, 75 cm
2 vented tissue culture flasks, 6 well plates, 100 
mm dishes 
Invitrogen BV, Groningen, The Netherlands 
Lipofectamine™ transfection reagent, Optimem, L-glutamine (200mM) 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
DMEM, 0.25% (w/v) trypsin-EDTA, poly-D-Lysine, new born calf serum, fetal calf serum 
2.1.3  Radiochemicals 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
 [γ-
32P]GTP, [
3H]RS-79948-197 
Perkin-Elmer Life and Analytical Sciences, Beaconsfield, Buckinghamshire, UK 
[
3H]prazosin, [
35S]GTPγS 
 
2.1.4  Antisera 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Donkey anti-mouse IgG-HRP conjugate, donkey anti-rabbit IgG-HRP conjugate, donkey 
anti-hamster IgG-HRP conjugate, anti-RGS4 antiserum 
A sheep polyclonal anti-GFP antiserum was generated in house. 
2.2  Buffers 
2.2.1  General Buffers 
HEPES Buffer 
130 mM NaCl, 5 mM KCl, 1 mM MgCl2,
 1 mM CaCl2, 20 mM HEPES, 10 mM D-glucose, 
0.01 mM EGTA.  The pH of this solution was adjusted to 7.4
 using NaOH.      51 
Laemmli Buffer (2x) 
0.4 M DTT, 0.17 M SDS, 40 mM Tris, 5 M urea, 0.01% (w/v) bromophenol blue 
Phosphate Buffered Saline (10x) 
137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 10.2 mM Na2HPO4, pH 7.4.  The solution 
was autoclaved prior to use. This solution was diluted 1:10 prior to use. 
RIPA Buffer (2x) 
100mM HEPES (pH7.4), 300mM NaCl, 2% (w/v) Triton X-100, 1% (w/v) Na-
deoxycholate, 0.2% (w/v) SDS, stored at 4
oC 
Tris-EDTA (TE) Buffer (membrane) 
10 mM Tris, 0.1 mM EDTA, pH 7.4 
Tris-EDTA (TE) Buffer (radioligand binding) 
75 mM Tris, 5 mM EDTA, pH 7.5 
Tris-EDTA-Magnesium (TEM) Buffer (radioligand binding) 
75 mM Tris, 5 mM EDTA, 12.5 mM MgCl2, pH 7.5 
2.2.2  Molecular Biology Solutions 
TAE Buffer (50x) 
40 mM Tris, 1 mM EDTA, 17.5% (w/v) glacial acetic acid.  This solution was diluted 1:50 
prior to use. 
DNA loading buffer 
0.25% (w/v) bromophenol blue, 40% sucrose (w/v) in H20 
LB Media (Luria-Bertani Medium) 
1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, pH 7.4.  Sterilised by 
autoclaving at 126
oC. 
Buffer 1 (for preparation of competent bacteria)      52 
0.03M C2H3O2K, 0.1M RbCl2, 0.01M CaCl2, 0.05M MnCl2, 15% (w/v) glycerol.  The 
solution was adjusted to pH 5.8 with acetic acid.  The solution was filter sterilised and 
stored at 4°C. 
Buffer 2 (for preparation of competent bacteria) 
10mM MOPS pH 6.5, 0.075M CaCl2, 0.01M RbCl2, 15% (w/v) glycerol.  The pH was 
corrected to pH 6.5 with concentrated HCl.  The solution was filter sterilised and stored at 
4°C. 
2.3  Molecular Biology Protocols 
2.3.1  LB agar plates 
LB was prepared as detailed previously in 2.2.2.  15 g/L of bacto-agar was added to LB 
and autoclaved.  On removal from the autoclave, the bottle was gently inverted to 
distribute the agar throughout the solution.  The mix was cooled to 50°C prior to addition 
of an antibiotic.  The final concentrations of antibiotics used were;  ampicillin – 100 
µg/mL or Zeocin – 50 µg/mL.  The medium was mixed gently and approximately 25 mL 
poured into 10 cm
2 petri dishes.  The dishes were left to set at room temperature before 
being stored at 4°C.  Unused plates were disposed of three weeks following preparation. 
2.3.2  Preparation of competent bacteria 
XL-1 blue cells were streaked out onto a minimal agar plate and incubated overnight at 
37°C.  A single colony was selected, inoculated into a 5 mL culture of LB and grown in a 
shaking incubator at 37°C until the optical density at 550 nm was 0.48 – approximately 90 
minutes of incubation.  The culture was then chilled on ice for 5 minutes before being 
centrifuged at 3220 x g for 10 minutes at 4°C.  All traces of LB were removed and then the 
pellet was resuspended in 20 mL of buffer 1 (as detailed above) by gently pipetting.  The 
suspension was incubated on ice for 5 minutes prior to being centrifuged as before.  The 
pellet was resuspended in 2 mL of buffer 2 (as detailed above) by pipetting and the 
suspension incubated on ice for 15 minutes.  The cells were then divided in 220 µL 
aliquots and stored at -80°C until required.      53 
2.3.3  Transformation 
An aliquot of competent bacteria was thawed on ice and 50 µL of cells per transformation 
reaction aliquoted into a sterile tube.  Between 1 and 10 µg of DNA was then added to the 
cells and incubated on ice for 15 minutes.  The cells were then subjected to a heat shock at 
42°C for 90 seconds and then returned to ice for 2 minutes.  450 µL of LB was added to 
the cells and the mix incubated for 45 minutes at 37°C in a shaking incubator.  200 µL of 
the mix was plated onto an LB plate containing the appropriate concentration of antibiotic 
and incubated inverted for 12-16 hours at 37°C. 
2.3.4  Preparation of plasmid DNA 
2.3.4.1  Mini-preps 
Mini-prep cDNA was purified from bacterial cultures using the Wizard™ Plus SV 
miniprep kit.  5 mL of bacterial culture was centrifuged at 16,000 x g for 10 minutes and 
the supernatant removed.  The pellet was resuspended in 250 µL of cell resuspension 
buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 100 µg/mL Rnase A) immediately 
followed by 250 µL of lysis buffer (0.2 M NaOH, 1% (w/v) SDS).  10 µL of alkaline 
phosphate was added to each sample and incubated for 5 minutes.  350 µL of neutralising 
buffer was then added (4.09 M guanidine hydrochloride, 0.76 M potassium acetate, 2.12 M 
glacial acetic acid, pH 4.2) to precipitate the bacterial chromosomal DNA.  This was 
centrifuged for 10 minutes at 16,000 x g and the supernatant applied to a DNA purification 
column.  The column was centrifuged briefly to bind the DNA and the column washed 
twice in wash buffer (60 mM potassium acetate, 10 mM Tris-HCl, pH 7.4, 60% (w/v) 
ethanol).  DNA was eluted by adding 100 µL sterile water.   
2.3.4.2  Maxi-preps 
The Qiagen Qiafilter kit was used to produce larger scale DNA samples.  As detailed 
previously, 5 mL of bacterial culture was grown overnight and this culture was used to 
inoculate a 100 mL LB culture.  This was incubated for 16-18 hours at 37°C in a shaking 
incubator.  Bacteria were pelleted by centrifugation for 30 minutes at 3220 x g at 4°C.  The 
pellet was then resuspended in 10 mL of chilled buffer P1 (50 mM Tris-HCl pH 8.0, 10 
mM EDTA, 100 µg/mL Rnase A) by vortexing and the cells lysed by adding 10 mL of      54 
buffer P2 (200 mM NaOH, 1% (w/v) SDS) and incubating for 10 minutes at room 
temperature.  10 mL of buffer P3 (3.0 M potassium acetate, pH 5.5) was added to 
neutralise the reaction and the solution immediately applied to a Qiafilter cartridge.  This 
was left for 10 minutes at room temperature to incubate.  During this time a Qiagen tip 500 
was equilibrated by adding 10 mL of buffer QBT (750 mM NaCl, 50 mM MOPS, pH 7.0, 
15% (w/v) isopropanol).  The plunger was then inserted into the cartridge and the lysate 
filtered into the equilibrated tip.  The column was washed with 60 mL of buffer QC (1.0 M 
NaCl, 50 mM MOPS pH 7.0, 15% (w/v) isopropanol).  The DNA was eluted by adding 15 
mL of buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.0, 15% (w/v) isopropanol).  The 
DNA was precipitated by the addition of 10.5 mL isopropanol and the mixture centrifuged 
at 12,000 x g for 30 minutes at 4°C.  The pellet was washed in 5 mL of room temperature 
70% (w/v) ethanol and again centrifuged for 15 minutes at 12,000 x g for 30 minutes at 
4°C.  The supernatant was carefully removed and the pellet allowed to air dry prior to 
being re-suspended in 1 mL of sterile water. 
2.3.5  DNA quantification 
Quantification of DNA samples prepared was performed by examining the absorbance of a 
1:200 dilution of sample at 260nm.  A A260 of 1 unit was taken to correspond to 50 µg/mL 
of double stranded DNA. 
2.3.6  Digestion of DNA with restriction endonucleases 
Restriction digests of DNA were performed in order to prepare for sub-cloning of 
polymerase chain reaction (PCR) fragments or to ensure the successful ligation of a 
construct.  Digests were prepared in a final volume of 20 µL using restriction enzymes as 
directed for each individual enzyme.  Reactions were incubated at 37°C for a minimum of 
1 hour before being examined using DNA gel electrophoresis. 
2.3.7  DNA gel electrophoresis 
Digested DNA samples were examined using gel electrophoresis to ensure correct ligation 
of a construct.  This method was also used to isolate a plasmid vector.  Samples were 
mixed with 2x loading buffer.  A 1% (w/v) agarose gel was prepared by mixing agarose 
with 1x TAE buffer and heating until the agarose had melted.  2.5 µg/mL ethidium 
bromide was added to the gel and then poured into horizontal gel tanks.  The gel was left to      55 
set and then 1x TAE buffer added.  The samples were then loaded onto the gel and were 
run for 20 to 40 minutes under a voltage of 50 to 100V then visualised under ultraviolet 
light.  The sizes of the fragments were assessed by comparison with a 1Kb ladder. 
2.3.8  DNA purification from agarose gels 
DNA was purified from the gel by excising the band of interest and using the Qiaquick gel 
extraction kit in accordance with the manufacturer’s instructions.  Briefly, the DNA-gel 
fragment was dissolved in buffer QG by heating to 50°C.  One gel volume of isopropanol 
was added to the mix and the solution transferred to a Qiaquick column.  The DNA was 
bound to a column by centrifugation.  The sample was washed using buffer PE 
supplemented with ethanol and then eluted from the column using sterile water. 
2.3.9  Alkaline phosphatase treatment of plasmid vectors 
The 5’ phosphate group from plasmid vectors was removed by incubation of 200 ng of 
digested vector with 2 units of alkaline phosphatase for 1 hour at 37°C.  The treated 
plasmid was then isolated from the reaction mixture by agarose gel electrophoresis and gel 
extraction as described previously. 
2.3.10   DNA ligations 
Constructs were generated by ligating digested PCR fragments into plasmid vector using 
T4 DNA ligase.  For each construct a ratio of 1:3 and 1:6 of vector to PCR product was 
used in a volume of 20 µL.  1 µL of  ligase was used with 2 µL of ligase buffer and the 
reaction incubated at 4°C for least 16 hours.  The ligation reactions were transformed as 
detailed in section 2.3.3. 
2.3.11   Polymerase Chain Reaction 
PCR reactions were established in a volume of 50 µL containing 10 ng of template DNA, 
0.2 mM dNTPs (dATP, dCTP, dGTP, dTTP), 25 pM of sense and anti-sense 
oligonucleotide primers, 1x Pfu polymerase buffer and 1 unit of Pfu polymerase.  
Reactions were carried out on an Eppendorf gradient Thermocycler.  PCR cycles used 
were;       56 
1. Preheating     95°C    5 minutes 
2. Denaturation   95°C    1 minute 
3. Annealing    50-60°C   1 minute 
4. Extension    72°C    3 minutes  
Repeat from step 2/      29 × 
5. End      72°C    10 minutes 
6. Hold      4°C 
 
The annealing temperatures were determined depending on the Tm of the primers used for 
each PCR. 
2.3.12   QuikChange Mutagenesis PCR 
The QuikChange site-directed mutagenesis PCR reactions were established in a volume of 
50 µL containing: 50 ng DNA template, 15 pM of both forward and reverse primers, 0.2 
mM dNTPs  and 2.5 units of Pfu DNA polymerase.  Reactions were cycled 30 times in an 
Eppendorf gradient Thermocycler system. PCR cycles used were;  
  Cycle 1:   95
oC for 30 seconds 
  Cycles 2-30:   95
oC for 30 seconds,  
50
oC for 1 minute  
68
oC for 1 minute per kbp of plasmid length 
The product was treated with 1µl DpnI restriction enzyme and incubated for 60 minutes at 
37
oC.  The digested mutated DNA and control were then transformed following the 
protocol described in section 2.3.3. 
2.4  Generation of constructs 
Wild-type human RGS4 was used as a PCR template for all RGS4 constructs. 
2.4.1  RGS4-GFP
2 
Primers were designed to amplify RGS4 and remove the stop codon;        57 
Sense 5’ -GGA TCC GCC ACC ATG TAT CCC TAC GAC GTC CCC GAT TAT GCG 
TGC AAA GGG CTT GCA GGT CTG CC-3’  
Anti-sense 5’ -AAA TCT AGA GGC ACA CTG AGG GAC CAG GG- 3’ 
The BamHI and XbaI sites present in the sense and anti-sense primers respectively are 
shown underlined.  The amplified fragment was digested and ligated into pcDNA3.  This 
construct was then digested with KpnI and ApaI and ligated in frame with GFP
2 into the 
vector pGFP
2-N1. 
2.4.2  GST-RGS4-GFP
2 
Primers were designed to amplify RGS4-GFP
2;    
Sense 5’ -GGA TCC GCC ACC ATG TAT CCC TAC GAC GTC CCC GAT TAT GCG 
TGC AAA GGG CTT GCA GGT CTG CC- 3’ 
Anti-sense 5’ -TTT TCC TTT TGC GGC CG CTT ACT TGT ACA GCT CGT CCA TGC 
CGA GAG T- 3’ 
The BamHI and NotI sites present in the sense and anti-sense primers respectively are 
shown underlined.  The amplified fragment was digested and ligated downstream of GST 
into the vector pGEX-6P1.  
2.4.3  RGS4-eYFP in pcDNA3 
Primers were designed to amplify RGS4 and remove the stop codon;  
Sense 5’ -GGA TCC GCC ACC ATG TAT CCC TAC GAC GTC CCC GAT TAT GCG 
TGC AAA GGG CTT GCA GGT CTG CC- 3’   
Anti-sense 5’ -AAA TCT AGA GGC ACA CTG AGG GAC CAG GG- 3’   
The BamHI and XbaI sites present in the sense and anti-sense primers respectively are 
shown underlined.  The amplified fragment was digested and ligated upstream and in 
frame with eYFP into the vector pcDNA3.      58 
2.4.4  RGS4
N88S-e-YFP 
Primers were designed to amplify RGS4
N88S and remove the stop codon;  
Sense 5’ -GGA TCC GCC ACC ATG TAT CCC TAC GAC GTC CCC GAT TAT GCG 
TGC AAA GGG CTT GCA GGT CTG CC- 3’   
Anti-sense 5’ -AAA TCT AGA GGC ACA CTG AGG GAC CAG GG- 3’  
The BamHI and XbaI sites present in the sense and anti-sense primers respectively are 
shown underlined.  The amplified fragment was digested and ligated upstream and in 
frame with eYFP into the vector pcDNA3. 
2.4.5  RGS4
N128A-eYFP 
Primers were designed to amplify RGS4
N128A and remove the stop codon;  
Sense 5’ -GGA TCC GCC ACC ATG TAT CCC TAC GAC GTC CCC GAT TAT GCG 
TGC AAA GGG CTT GCA GGT CTG CC- 3’   
Anti-sense 5’ -AAA TCT AGA GGC ACA CTG AGG GAC CAG GG- 3’  
The BamHI and XbaI sites present in the sense and anti-sense primers respectively are 
shown underlined.  The amplified fragment was digested and ligated upstream and in 
frame with eYFP into the vector pcDNA3. 
2.4.6  RGS4
N88SN128A-eYFP 
Primers were designed to amplify RGS4
N88SN128A and remove the stop codon;  
Sense 5’ -GGA TCC GCC ACC ATG TAT CCC TAC GAC GTC CCC GAT TAT GCG 
TGC AAA GGG CTT GCA GGT CTG CC- 3’ 
Anti-sense 5’ -AAA TCT AGA GGC ACA CTG AGG GAC CAG GG- 3’      59 
The BamHI and XbaI sites present in the sense and anti-sense primers respectively are 
shown underlined.  The amplified fragment was digested and ligated upstream and in 
frame with eYFP into the vector pcDNA3. 
2.4.7  TRHR-1-Gα α α α11
G188S 
Primers were designed to amplify rat TRHR-1 and remove the stop codon;  
Sense 5’ -AAA GGT ACC ATG GAG AAT GAA ACC GTC AGT- 3’   
Anti-sense 5’ -AAA GGT ACC TGT TTT CTC CTG TTT GGC- 3’ 
 The KpnI sites present in the sense and anti-sense primers respectively are shown 
underlined.  The amplified fragment was digested and ligated upstream and in frame with 
Gα11
G188S into the vector pcDNA3. 
2.4.8  GST-RGS4
S30C 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30C mutation in GST-RGS4 in the vector pGEX-6P1;  
Sense 5’ -GGT TTC CTG CAA AAA TGT CAT TCC TGT GAA CAC AAT TCT TCC- 
3’  
Anti-sense 5’ -GGA AGA ATT GTG TTC ACA GGA ATC ACA TTT TTG CAG CAG 
GAA ACC- 3’   
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21 competent cells.  
2.4.9   RGS4
S30C-eYFP  
Primers were designed to amplify RGS4
S30C and remove the stop codon;  
Sense 5’ -GGA TCC GCC ACC ATG TAT CCC TAC GAC GTC CCC GAT TAT GCG 
TGC AAA GGG CTT GCA GGT CTG CC- 3’       60 
 Anti-sense 5’ -AAA TCT AGA GGC ACA CTG AGG GAC CAG GG- 3’  
The BamHI and XbaI sites present in the sense and anti-sense primers respectively are 
shown underlined.  The amplified fragment was digested and ligated upstream and in 
frame with eYFP into the vector pcDNA3. 
2.4.10   GST-RGS4
S30A 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30A mutation in GST-RGS4 in the vector pGEX-6P1;  
Sense 5’ -GGT TTC CTG CAA AAA GCT GAT TCC TGT GAA CAC- 3’   
Anti-sense 5’ -GTG TTC ACA GGA ATC AGC TTT TTG CAG CAG GAA ACC- 3’  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21competent cells.  
2.4.11   RGS4
S30A – eYFP 
Primers described in section 2.4.11 were designed to synthesise two complimentary 
oligonucleotides containing the 
S30A mutation in RGS4-eYFP in the vector pcDNA3.  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into XL1- competent cells.  
2.4.12   GST-RGS4
S30E 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30E mutation in GST-RGS4 in the vector pGEX-6P1;  
Sense 5’ -GGT TTC CTG CAA AAA GAG GAT TCC TGT GAA CAC- 3’   
Anti-sense 5’ -GTG TTC ACA GGA ATC AGC TTT TTG CAG CAG GAA ACC- 3’  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21competent cells.       61 
2.4.13   RGS4
S30E –eYFP 
Primers described in section 2.4.12 were designed to synthesise two complimentary 
oligonucleotides containing the 
S30E mutation in RGS4-eYFP in the vector pcDNA3.  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into XL1-blue competent cells.  
2.4.14   GST-RGS4
S30F 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30F mutation in GST-RGS4 in the vector pGEX-6P1;  
Sense 5’ -GGT TTC CTG CTG CAA AAA TTC GAT TCC TGT GAA CAC AAT TCT 
TCC- 3’   
Anti-sense 5’ –GGA AGA ATT GTG TTC ACA GGA ATC AAG TTT TTG CAG CAG 
GAA ACC- 3’  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21competent cells.  
2.4.15   RGS4
S30F –eYFP 
Primers described in section 2.4.15 were designed to synthesise two complimentary 
oligonucleotides containing the 
S30F mutation in RGS4-eYFP in the vector pcDNA3.  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into XL1-Blue competent cells.  
2.4.16   GST-RGS4
S30K 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30K mutation in GST-RGS4 in the vector pGEX-6P1;  
Sense 5’ -GGT TTC CTG CTG CAA AAA AAA GAT TCC TGT GAA CAC AAT TCT 
TCC- 3’        62 
Anti-sense 5’ –GGA AGA ATT GTG TTC ACA GGA ATC TTT TTT TTG CAG CAG 
GAA ACC- 3’  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21 competent cells.  
2.4.17   RGS4
S30K –eYFP 
Primers described in section 2.4.17 were designed to synthesise two complimentary 
oligonucleotides containing the 
S30K mutation in RGS4-eYFP in the vector pcDNA3.  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into XL1-Blue competent cells.  
2.4.18   GST-RGS4
S30P 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30P mutation in GST-RGS4 in the vector pGEX-6P1;  
Sense 5’ -GGT TTC CTG CTG CAA AAA CCT GAT TCC TGT GAA CAC AAT TCT 
TCC- 3’   
Anti-sense 5’ –GGA AGA GTG TTC ACA GGA ATC GGA TTT TTG CAG CAG GAA 
ACC- 3’  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21competent cells. 
2.4.19   RGS4
S30P –eYFP 
Primers described in section 2.4.19 were designed to synthesise two complimentary 
oligonucleotides containing the 
S30P mutation in RGS4-eYFP in the vector pcDNA3.  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into XL1-Blue competent cells.       63 
2.4.20   GST-RGS4
S30M 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30M mutation in GST-RGS4 in the vector pGEX-6P1;  
Sense 5’ -GGT TTC CTG CAA AAA ATG GAT TCC TGT GAA CAC AAT TCT TCC- 
3’   
Anti-sense 5’ –GGA AGA ATT GTG TTC ACA GGA ATC TAC TTT TTG CAG CAG 
GAA ACC- 3’  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21competent cells.  
2.4.21  RGS4
S30M –eYFP 
Primers described in section 2.4.20 were designed to synthesise two complimentary 
oligonucleotides containing the 
S30M mutation in RGS4-eYFP in the vector pcDNA3.  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into XL1-Blue competent cells.  
2.4.22   GST-RGS16
S30C 
Primers were designed to synthesise two complimentary oligonucleotides containing the 
S30C mutation in GST-RGS16 in the vector pGEX-6P1;  
Sense 5’ - CTT TCT TCA CAA ATG TGA GCT GGG CTG- 3’   
Anti-sense 5’ –CGC AGC CCA GCT CAC ATT TGT GAA GAA AG- 3’  
Following temperature cycling the product was treated with DpnI to digest parental DNA 
and transformed into BL21competent cells.       64 
2.5  Cell culture 
2.5.1  Cell maintenance 
2.5.1.1  Human Embyonic Kidney Cells (HEK293T) 
HEK293T cells were grown in 75 cm
2 flasks in Dulbecco’s modified Eagle’s medium 
containing 10% (w/v) newborn calf serum and 2 mM L-glutamine.  The cells were 
maintained in a humidified incubator of 95% air / 5% CO2 at 37°C. 
2.5.1.2  EF88 cells 
EF88 cells were grown in 75 cm
2 flasks in Dulbecco’s modified Eagle’s medium 
containing 10% (w/v) fetal calf serum and 2 mM L-glutamine.  The cells were maintained 
in a humidified incubator of 95% air / 5% CO2 at 37°C. 
2.5.2  Cell subculture 
Once confluent, cells were sub-cultured by the addition of sterile 0.25% (w/v) trypsin-
EDTA solution.  The medium was removed from the flask and 2 mL of trypsin solution 
added.  The flask was gently rotated to cover the monolayer and replaced in the incubator 
for 3 minutes.  Once the cells had detached, 3 mL of fresh medium was added to the flask 
and the cells resuspended by gently pipetting.  The cells were then subcultured into either 
75 cm
2 flasks to maintain the cell line or 10 cm
2 dishes for transfection. 
2.5.3  Transient transfection of HEK293T cells 
Transfection of HEK293T cells was performed when the cells had reached 60-70% 
confluency.  Plasmid DNA was transfected using Lipofectamine in accordance with the 
manufacturer’s instructions.  Plasmid DNA was diluted to 0.1 µg/µL and the volume 
adjusted corresponding to the amount of DNA to be transfected and was transferred to a 15 
mL tissue culture tube.  A volume of Optimem was added in order to bring the volume in 
the tube to 600 µL.  A mix of Lipofectamine and Optimem was prepared in the ratio of 20 
µL Lipofectamine and 580 µL Optimem for each sample.  600 µL of this mix was gently 
added to the DNA mix and incubated for 30 minutes.  During this time the cells were 
washed with Optimem.  Following the incubation period, 4.8 mL of Optimem was added      65 
to the sample tubes and the mix transferred onto the cells.  The cells were returned to the 
incubator for 4-5 hours before removing the transfection mix and replacing with fresh 
media.  The media was changed 24 hours later and the cells harvested approximately 36 
hours post-transfection.  A similar protocol was used for transfection in a 6-well plate, 
however, the ratio of Lipofectamine to Optimem was 1:29. 
2.5.4  Pertussis toxin treatment 
P. tox is secreted by Bordella pertussis. This toxin catalyses the addition of ADP-ribose to 
the α subunit of Gi and prevents receptor activation of the G protein. Transiently 
transfected cells were treated with P. tox (25 ng/ml) for 16 to 18 hours prior to harvesting.  
2.5.5  Transient transfection of EF88 cells 
Transient transfection of EF88 cells was performed using the cell line nucleofection kit V 
when cells were in their logarithmic growth phase.  1x10
6 cells per nucleofection were 
resuspended in 100 µL room temperature Nucleofector Solution. This suspension was 
mixed with 1-5 µg plasmid DNA.  The sample was transferred into a cuvette and inserted 
into an Amaxa nucleofector and programme 20 selected.  500 µL of pre-warmed medium 
was added to the cuvette and transferred to 6 well plates containing 1.5 mL medium.  Cells 
were incubated in a humidified incubator with 95% air / 5% CO2 at 37°C.  Cells were used 
24 hours post nucleofection. 
2.5.6  Cell harvesting 
Transfected cells were harvested 36 hours post-transfection.  The media was removed and 
the cells washed 3 times in 1x PBS.  Cells were scraped off the dish in 5 mL of 1x PBS 
using a cell scraper and transferred to a 15 mL centrifuge tube.  The dish was washed again 
in 5 mL 1x PBS to remove additional cells before centrifuging the harvested cells for 5 
minutes at 201 x g at 4ºC.  The PBS was removed and the cell pellet frozen at -80ºC      66 
2.6  Protein biochemistry and other methods of analysis 
2.6.1  Cell membrane preparation 
Cell pellets from transfected cells were thawed and resuspended in 1 mL of TE 
(membrane) buffer.  The cells were homogenised using 40 strokes of a glass on Teflon 
homogeniser.  The cells were centrifuged at 1500 x g for 10 minutes in order to separate 
any unbroken cells and nuclei at 4ºC.  The supernatant was removed and passed through a 
25 gauge needle 10 times before being transferred to ultra-centrifuge tubes and subjected 
to centrifugation at 50,000 x g for 30 minutes using a Beckman Optima TLX 
Ultracentrifuge (Palo Alto, CA).  The supernatant was discarded and the pellet resuspended 
in 200 µL of TE buffer using a 25 gauge needle, passing through 10 times to ensure an 
even suspension.  The protein concentration was assessed using a BCA assay (see below 
2.6.2) and membranes diluted to 1 µg/µL and stored at – 80 ºC until required. 
2.6.2  BCA protein quantification 
Protein concentration of membrane preparations was assessed using a Bicinhoninic acid 
(BCA) assay.  This assay utilises BCA and copper sulphate solutions in which peptide 
bonds reduce the Cu
2+ ions to Cu
+ ions in correlation with protein concentration initiating a 
colour change caused by BCA binding reduced Cu
+.  This coloured solution has an 
absorption maximum of 562 nm, allowing quantification of the protein concentration.  A 
standard curve is also established using standard BSA solutions allowing the 
concentrations of unknown samples to be established.  Solutions used consisted of;  
reagent A – bicinchoninic acid solution and reagent B –  4% (w/v)CuSO4.  1 part reagent A 
was mixed with 49 parts reagent B and 200 µL of this solution was added to 10 µL of 
protein standard or unknown sample in a 96 well ELISA plate.  The assay was incubated at 
37ºC for 25 minutes before reading the absorbance. 
2.6.3  SDS-PAGE and western blotting 
Protein samples were resolved using SDS-PAGE.  Precast Novex Bis-tris gels were used at 
4-12% (w/v) acrylamide concentration.  NuPage MOPS running buffer was used for 
electrophoresis using the Xcell Surelock mini-cell gel tank apparatus.  The gels were run at 
200V for approximately 45 minutes.  The proteins were transferred onto nitrocellulose      67 
membrane using the XCell II blot module apparatus.  The membrane and components of 
the transfer apparatus were soaked in transfer buffer (0.2 M glycine, 25 mM Tris and 20% 
(w/v) methanol) before initiating transfer.  Proteins were transferred at 30V for 
approximately 1 hour.  Efficient transfer was investigated by staining with Ponceau stain 
(0.1% (w/v) Ponceau S, 3% (w/v) trichloroacetic acid).  In order to block non-specific 
binding sites, membranes were incubated in 5% (w/v) low fat milk, 0.1% (w/v) Tween 
20/PBS (w/v) solution at room temperature on a rotating shaker for 2 hours.  The 
membrane was incubated with primary antibody overnight in 5% (w/v) low fat milk, 0.1% 
(w/v) Tween 20/PBS solution at 4ºC.  Approximately 16 hours later the membrane was 
washed three times with 0.1% (w/v) Tween 20/PBS for 5 minutes each wash.  The 
secondary antibody which was horseradish peroxidase linked was incubated again in 5% 
(w/v) low fat milk, 0.1% (w/v) Tween 20/PBS solution for 1 hour at room temperature.  
Again the membrane was washed three times in 0.1% (w/v) Tween 20/PBS for 5 minutes 
each wash prior to application of ECL solution and developing of the blot.  The 
membranes were exposed to blue Kodak film and developed using an X-Omat machine.   
2.6.4  Purification of GST-tagged proteins 
The cloning vector PGEX-6P1containing the appropriate cDNA fused to glutathione S-
transferase were transformed in BL21 bacteria and the bacteria  were grown up until 
reaching an optical density at 600 nm of 1.0. Cell pellets were lysed by resuspending in 20 
mL of 1x PBS (with protease inhibitors) containing 0.5 mg/mL lysozyme followed by 
incubation at 4°C with rotation for 1 hour. The resuspended cells were sonicated for 1 
minute each on ice. DTT was added to a final concentration of 5 mM and Triton X-100 (as 
a 10% (w/v) stock) to a final concentration of 1% (w/v). The lysates were then incubated at 
4°C with rotation for 1 hour, and the insoluble material was removed by centrifugation at 
12,000 x g for 15 minutes at 4°C. 500 µL of a suspension of washed (three times with 10 
volumes of 1x PBS with protease inhibitors) glutathione Sepharose 4B beads was added to 
each cleared lysate and incubated at 4°C overnight with rotation. The lysates were spun at 
500 x g for 5 minutes at 4°C, and the supernatant was removed from the pellet of 
glutathione Sepharose beads. The beads were washed three times with 10 mL of 1x PBS 
with protease inhibitors, and the GST fusion proteins were eluted with 5 x 1.5 mL of 
glutathione solution (10 mM concentration of reduced glutathione in 50 mM Tris-HCl, pH 
8.0). The eluted proteins were analyzed by SDS-PAGE and BCA protein assay before 
being dialyzed against three changes of 1x PBS containing 5% (w/v) glycerol at 4°C over 2 
days before storage at -80°C.       68 
2.6.5  Fixed cell samples 
Cells grown on coverslips were transiently transfected and washed three times with ice-
cold 1x PBS.  Cells were fixed for 10 minutes at room temperature using 4% (w/v) 
paraformaldehyde in PBS/5% (w/v) sucrose solution.  The cells were washed a further 
three times in ice-cold 1x PBS prior to being fixed onto microscope slides with 40% (w/v) 
glycerol in PBS. 
2.7  Assays 
2.7.1  Radioligand binding 
2.7.1.1  [
3H]prasozin binding 
The expression of α1b-adrenoceptor was assessed using [
3H]prasozin. This was performed 
in 96 well deepwell plates in triplicate. Total binding was initiated by adding 2 µg protein 
to 50µL [
3H]prasozin (4 nM-0.05 nM) and 100µL TEM.  Non-specific binding was 
initiated by adding 2 µg protein, to 50 µL [
3H]prasozin (4 nM-0.05 nM), 50 µL 100 µM 
phentolamine and 50 µL TEM.  Reactions were incubated for 40 minutes at 25°C. Bound 
ligand was separated from free by vacuum filtration through GF/B filters. The filters were 
pretreated with 0.3% (w/v) polyethyleneimine in TEM and washed three times with cold 
TE. Bound ligand was estimated by liquid scintillation spectroscopy. The specific binding 
was calculated by subtracting non-specific binding from total binding. Data were analysed 
using GraphPad Prism software (San Diego, CA). Saturation data were fitted to non-linear 
regression curves. 
2.7.1.2   [
3H]RS-79948-197 binding 
The expression of α2a-adrenoceptor was assessed using [
3H]RS-79948-197.  This was 
performed in 96 deepwell plates in triplicate. Total binding was initiated by adding by 1 µg 
protein to 50 µL [
3H]RS-79948-197 (5 nM-0.05 nM) and 100 µL TEM.  Non-specific 
binding was initiated by adding 2 µg protein, to 50 µL [
3H]RS79948-197 (4 nM-0.05 nM), 
50 µL 100 µM idozoxan and 50 µL TEM.  The same protocol as 2.7.1.1 was followed 
except that the samples were incubated for 30 minutes at 30°C.      69 
2.7.2   High-affinity GTPase assay 
This assay was used to measure release of  
32Pi from [γ-
32P]GTP.  The reaction mixture 
contained 0.5 µM [γ-
32P]GTP (≈50,000cpm), 1 mM AppNH, 1 mM ATP, 1 mM ouabain, 
10 mM creatine phosphate, 5 units creatine phosphokinase, 100 mM NaCl, 5 mM MgCl2, 2 
mM DTT, 0.1 mM EDTA, 12.5 mM Tris-HCl and 50 µM GTP.  50 µL of assay mix was 
added to deep well plates with 2 µg of protein, 1 µM purified GST-RGS protein and the 
final volume adjusted to 100 µL with dH2O.  Basal rate was determined in the same 
conditions but in the presence of 100 µM GTP.  The reaction was initiated by transferring 
the block to a 37°C water bath for 30 minutes.  Once the incubation was complete the 
blocks were immersed in an ice bath and 0.9 mL of 20 mM phosphoric acid (pH 2.3) 
containing 5% (w/v) activated charcoal was added.  After centrifugation for 10 minutes at 
3220 x g, radioactivity was measured in 300 µL of the supernatant using a Packard 
Topcount NXT™ microplate scintillation counter.  All assays were performed on at least 
three membrane preparations derived from different transient transfections. Data expressed 
as the mean ±  standard error of the mean (SEM). 
High affinity GTPase assays were plotted to determine the Km and Vmax of RGS4.  Km and 
Vmax are determined by incubating the RGS4 with varying concentrations of substrate 
(GTP) and plotting the results as a graph of rate of reaction (V) against concentration of 
substrate ([S]), which will normally yield a hyperbolic curve, as shown in Figure 3.3. 
The relationship of this curve is defined by the Michaelis-Menten equation: 
v = Vmax / (1 + (Km/[S])) 
It can be difficult to fit the best hyperbola through the experimental points, and difficult to 
determine Vmax with any precision by estimating the limit of the hyperbola at infinite 
substrate concentration. A number of ways of re-arranging the Michaelis-Menten equation 
have been devised to obtain linear relationships which permit more precise fitting to the 
experimental points, and estimation of the values of Km and Vmax. 
The Eadie-Hofstee plot rearranges the Michaelis-Menten equation as: 
v = Vmax - Km x v / [S]      70 
plotting v against v / [S] to give a straight line as in Figure 3.4.  In this graph, the y 
intercept is the Vmax , the gradient is the -Km , and the x intercept is the Vmax / Km.  This plot 
overcomes the problem of uneven spacing of points, and undue weight given to points at 
low concentrations of substrate. However, it has the disadvantage that V, which is a 
dependent variable, is used on both axes, and hence errors in measuring the rate of reaction 
are multiplied, resulting in lower precision of the estimates of Km and Vmax. 
2.7.3   [
35S]GTPγ γ γ γS binding assay 
[
35S]GTPγS binding experiments were initiated by the addition of membranes containing 
between 50 and 100 fmol of receptor-G protein fusion construct to an assay buffer (20 mM 
HEPES pH 7.4, 3 mM MgCl2, 100 mM NaCl, 1 µM GDP, 0.2 mM ascorbic acid, 50 nCi 
[
35S]GTPγS) containing the indicated concentrations of receptor ligands. Non-specific 
binding was determined in the same conditions but in the presence of 100 µM GTPγS. 
Reactions were incubated for 15 minutes at 30°C and were terminated by the addition of 
0.5 mL of ice-cold buffer, containing 20 mM HEPES pH 7.4, 3 mM MgCl2 and 100 mM 
NaCl. The samples were centrifuged at 16,000 × g for 15 minutes at 4°C, and the resulting 
pellets were resuspended in solubilisation buffer (100 mM Tris, 200 mM NaCl, 1 mM 
EDTA, 1.25% (w/v) Nonidet P-40) plus 0.2% (w/v) SDS. Samples were precleared with 
Pansorbin followed by immunoprecipitation with an antiserum directed towards the C-
terminal of the G protein. Finally, the immunocomplexes were washed twice with 
solubilisation buffer, and bound [
35S]GTPγS estimated by liquid-scintillation spectrometry. 
2.7.4   [Ca
2+]i imaging 
2.7.4.1  Single cell [Ca
2+]i imaging 
Transfected cells were loaded with the Ca
2+sensitive dye Fura-2 by incubation for 20 
minutes at 37°C under reduced light in growth medium containing the dye's membrane-
permeant acetoxymethyl
 ester form (1.5 µM). Loaded cells were transferred to HEPES 
buffer and illuminated with an ultra
 high point intensity 75-watt xenon arc lamp 
(Optosource, Cairn
 Research, Faversham, Kent, UK) and subsequently imaged using a
 
Nikon Diaphot inverted microscope equipped with a Nikon 40× oil
 immersion Fluor 
objective lens (NA=1.3) and a monochromator
 (Optoscan, Cairn Research), which was 
used to alternate the excitation
 wavelength between 340/380 nm and to control the 
excitation band
 pass (340 nm band pass=10 nm;  380 nm band pass=8 nm). Fura-2
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fluorescence emission at 510 nm was monitored using a high resolution
 interline-transfer 
cooled digital CCD camera (Roper
 Scientific/Photometrics, Tucson, AZ). MetaFluor 
imaging software
 (version 4.6.8, Universal Imaging Corp., Downing, PA) was used
 for 
control of the monochromator, CCD camera, and for processing
 of the cell image data. 
Sequential images (2×2 binning) were
 collected every 2 seconds;  exposure to excitation 
light was 100ms/image.  Agonist was added after 60 seconds for 60 seconds using a 
perfusion system.  Sequential images were collected for a total of five minutes and 
MetaFluor software was used for analysis.  Pooled average ratio
 values measured from 
single cells were expressed as
 the mean ± SEM of at least 10 cells. 
2.7.5  Fluorescence microscopy 
2.7.5.1  Multiple fluorescence imaging  
Paraformaldehyde fixed HEK293T cells, expressing the appropriate fusion protein were 
imaged using an inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), 
oil-immersion Plan Fluor Apochromat lens and a CCD camera. Fluorescence
 excitation 
light was generated by an ultra high point intensity 75-watt xenon arc lamp coupled to a 
computer controlled Optoscan monochromator.  
To visualize the plasma membrane, cells were treated, (as specified by the manufacturer), 
with the reagents in the Image-iT™ plasma membrane and nuclear labelling kit, in which 
the plasma membrane is specifically labelled with wheat germ agglutinin (WGA)-Alexa 
Fluor 594 (red) and nuclei are stained simultaneously with Hoechst 33342 (blue).  The 
monochromator was set to 360/10, 500/8 nm and 575/12 nm for the sequential excitation 
of Hoechst, eYFP and WGA-Alexa Fluor 594 respectively. Hoechst, eYFP and Alexa 
Fluor 594 excitation light was reflected through the objective lens using the following 
single pass dichroics: 400DCLP for Hoechst, Q515LP for eYFP and Q595LP for Alexa 
Fluor 594. Hoechst, eYFP and fluorescence emission was controlled
 via a high-speed 
filterwheel device (Prior Instruments, MA, USA) containing the following emitters: 
HQ480/40 nm for Hoechst;  HQ535/30 nm for eYFP, and HQ645/75 nm for WGA-Alexa 
Fluor 594. Using these filter sets, the fluorophores were easily separated
 with no bleed 
through. Sequential 12 bit images, (2 x 2 binning, 200-400 milli-second exposure/image), 
were collected using a CCD camera operated in 12-bit mode.
 Computer control of all 
electronic hardware and camera acquisition was
 achieved using Metamorph software.       72 
2.7.5.2  Multiple fluorescence analysis 
The plasma membrane was identified and segmented into pixels by treating the cells with 
the membrane marker WGA-Alexa Fluor 594. Images were deconvolved using an iterative 
and constrained algorithm (Autodeblur software, version 9.3.6, Autoquant Imaging, 
Watervliet, NY).  Surface and cytosolic masks were created and superimposed. Expressed 
RGS-eYFP fluorescence pixel intensity values
 located at the plasma membrane and 
cytoplasm of
 the cell were quantified from each generated mask and were expressed as a 
percentage of the total eYFP intensity. The number of cells analysed from each 
experimental group was 3 and the statistical significance of any difference between mean
 
values was determined using a Student's t
 test.    73 
3    Chapter 3 
3.1  Introduction 
The intracellular localisation of RGS proteins is crucial for their regulatory action.  A 
commonly used fluorescent tag was introduced to RGS4 in order to investigate this 
localisation.  It was particularly important to establish that the presence of this fluorescent 
protein did not interfere with functional activity of RGS4.  
Green fluorescent protein (GFP) has become a valuable tool in the study of cellular 
localisation of proteins (Cubitt et al., 1995;Baumann et al., 1998).  GFP is an auto-
fluorescent protein of 27 kDa from the jellyfish Aequoria victoria.  Fusing the protein of 
interest to GFP allows direct visualisation of the protein in living cells without the need for 
immunocytochemistry. Several modified variants of GFP with distinct spectral properties 
have been isolated (Htun et al., 1996;Stauber et al., 1998).  One such variant, GFP
2, was 
originally developed to maximally absorb the energy released by the oxidation of the 
substrate DeepBlueC by Renilla luciferase for use in Bioluminescence Resonance Energy 
Transfer
2 (Packard Bioscience), a methodology widely used to study
 protein-protein 
interactions (Jensen et al., 2002;Ramsay et al., 2002).    
A red-shifted variant of GFP that has also been widely used in research is enhanced yellow 
fluorescent protein (eYFP). The spectral properties of eYFP allow a stronger fluorescence 
emission compared to wild-type GFP (Baumann et al., 1998).  Both GFP
2 and eYFP were 
individually ligated to the C-terminal of RGS4.   
The pGEX glutathione S-transferase (GST) system has been used extensively for high-
level expression of recombinant proteins (Smith and Johnson, 1988;Frangioni and Neel, 
1993). This previously successful strategy was therefore employed to produce recombinant 
RGS4 proteins.  RGS4 and RGS4-GFP
2 were inserted into the multiple cloning site of the 
pGEX plasmid, fusing the N-terminus of the predicted protein to GST.  GST, from the 
parasite Schistosoma japonicium, is a 26 kDa enzyme which binds reversibly but with high 
affinity to glutathione, allowing recombinant GST-RGS4 or GST-RGS4-GFP
2 to be 
purified.   
Functional activity of the recombinant RGS proteins was measured in high-affinity 
GTPase assays.  Such GTPase activity can be successfully measured by the use of fusion      74 
proteins between GPCRs and G protein α subunits.  In addition, the use of G protein α 
subunits mutationally modified to be resistant to P. tox-catalysed ADP-ribosylation (
C351I in 
Gαo1) allows the GTPase activity of the exogenous GPCR and G protein to be measured in 
isolation (Moon et al., 2001). The 1:1 stoichiometry of the GPCR to the Gα subunit in such 
fusion proteins permits ligand binding to determine the precise expression level of not only 
the receptor but also of the G protein.  The expression level and the measured GTPase 
activity allow the calculation of the turnover number of the G protein.  It has previously 
been published that transient expression of the α2A-adrenoceptor fused to Gαo1
C351I in cells 
with the subsequent addition of a recombinant RGS protein to cell membrane preparations, 
results in a concentration-dependent increase in the high-affinity GTPase activity (Bahia et 
al., 1998;Cavalli et al., 2000). Using this methodology the functional activity of 
fluorescently modified, recombinant RGS4 was compared to wild-type. 
Studies on the distribution patterns of RGS proteins have revealed diverse patterns of 
cellular localisation (Chatterjee and Fisher, 2000).  However, RGS proteins must 
ultimately localise near or at the plasma membrane in close proximity to G proteins to 
produce their effects as a GAP.  RGS4 has been reported to be located in the cytoplasm 
then translocated to the plasma membrane indirectly by G protein activation or by directly 
binding to G proteins at the plasma membrane.  Translocation of RGS4 to the plasma 
membrane has also been reported by co-expression of specific G proteins, or 
corresponding receptors that activate these specific G proteins (Roy et al., 2003).  
Defective G proteins, apparently unable to interact with RGS proteins, have also been 
reported conflictingly to be both able (Druey et al., 1998) and unable (Roy et al., 2003) to 
translocate RGS4 to the plasma membrane.  Following expression, immunoblotting and 
microscopy were used to study the intracellular localisation of RGS4-eYFP in the presence 
and absence of other co-expressed proteins. 
The aim of this chapter was to investigate the cellular localisation of transiently expressed 
RGS4 in HEK293T cells.  Confirmation that a fluorescent tag tethered to the C-terminal of 
RGS4 did not affect function was crucial before the levels of protein expression and the 
cellular localisation of RGS4 were investigated.      75 
3.2  Results 
3.2.1  Purification of recombinant RGS4 and RGS4-GFP
2 
Purified recombinant GST-fused proteins were resolved by SDS-PAGE and stained with 
Coomassie Blue.  Figure 3.1 shows similar induction and elution of purified (A) GST-
RGS4 and (B) GST-RGS4-GFP
2.  Quantitative evaluation of the pooled, eluted GST-fused 
proteins allowed determination of the concentration of each purified protein.  
3.2.2  Functional activity of recombinant RGS4 and RGS4-GFP
2 
In order to ensure that a C-terminal fluorescent tag on RGS4 did not disrupt the GAP 
activity of this RGS protein, it was important to compare the functional activity of the 
recombinant proteins.  Activity of GST-RGS4 and GST-RSG4-GFP
2 were compared using 
high-affinity GTPase assays. A fusion protein, in which the C-terminus of the porcine α2A-
adrenoceptor and the N-terminus of rat Gαo1, with a P. tox-insensitive mutation, were 
linked in frame was expressed in HEK293T cells.  Cells were pre-treated for 16 hours with 
an amount of P. tox (25 ng/mL) sufficient to cause ADP-ribosylation of endogenous P. tox-
sensitive G proteins (Wise et al., 1997b). The amount of transiently expressed α2A-
adrenoceptor-Gαo1
C351I fusion protein was routinely determined by performing saturation, 
specific binding studies using the α2-adrenoceptor antagonist [
3H]RS-79948-197 (Figure 
3.2). Levels of expression of the receptor-G protein varied between individual 
transfections, although typically were between 10-20 pmol/mg of membrane protein. 
High-affinity GTPase activity was then measured at a range of GTP concentrations in 
membranes of these cells (Figure 3.3).  Basal and adrenaline-stimulated (100 µM) GTPase 
activity were measured in the presence and absence of purified, recombinant RGS4 (1 
µM).  Non-linear regression analysis showed that in the absence of RGS4, adrenaline-
stimulated high-affinity GTPase was greater than basal activity. However, in the presence 
of RGS4 there was a strong enhancement of adrenaline-stimulated activity.   
To estimate the kinetic parameters (Km and
 Vmax) for RGS4, linear regression analysis was 
applied to determine the linear correlation
 between V and V/[GTP].  In this Eadie-Hofstee 
transformation (Figure 3.4), V is the rate of GTPase activity;  Vmax represents the 
maximum rate of GTPase activity and Km is the affinity constant of GTP (the slope of the 
line).  Analysis of basal and adrenaline-stimulated GTPase activity showed that the effect      76 
of adrenaline was to increase the Vmax without altering the Km for GTP (Table 3.1).  
However, addition of recombinant RGS4 (1 µM) to transfected membranes significantly 
increased adrenaline-stimulated Vmax of the α2A-adrenoceptor-Gαo1
C351I fusion protein and 
the Km for GTP (p<0.05).  These studies, as has been noted previously (Cavalli et al., 
2000), clearly show that RGS4 functioned as a GAP for the receptor-activated G protein as 
is reflected by an effect on both Vmax and Km.   
It should be noted however, that when assaying the relative increase in both Vmax and the 
Km for GTP of GST-RGS4, a more suitable experiment to show that the presence of RGS4 
was solely responsible for the increase in Vmax and Km would have been the addition of 
purified GST.  The control used here, no addition of a GST fusion protein, does not rule 
out the possibility that the presence of GST is somehow responsible for any differences in 
Vmax and Km . 
With knowledge of the levels of expression of the α2A-adrenoceptor-Gαo1
C351I fusion 
protein from [
3H]RS-79948-197 binding studies, adrenaline-stimulated GTPase turnover 
number was calculated to significantly increase from 2.3  ±  0.5 minute
-1 to 10.2  ± 1.2 
minute
-1 in the presence of 1 µM RGS4 (mean ± SEM, from three individual experiments, 
p<0.05). 
Following purification of recombinant RGS4-GFP
2, the GAP activity of this protein (0.8 
µM) was directly compared to wild-type recombinant RGS4 (0.8 µM).  Using 0.5 µM GTP 
as substrate, addition of a maximally effective concentration of the α2A-adrenoceptor 
agonist adrenaline (100 µM) (Carr et al., 1998) caused a parallel increase in high-affinity 
GTPase activity for both RGS4 and RGS4-GFP
2 (Figure 3.5).  Importantly, the turnover 
number for each GST-fusion proteins was not significantly different from each other 
(Figure 3.6) (p>0.05).  These studies indicate that GFP
2 attached to the C-terminus of 
RGS4 does not affect the GAP activity. 
3.2.3  Intracellular localisation of RGS4  
The intracellular localisation of RGS4 was examined by transfection of HEK293T cells 
with C-terminally eYFP-tagged RGS4. Figure 3.7 shows microscope images of cells 
transiently expressing RGS4-eYFP.  The blue colour (A) represents Hoechst 33342 DNA 
staining that was used to identify the nuclei in these cells. The green colour (B) represents 
eYFP fluorescence from expressed RGS4-eYFP.  The red colour (C) represents Wheat      77 
Germ Agglutinin (WGA) -Alexa Fluor 594 used to label the plasma membrane.  To 
identify any RGS4-eYFP localised at the plasma membrane, an overlay image is also 
shown (D).  In these overlay images a yellow colour represents RGS4-eYFP that is co-
localised with WGA-Alexa Fluor 594 at the plasma membrane.  These images clearly 
demonstrate that the vast majority of transiently transfected RGS4-eYFP in HEK293T 
cells is localised within the cytoplasm.   
These images were then used to compare the percentage redistribution of transiently 
expressed RGS4-eYFP fluorescence at the plasma membrane versus the cytoplasm. Images 
were deconvolved and the surface and cytosolic masks were created and superimposed. 
Total fluorescence pixel intensity values corresponding to eYFP located at the membrane 
and cytoplasm of the cell were quantified and were expressed as a percentage of the total 
fluorescent eYFP intensity.  This comparison confirmed that RGS4 in HEK293T cells is 
localised predominantly within the cytoplasm.  Figure 3.7(E) illustrates a significant 
difference (p<0.05) between fluorescence intensity of RGS4-eYFP within the cytoplasm 
(83.7 ± 2.0 %) compared to fluorescence intensity of RGS4-eYFP at the plasma membrane 
(16.3 ± 2.0%).  Using an antiserum specifically raised against RGS4, an immunoblot 
further demonstrated the predominant cytoplasmic localisation of transiently expressed 
RGS4-eYFP in HEK293T cells (Figure 3.7 (F)).   
3.2.4  Effect of G proteins on intracellular localisation of RGS4 
HEK293T cells endogenously express many G proteins including a number of P. tox-
sensitive subtypes such as Gαi1.  However, over-expressing exogenous Gαi1 has previously 
been shown to promote the translocation of RGS4 from the cytoplasm to the plasma 
membrane (Roy et al., 2003).  In this study, microscopy and immunoblotting of transiently 
co-transfected RGS4-eYFP and Gαi1 in HEK293T cells were used to confirm data by Roy 
et al., (2003) (Figure 3.8).  The overlay image of cells co-expressing both RGS4-eYFP and 
Gαi1 illustrates that over-expressing exogenous Gαi1 promotes the translocation RGS4-
eYFP from the cytoplasm to the plasma membrane in HEK293T cells. 
Figure 3.8 (D) shows the comparison of percentage eYFP fluorescence of transiently 
expressed RGS4-eYFP at the plasma membrane (38.6 ± 3.1%) and in the cytoplasm (61.4 
± 3.1 %) in the presence of exogenous Gαi1.  When compared to HEK293T cells 
transiently transfected with RGS4-eYFP alone (Figure 3.7 (E)), over-expression of Gαi1 in 
HEK293T cells was sufficient to cause translocation of ~22% of RGS4-eYFP to the      78 
plasma membrane.  Immunoblots using an antiserum raised against GFP, which also 
detects YFP, allowed comparison of RGS4-eYFP expression in both membrane and 
cytosolic fractions of HEK293T cells transiently co-transfected with Gαi1 (Figure 3.8(E)).  
When compared to the immunblot of HEK293T cells transiently transfected with RGS4-
eYFP alone, over-expression of exogenous Gαi1 clearly resulted in a translocation of 
RGS4-eYFP from the cytoplasm to the plasma membrane. 
Previous studies have shown that constitutively active forms of Gαi2 cause RGS4 to 
become localised at the plasma membrane (Druey et al., 1998;Roy et al., 2003).  The 
conservation of residues between Gαi2 and Gαi1 allowed the constitutive mutation to be 
transferred.  Figure 3.9 (A-E) shows transiently co-transfected RGS4-eYFP and the 
constitutively active G protein, Gαi1
Q204L, in HEK293T cells.  The co-localisation of 
RGS4-eYFP and WGA-Alexa Fluor 594 in the overlay image (Figure 3.9 (C)) illustrates 
that expression of Gαi1
Q204L promotes the translocation RGS4-eYFP from the cytoplasm to 
the plasma membrane in HEK293T cells.  In the presence of Gαi1
Q204L the percentage of 
RGS4-eYFP fluorescence at the plasma membrane was 57.3 ± 6.4% compared to RGS4-
eYFP fluorescence within the cytoplasm, 42.7 ± 6.4%.  Interestingly, the constitutively 
active G protein mutation increased the percentage of RGS4-eYFP fluorescence at the 
plasma membrane compared to wild-type Gαi1.  Figure 3.9 (E) shows an immunoblot of 
membrane and cytosolic fractions of HEK293T cells transiently co-transfected with RGS4-
eYFP and Gαi1
Q204L
.  Expression of Gαi1
Q204L resulted in translocation of RGS4-eYFP to 
the plasma membrane.  Again, the constitutively active G protein mutation increased the 
translocation of RGS4-eYFP to the plasma membrane compared to wild-type Gαi1  
It was thought perhaps that a greater expression of transiently transfected Gαi1
Q204L 
compared to Gαi1 could be responsible for the constitutively active G protein increasing the 
translocation of RGS4-eYFP to the plasma membrane.  Loading an equal volume of cell 
lysates transiently expressing Gαi1 (lane 2)
 or Gαi1
Q204L (lane 3), Figure 3.10 shows a 
greater intensity of the Gαi1 band compared to Gαi1
Q204L.  This suggests that the 
constitutively active G protein is expressed at lower levels when directly compared to 
expression of wild-type Gαi1.  The increased expression of Gαi1
Q204L is therefore not 
responsible for the increased translocation of RGS4-eYFP to the plasma membrane.  
Instead, properties of the constitutively active G protein must influence the translocation.  
Activation of Gαi1 by receptor is therefore not required for translocation of RGS4-eYFP 
from the cytoplasm to the plasma membrane in HEK293T cells, however constitutive 
activity of Gαi1 causes the translocation of RGS4-eYFP to be more distinct.      79 
3.2.5  Effect of receptors on cellular localisation of RGS4 
It has been reported that that co-transfection of both RGS4-GFP and the M2 muscarinic 
receptor promotes translocation of RGS4 to the plasma membrane (Roy et al., 2003).  
Receptors assist G protein activation and therefore may modulate RGS-G protein 
interaction.  The Gαi1 coupled, α2A-adrenoceptor was therefore co-transfected with RGS4-
eYFP in HEK293T cells and microscopy and immunoblotting were used to study the effect 
of the α2A-adrenoceptor expression on the cellular localisation of RGS4-eYFP (Figure 
3.11).  Microscopy images illustrate that RGS4-eYFP becomes localised to the plasma 
membrane in the presence of the α2A-adrenoceptor, in a similar pattern to the effect of the 
cognate G protein (Figure 3.11 (A), (B), (C)).  The majority of RGS4-eYFP fluorescence 
was still localised (p<0.05) within the cytosol (76.6 ± 2.4 %) (Figure 3.11 (D)).  However, 
~ 7% of total RGS4-eYFP was still translocated from the cytosol to the plasma membrane 
in the presence of the α2A-adrenoceptor when the percentage fluorescence of co-expressed 
RGS4-eYFP and the α2A-adrenoceptor (23.4 ± 2.4 %) were compared to RGS4-eYFP 
transfected alone (16.27 ± 2.05 %).  (Figure 3.11 (E)) clearly shows that there is an 
increase in RGS4-eYFP at the plasma membrane in the presence of the receptor.  RGS4-
eYFP is translocated from the cytosol to the plasma membrane in the presence of the α2A-
adrenoceptor but this translocation in HEK293T cells appears to be less than in the 
presence of Gαi1 (Figure 3.8 (D)).  This pattern of RGS4-eYFP translocation was also 
reflected in immunoblots of membrane and cytosolic cell lysate fractions.  Following co-
transfection of RGS4-eYFP and the α2A-adrenoceptor, immunoblots (Figure 3.11 (E)) 
showed an increase in the intensity RGS4-eYFP located in the membrane compared to 
when RGS4-eYFP was transfected alone (Figure 3.7 (F)) but less than when compared to 
co-transfection of RGS4-eYFP and Gαi1 (Figure 3.8 (E)).   
Agonist activation of the α2A-adrenoceptor with UK14304 (100 µM) was hypothesised to 
further activate the receptor and therefore cause a greater percentage translocation of 
RGS4-eYFP to the plasma membrane (Figure 3.12).  However, the overlay image (Figure 
3.12 (C)) showed no further co-localisation of RGS4-eYFP and the WGA-Alexa Fluor 
594-labelled plasma membrane marker.  Similarly, the percentage fluorescence showed no 
difference compared to unstimulated cells transfected with RGS4-eYFP and the α2A-
adrenoceptor; cytosolic RGS4-eYFP (22.4 ± 1.9%) and plasma membrane associated 
RGS4-eYFP (77.6 ± 1.9%).  The immunoblots also showed comparable intensity of the 
RGS4-eYFP in the membrane and cytosolic HEK293T cell lysates in agonist-activated      80 
α2A-adrenoceptor (Figure 3.12 (E)) and unstimulated α2A-adrenoceptor expressing cells 
(Figure 3.11 (E)).  Agonist-stimulation of the α2A-adrenoceptor did not further increase 
RGS4-eYFP translocation to the plasma membrane. 
These immunblots showing the relative fractions of RGS4 in the membrane and cytosolic 
fractions were not stripped and reprobed with appropriate marker proteins.  Reprobing with 
an antibody raised against a defined membrane and cytosolic protein would have more 
clearly defined the fractions as “membrane” or “cytosol” to show no cross contamination 
of samples. 
Measuring RGS4-eYFP fluorescence in HEK293T cell membranes further compared the 
effects of co-transfection of G protein, receptor and activated receptor on the cellular 
localisation of RGS4-eYFP.  Figure 3.13 shows the co-transfection of Gαi1 has the greatest 
percentage effect (235.4 ± 20.7%) on RGS4-eYFP translocation to the plasma membrane.  
The presence of the α2A-adrenoceptor or UK14304 (100µM) stimulated α2A-adrenoceptor 
translocated RGS4-eYFP to the plasma membrane to a similar degree; 169.9 ± 10.0%, 
152.8 ± 12.3% respectively. 
Again, however, with retrospect, it can be noted that a parallel data set to that of Figure 
3.13 should have been included, whereby eYFP was expressed with the indicated 
receptor/G protein.  This set of experiments would have conclusively shown that RGS4 
was solely responsible for the increase translocation of the fluorescent protein.      81 
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Figure 3.1 Coomassie Blue staining for purified GST-RGS4 and GST-RGS4-GFP
2  
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding (A) GST-RGS4 or 
(B) GST-RGS4-GFP
2.  GST-fused proteins were induced and purified and equal volumes 
of each induced fraction or purified elution fraction were resolved by SDS-PAGE and 
stained with Coomassie Blue. Induced cell lysates of BL21 bacteria before addition of 
glutathione sepharose beads (lane 1). Induced cell lysates of BL21 bacteria after incubation 
with glutathione sepharose beads (lane 2). Elution 1 (lane 3). Elution 2 (lane 4). Elution 3 
(lane 5). Elution 4 (lane 6). 
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Figure 3.2 Specific binding of [
3H]RS-79948-197  to the α2A-adrenoceptor-Gαo1
C351I 
fusion protein   
HEK293T cells were transfected to express the α2A-adrenoceptor-Gαo1
C351I fusion protein.  
Cells were treated with P.tox (25 ng/ml for 16 hours) and then membranes were prepared.  
Expression levels of the α2A-adrenoceptor-Gαo1
C351I fusion protein were detected by the 
binding of 0.00-3.4 nM [
3H]RS-79948-197 to 1 µg of membranes.  Non-specific binding 
was determined in the presence of 100 µM idozoxan in parallel assays.   Data shown are 
from triplicate determinations (mean ± SEM.) and are representative of six individual 
experiments performed. 
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Figure 3.3 GTPase activity in cell membranes expressing the α2A-adrenoceptor-
Gαo1
C351I fusion protein in the presence and absence of GST-RGS4 
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and then membranes 
prepared.  High-affinity GTPase activity in the absence (filled) or presence of 100 µM 
adrenaline (open) was measured at various concentrations of GTP in the presence (circles) 
or absence (squares) of GST-RGS4.  Data shown are from triplicate determinations and are 
representative of three individual experiments performed. 
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Figure 3.4  Kinetic analysis of GTPase activity in cell membranes expressing the α2A-
adrenoceptor-Gα α α αo1
C351I fusion protein in the presence and absence of GST-RGS4 
Data generated from Figure 3.3 shown in Eadie-Hofstee transformation to show Km and 
Vmax.  High-affinity GTPase activity in the absence (filled) or presence of 100 µM 
adrenaline (open) was measured at various concentrations of GTP in the presence (circles) 
or absence (squares) of GST-RGS4.  Data shown are from triplicate determinations and are 
representative of three individual experiments performed. 
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    Vmax 
(pmol/mg/min) 
Km 
(nM) 
Basal  7 ± 1  137 ± 49  No RGS 
+ Adrenaline 
(100 µM) 
36 ± 1 *  136 ± 7 
Basal  15 ± 1  325 ± 52  + 1 µM RGS4 
+ Adrenaline 
(100 µM) 
233 ± 13 *, **  843 ± 61*, ** 
 
 
Table 3.1 Enzyme kinetics of GAP activity of RGS4  
Data generated from Figure 3.4 are tabulated for comparison of enzyme kinetic results.  
Values of Vmax and Km are compared in the presence and absence of adrenaline (100 µM) 
and presence or absence of RGS4 (1 µM) in cell membranes expressing the α2A-
adrenoceptor-Gαo1
C351I fusion protein.  Data shown are mean ± SEM from three individual 
experiments. * Denotes significantly different from absence of agonist, p<0.05. ** Denotes 
significantly different from adrenaline-stimulated kinetics in absence of 1 µM RGS4, 
p<0.01. 
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Figure 3.5 Comparison of GAP activity of GST-RGS4 and GST-RGS4-GFP
2  
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P.tox (25 ng/ml for 16 hours) and then membranes 
prepared.  High-affinity GTPase activity (at 0.5 µM GTP) in the presence of 0.8 µM GST-
RGS4 or presence of 0.8 µM GST-RGS4-GFP
2 was measured in the absence (open bar) or 
presence of 100 µM adrenaline (filled bar). Data shown are mean ± SEM of three 
individual experiments performed. 
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Figure 3.6 Comparison of turnover number of Gαo1 in the presence of GST-RGS4 or 
GST-RGS4-GFP
2  
The turnover number of Gαo1 in the presence of GST-RGS4 (open bar) or GST-RGS4-
GFP
2 (filled bar) is shown.  The turnover number was calculated from expression level of 
the α2A-adrenoceptor-Gαo1
C351I fusion protein and the high-affinity GTPase activity of the 
GST fusion protein in these membranes.  Data shown are mean ± SEM. of three individual 
experiments performed. 
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Figure 3.7 The cellular localisation of RGS4-eYFP   
HEK293T cells grown on coverslips were transiently transfected with RGS4-eYFP and 
visualised with (A) Hoechst 33342 nuclei staining (blue) (B) RGS4-eYFP (green) or (C) 
WGA-Alexa Fluor 594 plasma membrane staining kit (red).  Images were colour combined 
to create merged images (D).  Results shown are of a single experiment and are 
representative of three experiments performed. 
(E) HEK293T transfected cells were also measured for RGS4-eYFP fluorescence intensity 
at the plasma membrane (open bar) and cytoplasm (closed bar). Images were deconvolved 
using an iterative and constrained algorithm.  Surface and cytosolic masks were created 
and superimposed and fluorescence pixel intensity values
 corresponding to RGS4-eYFP 
located at the plasma membrane and cytoplasm of
 the cell were quantified from each 
generated mask. Fluorescence was expressed as a percentage of the total RGS4-eYFP 
intensity using a mean of 3 cells ± SEM. Statistical significance was determined using a 
Student’s t test, * p<0.01. 
(F) Cells transiently transfected with RGS4-GFP
2 were separated into membrane (lane 1) 
and cytosolic (lane 2) fractions, resolved by SDS-PAGE and immunoblotted with an anti-
RGS4 antiserum.  Results shown are of a single experiment and are representative of three 
experiments performed. 
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Figure 3.8 The cellular localisation of RGS4-eYFP when co-expressed with Gαi1   
RGS4-eYFP is translocated to the plasma membrane when transiently co-transfected with 
Gαi1.  (A) HEK293T cells grown on coverslips transiently transfected with RGS4-eYFP 
and Gαi1.  (B) HEK293T cells grown on coverslips transiently transfected with RGS4-
eYFP and Gαi1 with WGA-Alexa Fluor 594 plasma membrane staining kit.  Images colour 
combined to create merged images (C).  Results shown are of a single experiment and are 
representative of three experiments performed. 
(D) HEK293T cells co-transfected with both RGS4-eYFP and Gαi1 were also measured for 
RGS4-eYFP fluorescence intensity at the plasma membrane (open bar) and cytoplasm 
(closed bar). Images were deconvolved using an iterative and constrained algorithm.  
Surface and cytosolic masks were created and superimposed and fluorescence pixel 
intensity values
 corresponding to RGS4-eYFP located at the plasma membrane and 
cytoplasm of
 the cell were quantified from each generated mask. Fluorescence was 
expressed as a percentage of the total RGS4-eYFP intensity using a mean of 3 
cells ± SEM. Statistical significance was determined using a Student’s t test, * p<0.01. 
(E) HEK293T cells transiently transfected with RGS4-eYFP and Gαi1
 were separated into 
membrane (lane 1) and cytosolic (lane 2) fractions and resolved by SDS-PAGE and 
immunoblotted with an anti-GFP antiserum.  Results shown are of a single experiment and 
are representative of three experiments performed. 
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Figure 3.9  The cellular localisation of RGS4-eYFP when co-expressed with Gαi1
Q204L 
RGS4-eYFP is translocated to the plasma membrane when transiently co-transfected with 
Gαi1
Q204L.  (A) HEK293T cells grown on coverslips transiently transfected with RGS4-
eYFP and Gαi1
Q204L.  (B) HEK293T cells grown on coverslips transiently transfected with 
RGS4-eYFP and Gαi1
Q204L with WGA-Alexa Fluor 594 plasma membrane staining kit.  
Images colour combined to create merged images (C).  Results shown are of a single 
experiment and are representative of three experiments performed. 
(D) HEK293T cells co-transfected with both RGS4-eYFP and Gαi1
Q204L were also 
measured for RGS4-eYFP fluorescence intensity at the plasma membrane (open bar) and 
cytoplasm (closed bar). Images were deconvolved using an iterative and constrained 
algorithm.  Surface and cytosolic masks were created and superimposed and fluorescence 
pixel intensity values
 corresponding to RGS4-eYFP located at the plasma membrane and 
cytoplasm of
 the cell were quantified from each generated mask. Fluorescence was 
expressed as a percentage of the total RGS4-eYFP intensity using a mean of 3 
cells ± SEM. Statistical significance was determined using a Student’s t test, * p<0.01. 
(E) HEK293T cells were transiently co-transfected with RGS4-GFP
2 and Gαi1
Q204L.  
Membrane (lane 1) and cytosolic (lane 2) fractions were separated and resolved by SDS-
PAGE and then immunoblotted with an anti-GFP antiserum.  Results shown are of a single 
experiment and are representative of three experiments performed. 
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Figure 3.10 Expression and immunological detection of Gαi1 and Gαi1
Q204L
  
HEK293T cells were transfected to transiently express Gαi1 (lane 2) or Gαi1
Q204L (lane 3).  
Untransfected HEK293T cell lysates were included as a control (lane1). Cell lysates were 
resolved by SDS-PAGE and then immunoblotted with an antiserum that identifies Gαi1.  
Results shown are of a single experiment and are representative of three experiments 
performed. 
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Figure 3.11 The cellular localisation of RGS4-eYFP when co-expressed with the α2A-
adrenoceptor   
RGS4-eYFP is translocated to the plasma membrane when transiently co-transfected with 
RGS4-eYFP and α2A-adrenoceptor.  (A) HEK293T cells grown on coverslips transiently 
transfected with RGS4-eYFP and α2A-adrenoceptor.  (B) HEK293T cells grown on 
coverslips transiently transfected with RGS4-eYFP and α2A-adrenoceptor with WGA-
Alexa Fluor 594 plasma membrane staining kit.  Images colour combined to create merged 
images (C).  Results shown are of a single experiment, representative of three experiments 
performed. 
(D) HEK293T cells co-transfected with both RGS4-eYFP and the α2A-adrenoceptor were 
also measured for RGS4-eYFP fluorescence intensity at the plasma membrane (open bar) 
and cytoplasm (closed bar). Images were deconvolved using an iterative and constrained 
algorithm.  Surface and cytosolic masks were created and superimposed and fluorescence 
pixel intensity values
 corresponding to RGS4-eYFP located at the plasma membrane and 
cytoplasm of
 the cell were quantified from each generated mask. Fluorescence was 
expressed as a percentage of the total RGS4-eYFP intensity using a mean of 3 
cells ± SEM. Statistical significance was determined using a Student’s t test, * p<0.05. 
(E) HEK293T cells were transiently co-transfected with RGS4-eYFP and the α2A-
adrenoceptor.  Membrane (lane 1) and cytosolic (lane 2) fractions were separated and 
resolved by SDS-PAGE and then immunoblotted with an anti-GFP antiserum.  Results 
shown are of a single experiment, representative of three experiments performed. 
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Figure 3.12 The cellular localisation of RGS4-eYFP when co-expressed with the α2A-
adrenoceptor and stimulated with UK14304   
RGS4-eYFP is translocated to the plasma membrane when transiently co-transfected with 
the α2A-adrenoceptor then stimulated with UK14304 (100 µM) for 30 minutes.  (A) 
HEK293T cells were grown on coverslips and transiently transfected with both RGS4-
eYFP and the α2A-adrenoceptor then subsequently stimulated with UK14304 (100 µM) for 
30 minutes.  (B) HEK293T cells grown on coverslips, transiently transfected with both 
RGS4-eYFP and the α2A-adrenoceptor were stimulated with UK14304 (100 µM) for 30 
minutes, with WGA-Alexa Fluor 594-labelled plasma membrane staining kit.  Images 
colour combined to create merged images (C). 
(D) HEK293T cells transiently transfected with RGS4-eYFP and the α2A-adrenoceptor then 
subsequently stimulated with UK14304 (100 µM) for 30 minutes were measured for 
RGS4-eYFP fluorescence intensity at the plasma membrane (open bar) and cytoplasm 
(closed bar). Images were deconvolved using an iterative and constrained algorithm.  
Surface and cytosolic masks were created and superimposed and fluorescence pixel 
intensity values
 corresponding to RGS4-eYFP located at the plasma membrane and 
cytoplasm of
 the cell were quantified from each generated mask. Fluorescence was 
expressed as a percentage of the total RGS4-eYFP intensity using a mean of 3 
cells ± SEM. Statistical significance was determined using a Student’s t test, * p<0.05. 
(E) HEK293T cells transiently transfected with RGS4-eYFP and the α2A-adrenoceptor then 
subsequently stimulated with UK14304 (100 µM) for 30 minutes were separated into 
membrane (lane 1) and cytosolic (lane 2) fractions and resolved by SDS-PAGE and 
immunoblotted with an anti-GFP antiserum.  Results shown are of a single experiment and 
are representative of three experiments performed. 
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Figure 3.13 Comparison of percentage RGS4-eYFP fluorescence at the plasma 
membrane 
HEK293T cells were transiently transfected to express RGS4-eYFP, RGS4-eYFP co-
transfected with Gαi1 , RGS4-eYFP co-transfected with the α2A-adrenoceptor or RGS4-
eYFP co-transfected with the α2A-adrenoceptor and stimulated with 100 µM UK14304 for 
30 minutes.  The membrane fraction of these cells was measured for eYFP fluorescence 
and expressed as a percentage compared to RGS4-eYFP (defined as 100%).  Data shown 
are from triplicate determinations (mean ± SEM.) and are representative of three 
experiments performed. 
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3.3  Discussion 
The introduction of N- and C-terminal modifications on RGS4 could potentially impair 
function or cellular localisation of the protein.  The in vitro function
 of several B/R4 RGS 
proteins, including RGS4, appears to be uncompromised by the
 addition of an N-terminal 
tag (Berman et al., 1996b;Chen et al., 1997).    Similarly, the addition of a C-terminal tag 
has also been shown to have no effect on the functionality or the localisation of RGS4 
(Chatterjee and Fisher, 2000).  In this study, addition of GFP
2 to the C-terminal of RGS4 
did not change the GAP activity of the protein compared to wild-type RGS4. 
High-affinity GTPase assays measure the rate of GTP hydrolysis to GDP (McKenzie and 
Milligan, 1990;Wise et al., 1997a;Wise et al., 1997b).  G proteins fused to the C-terminal 
of GPCRs were first used in high-affinity GTPase assays by Wise et al., (1997a). The 
expression of such fusion proteins defines a 1:1 stoichiometry of receptor and G protein.  
Each receptor is in equivalent proximity to the G protein and furthermore, receptor-G 
protein fusion proteins function effectively as agonist-activated GTPases.  The α2A-
adrenoceptor-Gαo1
C351I fusion protein has previously been used to characterise RGS4 
GTPase activity (Cavalli et al., 2000;Bahia et al., 2003).  A mutagenic alteration in the G 
protein four amino acids from the C terminal at a conserved cysteine residue (
C35Il in Gαo1) 
defines that the G protein cannot be ADP-ribosylated and therefore becomes resistant to P. 
tox treatment.  P. tox catalyses ADP-ribosylation on a sensitive G protein α subunit, 
therefore making it unable to exchange GDP for GTP in response to receptor stimulation.  
Thus, P. tox treatment abolishes signalling through the endogenous pool of inhibitory G 
proteins.  G protein families endogenously expressed in HEK293T cells such as, Gαs, Gαq 
and Gα12, which are not sensitive to P. tox, produce too limited a signal to be detected with 
the high-affinity GTPase assay.  The expression of the α2A-adrenoceptor-Gαo1
C351I fusion 
protein and P. tox treatment of cells therefore allows the GTPase signal to be attributed 
solely to the α2A-adrenoceptor-Gαo1
C351I fusion protein.  
To study the enzyme kinetics of the high-affinity GTPase assay, various concentrations of 
GTP acting as a substrate on the α2A-adrenoceptor-Gαo1
C351I fusion protein can be used
 
(Cavalli et al., 2000;Bahia et al., 2003).  Such a successful strategy was also employed in 
this study.  As expected, in the absence of recombinant RGS4, the rate of GTPase activity 
was increased by adrenaline but did not alter the Km.  RGS family members
 act 
catalytically;  relatively small amounts of RGS protein can substantially increase the Km 
and the Vmax of GTP hydrolysis.  It could therefore be deduced by the lack of alteration of      101 
Km in the absence of added RGS4, that the endogenous levels of RGS proteins present in 
the HEK293T cell membrane
 preparation are low.   
Addition of recombinant RGS4 to the high-affinity GTPase assay resulted in an increase in 
both Vmax and the Km for GTP as anticipated by the basic catalytic mechanism of RGS 
function .  As such a  single concentration of GTP was initially sufficient to demonstrate 
that the fluorescently modified RGS4 was functionally comparable to wild-type.  Further 
investigations using various concentrations of GTP acting as a substrate on the α2A-
adrenoceptor-Gαo1
C351I fusion protein allowed the determination of the turnover number of 
RGS4-GFP
2 and showed that addition of GFP
2 to the C-terminal of RGS4 did not change 
the GAP activity of the protein compared to wild-type RGS4. 
RGS proteins have been reported to physically interact with Gα subunits, stabilising the 
transition state conformation of the G protein and increasing the intrinsic GTPase activity 
(Berman et al., 1996b).  RGS4 is thought to be recruited
 from cytosol to the plasma 
membrane by Gα subunits
 particularly those of the Gαi and Gαq subfamilies (Druey et al., 
1998;Srinivasa et al., 1998).  The cytoplasmic localisation of RGS4 allows access to the 
inner face of the plasma membrane to interact with G proteins and receptors and effectors.  
However, the mechanisms of plasma membrane association are still uncertain.   
The present results sought to clarify the cellular localisation and trafficking of RGS4 in 
mammalian cells.  Many studies have observed that transiently transfected RGS4 is 
localised in the cytoplasm (Druey et al., 1998;Chatterjee and Fisher, 2000).  As mentioned 
previously, the N-terminus of RGS4 is extremely important for cellular localisation.  
Indeed, a sequence element at the N-terminus of the RGS domain has been identified to 
cause cytoplasmic retention of RGS4.  A retroviral-like sequence has been shown to 
mediate nuclear-cytoplasmic export of RGS4 by interaction with the exportin-1-RanGTP 
complex (Chatterjee and Fisher, 2000).  However, it was noticed in the present study that 
although the vast majority of RGS4-eYFP is cytoplasmic, a relatively small proportion of 
RGS4-eYFP is membrane associated at any given time (Figure 3.7).   
Previously, it has been shown that the presence of melatonin causes nuclear exclusion of 
the androgen receptor.  The generally accepted mechanism for this nuclear exclusion 
involves the Gαi mediated increase of intracellular cyclic guanosine monophosphate 
(cGMP) concentrations, calcium entry into the cell and protein kinase C (PKC) activation.   
Importantly, this mechanism also leads to the enhanced cytoplasmic distribution of RGS2      102 
and RGS10 in prostate carcinoma cells.  It was also discovered that in these cells stably 
expressing the androgen receptor, RGS4 surprisingly accumulated in the nucleus and 
showed no recruitment from the cytoplasm to the plasma membrane in the presence of 
melatonin (Rimler et al., 2006).  This has lead to speculation that in addition to the 
regulation of membrane bound G proteins, RGS4 may perhaps have other undiscovered 
regulatory functions including modulating the intensity and the duration of signal 
transduction.   
Numerous studies have provided evidence that RGS proteins interact directly with Gα 
subunits. In a yeast two-hybrid screen, GAIP was
 found to interact specifically with 
members of the Gαi subfamily,
 Gαi1, Gαi2, Gαi3, Gαiz, and Gαo (De Vries and Farquhar, 
2002).  A co-immunoprecipitation study found that RGS2 binds Gαs protein in vitro 
(Tseng and Zhang, 1998).   It has been demonstrated that RGS3 binds to Gαq, but not Gαs 
(Neill et al., 1997) and that RGS1 and RGS4 interacts with Gαi, but not Gαs (Watson et al., 
1996;Berman et al., 1996b).  However, recent studies failed to prove binding between
 
RGS2 and Gαs in vivo (Chen et al., 1997;Heximer et al., 1997) despite the understanding 
that RGS2 is recruited to the plasma membrane after co-expression of Gαs (Roy et al., 
2006) and inhibits cAMP signalling (Sinnarajah et al., 2001). Thus, the interaction between
 
RGS and heterotrimeric G proteins may possibly be cell specific and further
 investigation 
is required.
  
The RGS-Gα protein interaction may also be increased by receptors (Ingi et al., 1998;Zeng 
et al., 1998;Xu et al., 1999).  GPCRs could influence RGS orientation, promoting 
localisation at the plasma membrane (Hollinger and Hepler, 2002), or perhaps expression 
of GPCRs could induce a greater pool of endogenous RGS proteins (Druey et al., 
1996;Tseng and Zhang, 1998).  Importantly, a recent study found that RGS2 binds 
selectively to the third intracellular
 loop of the M1 muscarinic receptor (Bernstein et al., 
2004) and to the third intracellular loop of the α1a-adrenoceptor (Hague et al., 2005). There 
is a high degree of selectivity of interactions between RGS proteins and receptors but to 
date no corresponding binding regions have been identified (Zeng et al., 1998).  It may be 
reasoned that the selectivity of RGS proteins for receptors must regulate very specific 
physiological responses.  In this study, cytoplamsic RGS4 was recruited to the plasma 
membrane following co-expression with the α2A-adrenoceptor in HEK293T cells. No 
further recruitment of RGS4 to the plasma membrane was observed when the α2A-
adrenoceptor was stimulated with agonist.  Endogenous G proteins in HEK293T cells are 
perhaps sufficiently activated by presence of the receptor, or are able to serve as better      103 
RGS targets when coupled to receptors enabling the RGS4-eYFP to be translocated to the 
plasma membrane in the absence of agonist.  This translocation of RGS4-eYFP in the 
presence of the α2A-adrenoceptor suggested that further study using cells transfected with 
the α2A-adrenoceptor and over expressing exogenous Gαi was not required.  Perhaps 
further investigation may reveal that there is a simple physical association between the 
RGS4 and the α2A-adrenoceptor, which allows RGS4-eYFP to be translocated to the 
plasma membrane. 
Mutation of glutamic acid 204 of Gαi1 to leucine abolishes the hydrolysis of GTP to GDP 
on the Gα protein. Glutamic acid 204  stabilises the negative charge on the phosphate 
leaving group in the transition state of the reaction complex and orientates the attacking 
water molecule to allow GTP hydrolysis (Graziano and Gilman, 1989).  The expression of 
the constitutively active Gαi2 mutant (Gαi2
Q205L)
 showed translocation of cytosolic RGS4 to 
the plasma membrane (Druey et al., 1998). Constitutively activated forms of the G protein, 
Gαq (Gαq
Q209L and Gαq
R183C) have also been researched and co-expression with RGS4 also 
show the translocation of RGS4 to the plasma membrane (Heximer et al., 2001;Roy et al., 
2003).  The use of constitutively active G proteins was also used in the present study.  The 
corresponding constitutively active mutant of the Gαi1 G protein (Gαi1
Q204L) showed 
increased recruitment of RGS4 to the plasma membrane compared to wild-type Gαi1.  This 
was not caused by a higher expression of Gαi1
Q204L compared to Gαi1 suggesting that the 
conformation of the constitutively active G protein is more favourable for the recruitment 
of RGS4-eYFP to the plasma membrane.  
The data shown in this chapter confirm that the over-expression of exogenous Gαi1 recruits 
RGS4-eYFP to the plasma membrane in HEK293T cells.  When a cognate receptor that 
activates this G protein was co-transfected in place of the G protein, corresponding patterns 
of translocation were observed.  The ability of a transfected receptor, unstimulated by 
agonist, to increase levels of RGS4 at the plasma membrane implies that RGS4 is recruited 
to the plasma membrane almost certainly in response to an increased number of RGS4 
protein binding targets.  However, more RGS binding sites at the plasma membrane may 
be sufficient to trigger translocation of RGS4 in intact cells, spontaneously activating 
endogenous G proteins to cause RGS4 translocation.  The transient transfection of RGS4-
eYFP may have concealed any differences in cellular translocation patterns.  Perhaps 
future technical advances and investigation on endogenous RGS4 will reveal currently 
unrecognised localisation patterns of RGS proteins.      104 
4  Chapter 4 
4.1  Introduction 
Previously, a deletion of the fission yeast S. pombe RGS gene, rgs1, produced an increased 
sensitivity of pheromone signalling as measured by pheromone-dependent transcription 
(Watson et al., 1999).  In fact, loss of rgs1 not only made the yeast cells more sensitive to 
pheromone stimulation but also increased production of the reporter gene, β-galactosidase, 
in the absence of mating factor. These changes were due to the loss of rgs1, as they were 
overcome by expression of an exogenous Rgs1p (Didmon et al., 2002).  It was reasoned 
that if such loss-of-function mutations in yeast amplify pheromone signalling, gain-of-
function (GOF) mutations that block signalling could also be obtained.  Thus, a GOF 
mutation in an RGS gene would be anticipated to increase RGS activity to further inhibit 
cellular signalling. Indeed, RGS GOF mutations were detected in S. cervisiae by growth on 
plates containing very high (normally lethal) concentrations of α-factor (6 µM) (Dohlman 
et al., 1995).   
The simplicity of the yeast pheromone signalling cascade has allowed large scale screens 
to identify RGS GOF mutants.  Sz. pombe consists of three main signalling components, a 
GPCR, a Gα subunit and a single RGS protein.  The use of a Sz. pombe screen to identify 
RGS4 mutants by Hill et al., (personal communication) was the first description of a GOF 
mutant in a mammalian RGS.  RGS4
S30C showed decreased production of β-galactosidase 
and decreased sensitivity of pheromone signalling.  Residue 30 in RGS4 is located in the 
N-terminal domain of RGS4.  Traditionally, the RGS box was thought to exclusively 
confer GAP activity to RGS proteins.  It was therefore initially surprising that mutation of 
a single amino acid, especially in the N-terminal domain of RGS4, decreased sensitivity of 
pheromone signalling and pheromone-dependent transcription.   
A series of deletion mutants have previously been used to define particular regions of 
RGS4 that confer specific functions (Zeng et al., 1998).  RGS4 is most easily split into 
three such deletion mutants, allowing functions to be attributed to the RGS box, the 
flanking N-terminal, or C-terminal domains.  Clearly, all three domains must work 
cooperatively to regulate selective inhibition of G protein signalling but findings have 
shown that the flanking regions of RGS4 were essential for optimal GAP activity in 
receptor-G protein signalling.  In particular, it was shown that the N-terminal domain of      105 
RGS4 is essential for high potency inhibition of G protein signalling and receptor 
selectivity.   
Further studies of the N-terminal of RGS4 used a 33 amino acid N-terminal peptide of 
RGS4 (P1-33).  This peptide was shown to effectively inhibit Gαq-mediated Ca
2+ signalling.  
Importantly, this inhibition was selective for the M3 muscarinic receptor over the 
cholecytokinin receptor (Zeng et al., 1998).  The N-terminus of RGS4 may therefore help 
position RGS4 between the receptor and the G protein optimally positioning the RGS box 
for effective GAP activity. 
RGS4 has been implicated in regulating a number of signalling pathways.  A mammalian 
GOF mutant in RGS4 could therefore produce new insights into the physiological 
relevance of RGS4.  The aim of the studies in this chapter was to investigate RGS4
S30C in 
vitro and in intact mammalian cells.  High-affinity GTPase assays measured the sensitivity 
of the mutant to agonist and moreover, the rate of GTPase activity.  The cellular 
localisation of RGS4
S30C was also investigated.  Importantly, the ability of the GOF 
mutation to be transferred into another member of the B/R4 RGS family, RGS16, and the 
selectivity of these RGS proteins for different Gα subtypes was also studied.  The G 
protein selectivity, potency and GAP activity of other selected residue 30, RGS4 mutants 
were also investigated. 
4.2  Results 
4.2.1  Identification of RGS4 mutants 
Mutations within the RGS4 open reading frame resulting in increased activity were 
identified by Hill et al., (personal communication).  A previously identified Sz.  pombe 
yeast strain (JY731) was employed which incorporates a pheromone-inducible reporter, 
sxa2>ura4, but lacks the endogenous RGS protein, Rgs1p (Didmon et al., 2002).  
Signalling responses were assayed utilising agar plates containing 5-fluoro-orotic acid 
(FOA) and varying concentrations of the yeast pheromone, P-factor. Exposure of the ura4 
reporter strain to P-factor results in pheromone-dependent production of orotidine 5’-
monophosphate decarboxylase (Ura4). Ura4 subsequently converts FOA into a toxic 
product, killing signalling cells (Boeke et al., 1984).   GOF mutants were isolated by 
identifying yeast colonies capable of reducing signalling of the strain JY731, permitting 
growth at 10 nM of P-factor.  A further round of selection was carried out on agar plates      106 
lacking uracil but containing 1 µM of P-factor.  This second round of selection eliminated 
any false positives colonies, e.g. colonies that contained spontaneous mutations in the ura4 
gene rendering the Ura4 protein inactive. 25 such RGS4 GOF mutant plasmids were 
identified in this yeast-based screen.  Sequence analysis showed that mutations included 
point mutations, base pair deletions and or duplications of the open reading frame.  The 
most abundant of the mutants was a serine to cysteine mutation at residue 30 (RGS4
S30C).  
This specific mutation was remade by site-directed mutagenesis in both pcDNA3 and 
pGEX6-P1 vectors.  Residue 30 in RGS4 was subsequently mutated to alanine, glutamic 
acid, lysine, methionine, phenylalanine or proline.  For comparison, these amino acid 
structures are shown in Figure 4.1 
Figure 4.2 shows SDS-PAGE gels of purified GST-fused recombinant (A) RGS4 and (B) 
RGS4
S30C stained with Coomassie Blue.  Similar induction and purification of each protein 
is shown at around 50 kDa.  Quantitative evaluation of the pooled eluted proteins using the 
BCA assay allowed the concentration of each eluted protein to be determined. 
4.2.2  Functional activity of RGS4
S30C  
High-affinity GTPase assays were used to compare the functional activity of RGS4
S30C and 
wild-type RGS4. The GTPase activity of the Gαo1 subunit was determined following 
transient expression of the α2A-adrenoceptor-Gαo1
C351I fusion protein in HEK293T cells as 
before (Chapter 3 Section 3.3), and it was therefore important to establish if the presence 
of either RGS protein disrupted the binding of adrenaline to the α2A-adrenoceptor. 
The α2A-adrenoceptor-Gαo1
C351I fusion protein was transiently expressed in HEK293T cells 
and cells were pre-treated with P. tox (25 ng/ml, 16 hours) before membranes were 
prepared.  2 µg of membranes transiently expressing the α2A-adrenoceptor-Gαo1
C351I fusion 
protein were used to compare the ability of adrenaline to compete with [
3H]RS-79948-197 
for binding to α2A-adrenoceptor in the absence of an RGS protein or in the presence of 1 
µM GST-RGS4 or 1 µM GST-RGS4
S30C (Figure 4.3).  The total [
3H]RS-79948-197 bound 
specifically in the absence of RGS protein was represented as 100%.  The presence of 
either RGS protein did not alter the affinity of adrenaline for α2A-adrenoceptor (Figure 
4.4). 
These membranes expressing the α2A-adrenoceptor-Gαo1
C351I fusion protein were 
challenged with varying concentrations of adrenaline (1 mM – 0.1 nM) in the absence of      107 
RGS protein or in the presence of 1 µM GST-RGS4 or 1 µM GST-RGS4
S30C, and high-
affinity GTPase activity measured (Figure 4.5).  The intrinsic rate of Gαo1 GTPase activity 
(in the absence of RGS protein) was stimulated in a concentration-dependent manner with  
pEC50 7.18 ± 0.07.  The presence of GST-RGS4 did not significantly increase the basal 
high-affinity GTPase activity but increased the maximal adrenaline-stimulated GTPase 
activity of Gαo1 and significantly decreased the potency of adrenaline to stimulate high-
affinity GTPase activity (pEC50 6.72 ± 0.08, p<0.01) (Figure 4.6). 
The addition of purified GST-RGS4
S30C to HEK293T membranes expressing the α2A-
adrenoceptor-Gαo1Cys
351Ile fusion protein resulted in an increase in the basal GTPase 
activity (p<0.05) and a larger increase in the maximal adrenaline stimulated GTPase 
activity of Gαo1 than was produced by addition of purified GST-RGS4.  The potency of 
adrenaline was further significantly decreased (pEC50 6.46 ± 0.11, p<0.01) (Figure 4.6).  
This decrease in pEC50 is consistent with an increase in activity of the RGS.    
A similar pattern of increased GTPase activity by GST-RGS4
S30C was also seen when the 
α2A-adrenoceptor-Gαo1
C351I fusion protein expressing membranes were challenged with the 
α2-adrenoceptor selective agonist UK14304 (Figure 4.7).  The intrinsic rate of Gαo1 
GTPase activity (in the absence of RGS protein) was stimulated in a concentration 
dependent manner with pEC50 7.71 ± 0.15.  The presence of GST-RGS4 did not 
significantly increase the basal high-affinity GTPase activity but increased the maximal 
UK14304 stimulated GTPase activity of Gαo1 and significantly decreased the potency of 
UK14304 to stimulate high-affinity GTPase activity (pEC50 7.23 ± 0.12, p<0.01).  
Compared to addition of wild-type RGS4, addition of purified RGS4
S30C resulted in a 
larger increase in the maximal UK14304-stimulated GTPase activity of Gαo1 and the 
potency of UK14304 was further significantly decreased (pEC50 6.76 ± 0.18, p<0.01) 
(Figure 4.8).  The enhanced high-affinity GTPase activity of Gαo1 by RGS4
S30C seen is 
therefore not restricted to the action of a single ligand. 
In contrast, when the G protein fused to α2A-adrenoceptor was replaced with Gαi1, addition 
of purified GST-RGS4 displayed little capacity to increase the high-affinity GTPase 
activity and GST-RGS4
S30C did not act as a GOF mutant (Figure 4.9). Furthermore, 
comparison of the addition of purified RGS4
S30C and addition of purified wild-type RGS4, 
shows no difference in the potency of adrenaline-stimulated GTPase activity of Gαi1 
(Figure 4.10) (p>0.05).  This indicates that RGS4 is G protein selective and this selectivity 
is preserved in RGS4
S30C.      108 
From the increase in functional activity of Gαo1 produced by the presence of RGS4
S30C, it 
was thought necessary to examine the effect this mutated RGS protein had on the activity 
of downstream signalling.  Expression of the α1b-adrenoceptor-Gα11 fusion protein elevates 
intracellular Ca
2+ in response to the α-adenoceptor agonist phenylephrine (Stevens et al., 
2001).  This effect was inhibited by the co-expression of an RGS protein and therefore, co-
expression of a more active RGS protein might be able to further inhibit [Ca
2+]i release.  
The stop codon of RGS4 and RGS4
S30C were removed and both proteins were 
independently fused in-frame to eYFP.  The presence of this fluorescent tag allowed 
detection of cells positively transfected with these proteins.  Co-expression of the α1b-
adrenoceptor-Gα11 fusion protein and RGS4-eYFP resulted in a decrease in the maximal 
extent of agonist mediated elevation of [Ca
2+]i compared to expression of α1b-adrenoceptor-
Gα11 fusion protein alone.  However, expression of RGS4
S30C-eYFP did not result in any 
further inhibition in extent or alter the kinetics of the signalling response compared to 
RGS4 (Figure 4.11). 
4.2.3  Functional activity of RGS16
S30C 
Sequence alignment of RGS proteins in the B/R4 subfamily revealed that the serine residue 
at position 30 in RGS4 was conserved in RGS2, RGS8 and RGS16 (Figure 4.12).  To 
determine if the GOF mutation present in RGS4 was transposable to RGS16, high-affinity 
GTPase assays were performed as before.  It was observed that the potency for adrenaline 
on the addition of purified GST-RGS16 was pEC50 5.68 ± 0.3 (Figure 4.14).  Addition of 
purified GST-RGS16
S30C increased the maximal adrenaline stimulated GTPase activity of 
Gαo1 and significantly decreased the potency for adrenaline compared to GST-RGS16 
(pEC50 5.39 ± 0.36, p<0.01) (Figure 4.14).  Importantly, however, there was no difference 
in the GTPase activity (Figure 4.15) or the potency for adrenaline (Figure 4.16) when α2A-
adrenoceptor was fused to Gαi1 (p>0.05).  In addition to altering the potency for 
adrenaline, addition of purified GST-RGS16
S30C increased the basal GTPase activity of 
α2A-adrenoceptor-Gαo1 but not of α2A-adrenoceptor-Gαi1.  This increase in basal activity 
did not seem to be agonist mediated, as the increase was apparent even without the 
presence of adrenaline.  Thus, the RGS4
S30C mutation is transposable between the B/R4 
subfamily to preserve the enhanced Gαo1 activity and G protein selectivity.      109 
4.2.4  Expression of RGS4
S30C–eYFP 
The effect of the RGS4
S30C mutation on expression was determined.  RGS4-eYFP and 
RGS4
S30C-eYFP were transiently expressed in HEK293T cells and cell lysates were 
separated by SDS-PAGE and expression levels detected with an antiserum directed against 
GFP (Figure 4.17).  Bands corresponding to RGS4-eYFP (lane 2) and RGS4
 S30C-eYFP 
(lane 3) were of comparable intensity indicating similar expression of the two proteins.  
Cell lysates of vector alone transfected cells were included as a control (lane 1). Increased 
expression of RGS4
S30C is therefore not responsible for the GOF properties of RGS4
S30C. 
4.2.5  Localisation of RGS4
S30C –eYFP 
It was hypothesised that a change in the subcellular localisation of RGS4
S30C may enhance 
the activity of RGS4.  Increased localisation of RGS4
S30C-eYFP at the plasma membrane 
compared to RGS4-eYFP might allow the mutated protein to be in closer proximity to 
other signalling complexes located at the plasma membrane subsequently enhancing the 
apparent activity of the RGS protein.  The subcellular localisation of transiently expressed 
RGS4
S30C-eYFP in HEK293T cells was visualised by microscopy (Figure 4.18).  Panel (A) 
demonstrates that analogous to RGS4-eYFP, RGS4
S30C-eYFP was predominantly 
cytosolic.  This was confirmed by pixel by pixel analysis of the distribution of eYFP 
fluorescence intensity (Figure 4.19).  The RGS4
S30C mutation did not affect RGS4 
localisation. 
As before (Chapter 3, Section 3.5 and Section 3.6), the intracellular localisation of 
RGS4
S30C-eYFP was examined by co-expression of other signalling proteins (Figure 4.18).  
RGS4
S30C-eYFP co-expressed with Gαi1 (Figure 4.18 (B)), the α2A-adrenoceptor (Figure 
4.18 (C)), or the α2A-adrenoceptor stimulated with UK14304 for 30 minutes (Figure 4.18 
(D)).  All these conditions show the translocation of RGS4
S30C-eYFP to the plasma 
membrane.  No obvious difference between RGS4 and RGS4
S30C translocation could be 
detected using this methodology. 
The subcellular localisation and translocation pattern of RGS4
S30C was also confirmed by 
determining the percentage fluorescence of RGS4
S30C-eYFP in the plasma membrane of 
the transfected HEK293T cells.  Percentage fluorescence of RGS4
S30C-eYFP in the plasma 
membrane (defined as 100%) was directly compared to the percentage fluorescence of 
RGS4
S30C-eYFP co-expressed with other signalling proteins, Gαi1, α2A-adrenoceptor, or      110 
agonist stimulated α2A-adrenoceptor (Figure 4.20). The co-expression with other signalling 
proteins all increased the percentage fluorescence of RGS4
S30C-eYFP in the plasma 
membrane. In a similar pattern to RGS4-eYFP (Chapter 3, Section 1.6), RGS4
S30C-eYFP 
co-transfected with Gαi1 had the greatest percentage effect (188 ± 12%) on RGS4
S30C-
eYFP translocation to the plasma membrane.  The presence of the α2A-adrenoceptor or the 
α2A-adrenoceptor stimulated by UK14304 (100 µM) both translocated RGS4-eYFP to the 
plasma membrane, 161 ± 81% and 157 ± 33% respectively.  This further confirmed that 
the RGS4
S30C mutation did not affect localisation as the percentage fluorescence of 
RGS4
S30C-eYFP in the plasma membrane was not different from the translocation of 
RGS4-eYFP. 
4.2.6  Importance of residue 30 in RGS4 
The presence of serine 30 in RGS4 is clearly important for wild-type functioning of RGS4 
and mutating this residue to cysteine increases the activity of this protein.  To assess what 
other amino acid side chains did to the function of this protein, residue 30 was mutated to 
various other amino acids including;  alanine, glutamic acid, lysine, methionine, 
phenylalanine, or proline. 
4.2.6.1  Purification of GST-RGS4
S30X 
All RGS4
S30X mutations (where X denotes one of the above amino acids) fused to GST 
were made by PCR based site-directed mutagenesis. SDS-PAGE gels of induced and 
purified recombinant GST-fused proteins stained with Coomassie Blue are shown, 
RGS4
S30A (Figure 4.21), RGS4
S30E (Figure 4.22), RGS4
S30K (Figure 4.33), RGS4
S30M 
(Figure 4.24), RGS4
S30F (Figure 4.25), RGS4
S30P (Figure 4.26).  Similar induction and 
purification of each GST fused protein is shown.  The exact protein concentration of each 
eluted protein was routinely determined using the BCA assay. 
4.2.6.2  Functional activity of RGS4
S30X 
The ability of GST-RGS4
S30X mutants to increase the high-affinity GTPase activity of the 
α2A-adrenoceptor-Gαo1Cys
351Ile fusion protein challenged with varying concentrations of 
adrenaline (1 mM – 0.1 nM) was determined.  All assays were done in the absence of RGS 
protein or addition of purified RGS4 or RGS4
S30X: RGS4
S30A (Figure 4.27), RGS4
S30E 
(Figure 4.29), RGS4
S30K (Figure 4.31), RGS4
S30M (Figure 4.33), RGS4
S30F (Figure 4.35),      111 
RGS4
S30P (Figure 4.37).  The maximal adrenaline stimulated GTPase activity of Gαo1 of 
each mutant demonstrated that RGS4
S30A, RGS4
S30F and RGS4
S30K all showed a significant 
increases in high-affinity GTPase activity compared to wild-type RGS4 (p<0.01).  
Addition of purified RGS4
S30E   had no effect on the maximal adrenaline-stimulated 
GTPase activity of Gαo1 compared to wild-type RGS4 and, interestingly, the addition of 
either RGS4
S30M or RGS4
S30P both decreased the maximal adrenaline-stimulated high-
affinity GTPase activity of Gαo1 compared to wild-type RGS4. 
The ability of these mutants to change the value of Vmax has also been considered. 
However, to do this, all high-affinity GTPase graphs were normalised and high-affinity 
GTPase activity expressed as a percentage.  This analysis disguised differences in basal 
activity and it was thought not to show a true representation of the effect of the mutation 
on high-affinity GTPase activity. 
The potency of adrenaline to stimulate high-affinity GTPase activity of the α2A-
adrenoceptor-Gαo1Cys
351Ile fusion protein was significantly decreased for RGS4
S30A 
compared to wild-type RGS4 (RGS4 pEC50 6.81 ± 0.06, RGS4
S30A pEC50 6.36 ± 0.20, 
p<0.01) (Figure 4.28), RGS4
S30F (RGS4 pEC50 6.48 ± 0.05, RGS4
S30A pEC50 6.11 ± 0.24, 
p<0.01) (Figure 4.36) and RGS4
S30K (RGS4 pEC50 6.48 ± 0.05, RGS4
S30A pEC50 6.21 ± 
0.04, p<0.01) (Figure 4.32).  See Table 4.1 for summary and statistics. Surprisingly, the 
addition of purified RGS4
S30M to the membranes expressing the α2A-adrenoceptor-
Gαo1Cys
351Ile fusion protein although decreasing the maximum GTPase activity, increased 
the pEC50 (Figure 4.34).  In contrast RGS4
S30P (Figure 4.38) decreased the GTPase activity 
of Gαo1 but did not affect the pEC50.  The calculated pEC50 values for each assay are 
shown in Table 4.1.  Student’s t tests were performed to compare the significance of the 
pEC50 values compared to WT RGS4.  From these results, RGS4
S30C and RGS4
S30F 
(p<0.05), RGS4
S30Aand RGS4
S30K  (p<0.005) were shown to significantly decrease the pEC50 
value compared to wild-type RGS4.  These GOF mutants increase the maximal activity of 
Gαo1 and increase the concentration of adrenaline required to produce half maximal 
GTPase activity.   
It should be noted however, that there may be some limitations to the statistical analyis.  
The experiments performed to produce the date in Table 4.1 for RGS4
S30K , RGS4
S30FM , 
RGS4
S30F and RGS4
S30P  were done using the same wild type controls.  The data presented 
here may not be as significantly different, as reported here.      112 
4.2.6.3  Expression of RGS4
S30X –eYFP 
All RGS4
S30X mutations were C-terminally tagged with eYFP in pcDNA3.  HEK293T cells 
were transfected with constructs containing RGS4-eYFP, RGS4
S30A-eYFP or RGS4
S30E-
eYFP. To determine expression levels, cell lysates were separated by SDS-PAGE and 
detected using an antiserum directed against GFP.  Relative expressions of RGS4-eYFP 
mutants (lane 3) were compared to RGS4-eYFP (lane 2) and vector only control (lane 1).  
RGS4
S30A (Figure 4.39), RGS4
S30E (Figure 4.40) show bands equal intensity of mutant 
RGS4 and wild-type RGS4 indicating equivalent expression of the two proteins. 
4.2.6.4  Localisation of RGS4
S30X –eYFP 
To determine the cellular localisation of RGS4
S30X of HEK293T cells transiently 
expressing RGS4
S30A-eYFP (Figure 4.41), RGS4
S30E-eYFP (Figure 4.42), RGS4
S30K-eYFP
 
(Figure 4.43), RGS4
S30M-eYFP (Figure 4.44), RGS4
S30F-eYFP (Figure 4.45), RGS4
S30P-
eYFP
 (Figure 4.46) were visualised by microscopy.  Panel (A) shows all RGS4
S30X-eYFP 
mutants were localised predominantly within the cytoplasm.  As before, the intracellular 
localisation of all mutants was examined by co-expression of (B) Gαi1, (C) α2A-
adrenoceptor or (D) α2A-adrenoceptor and stimulated with UK14304 for 30 minutes.  The 
yellow co-localisation of RGS4
S30X-eYFP with WGA-Alexa Fluor 594-labelled membrane 
staining in image (iv) in panels (B), (C) and (D) suggest that co-expression with other 
signalling proteins translocates all RGS4
S30X-eYFP to the plasma membrane.  It was 
demonstrated that all of the tested RGS4
S30X mutations did not vary the cellular localisation 
of the protein compared to wild-type RGS4.      113 
 
                                                                                                                                                                                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Amino acids selected for substitution of serine 30 in RGS4 
Serine 30 in RGS4 was selected for site directed mutagenesis.  An amino acid with side 
chain (X) is shown where X is serine, cysteine, alanine, glutamic acid, lysine, methionine, 
phenylalanine or proline.      114 
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Figure 4.2 Coomassie Blue staining of purified GST-RGS4 and GST-RGS4
S30C 
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding (A) GST-RGS4 or 
(B) GST-RGS4
S30C.  GST-fused proteins were induced and purified and equal volumes of 
each fraction were resolved by SDS-PAGE and stained with Coomassie Blue. Cell lysates 
of BL21 before addition of glutathione sepharose beads (lane 1), cell lysates of BL21after 
over-night incubation with glutathione sepharose beads (lane 2), elution 1 (lane 3), elution 
2 (lane 4), elution 3 (lane 5), elution 4 (lane 6). 
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Figure 4.3  The ability of adrenaline to compete with [
3H]RS-79948-197  for binding 
to the α α α α2A-adrenoceptor-Gα α α αo1
C351I fusion protein in the presence and absence of RGS4 
or RGS4
S30C 
HEK293T cells were transfected to express the α2A-adrenoceptor-Gαo1
C351I fusion protein.  
Cells were treated with P. tox (25 ng/ml for 16 hours) then membranes were prepared.  The 
ability of adrenaline (1 mM - 1 nM) to compete with 0.5 nM [
3H]RS-79948-197 was 
determined in the absence (black) or presence of 1 µM GST-RGS4 (red) or 1 µM GST-
RGS4
S30C (blue).   Data shown are from triplicate determinations (mean ± SEM) and are 
representative of three individual experiments performed. 
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Figure 4.4 Comparison of GST-RGS4 or GST-RGS4
S30C on the ability of adrenaline 
to compete with [
3H]RS-79948-197 for binding to the α2A-adrenoceptor-Gαo1
C351I 
fusion protein    
The ability of adrenaline to compete with 0.5 nM [
3H]RS-79948-197 was determined in the 
absence (black) or presence of 1 µM GST-RGS4 (red) or 1 µM GST-RGS4
S30C (blue).   
The IC50 results from Figure 4.3 are presented for comparison of results.  Results shown 
are mean ± SEM. from three individual experiments performed.   
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Figure 4.5 Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence and absence of GST-RGS4 or GST-RGS4
S30C   
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline (0.1 nM – 1 mM) to 
stimulate high-affinity GTPase activity was then measured in the absence (black) or 
presence of 1 µM GST-RGS4 (red) or 1 µM GST-RGS4
S30C (blue) using 0.5 µM 
[γ
32P]GTP.  Data shown are from quadruplicate determinations (mean ± SEM) and are 
representative of three individual experiments performed. 
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Figure 4.6 Comparison of GST-RGS4 or GST-RGS4
S30C on pEC50 values of 
adrenaline to stimulate the GTPase activity of the α2A-adrenoceptor-Gαo1
C351I fusion 
protein  
The pEC50 results from Figure 4.5 are presented for comparison. The pEC50 in the absence 
of RGS protein (black), presence of GST-RGS4 (red) or presence of GST-RGS4
S30C (blue) 
are mean ± SEM. from three individual experiments performed.  * denotes significantly 
different from the α2A-adrenoceptor-Gαo1
C351I fusion protein and ** denotes significantly 
different from the α2A-adrenoceptor-Gαo1
C351I fusion protein + 1 µM GST-RGS4 (p<0.01).   
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Figure 4.7 UK14304-stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence and absence of GST-RGS4 or GST-RGS4
S30C   
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of UK14304 to stimulate high-affinity 
GTPase activity was then measured in the absence (black) and presence of 1 µM GST-
RGS4 (red) or 1 µM GST-RGS4
S30C (blue) using 0.5 µM [γ
32P]GTP.  Data shown are from 
quadruplicate determinations (mean ± SEM) and are representative of three individual 
experiments performed. 
 
 
 
 
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2
20
40
60
80
100
120
140
160
180
UK14304 [Log M]
G
T
P
 
h
y
d
r
o
y
l
s
i
s
 
(
p
m
o
l
/
m
g
/
m
i
n
)     120 
 
 
 
 
 
 
 
 
Figure 4.8 Comparison of GST-RGS4 or GST-RGS4
S30C on pEC50 values of UK14304 
to stimulate the GTPase activity of the α2A-adrenoceptor-Gαo1
C351I fusion protein    
The pEC50 results from Figure 4.7 are presented for comparison. The pEC50 in the absence 
of RGS protein (black), presence of GST-RGS4 (red) or presence of GST-RGS4
S30C (blue) 
are mean ± SEM. from three individual experiments performed.  * denotes significantly 
different from the α2A-adrenoceptor-Gαo1
C351I fusion protein and ** denotes significantly 
different from the α2A-adrenoceptor-Gαo1
C351I fusion protein + 1 µM GST-RGS4 (p<0.01). 
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Figure 4.9 Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαi1
C351I 
fusion protein in the presence and absence of GST-RGS4 or GST-RGS4
S30C   
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαi1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured in the absence (black) or presence of 100 nM GST-
RGS4 (red) or 100 nM GST-RGS4
S30C (blue) using 0.5 µM [γ
32P]GTP.  Data shown are 
from quadruplicate determinations (mean ± SEM) and are representative of three 
individual experiments performed. 
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Figure 4.10 Comparison of GST-RGS4 or GST-RGS4
S30C on pEC50 values of 
adrenaline to stimulate the GTPase activity of the α2A-adrenoceptor-Gαi1
C351I fusion 
protein  
The pEC50 results from Figure 4.9 are presented for comparison. The pEC50 in the absence 
of RGS protein (black), presence of GST-RGS4 (red) or presence of GST-RGS4
S30C (blue) 
are mean ± SEM. from three individual experiments. Results are mean ± SEM. for three 
individual experiments performed.  * denotes significantly different from the α2A-
adrenoceptor-Gαi1Cys
351Ile fusion protein (p<0.01). 
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Figure 4.11 Phenylephrine-stimulated elevation of [Ca
2+]i  in cells expressing the α1b-
adrenoceptor-Gα11 fusion protein, in the presence and absence of RGS4-eYFP 
RGS4
S30C-eYFP   
HEK293T cells were transfected to express the α1b-adrenoceptor-Gα11 fusion protein 
(black line), α1b-adrenoceptor-Gα11 fusion protein + RGS4-eYFP (red line) or α1b-
adrenoceptor-Gα11 fusion protein + RGS4
S30C-eYFP (blue line).  Cells were loaded with 
Fura-2 and intracellular [Ca
2+] levels imaged before and after 3 µM phenylephrine was 
perfused over the cells for 60 seconds.  Data represents means ± SEM. from 54 α1b-
adrenoceptor-Gα11), 25 α1b-adrenoceptor-Gα11 + RGS4-eYFP) and 23 α1b-adrenoceptor-
Gα11 + RGS4
S30C-eYFP) cells from 3 individual experiments performed. 
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Figure 4.12 Comparison of serine 30 in the B/R4 subfamily of RGS proteins 
The serine 30 residue in RGS4 is conserved amongst members of the B/R4 family.  The N-
terminal region of the protein sequence of four members of the B/R4 family of RGS 
proteins is compared.  Amino acid sequences of RGS2, RGS4, RGS8 and RGS16 are 
denoted using single-letter code.  Sequences were aligned using MultAlin version 5.4.1. 
with symbol comparison table blosum62, gap weight 12 and gap length weight 2 (Corpet, 
1988).  Gaps introduced to maximise alignment are indicated by -. The conserved serine 
residue is highlighted in black and the start of the predicted RGS domain is highlighted in 
grey. 
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Figure 4.13  Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence and absence of GST-RGS16 or GST-RGS16
S30C  
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured in the absence (black) or presence of 100 nM GST-
RGS16 (orange) or 100 nM GST-RGS16
S30C (green) using 0.5 µM [γ
32P]GTP.  Data 
shown are from quadruplicate determinations (mean ± SEM) and are representative of 
three individual experiments performed. 
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Figure 4.14 Comparison of GST-RGS16 or GST-RGS16
S30C on pEC50 values of 
adrenaline to stimulate the GTPase activity of the α2A-adrenoceptor-Gαo1
C351I fusion 
protein  
The pEC50 results from Figure 4.13 are presented for comparison of results.  The pEC50 in 
the absence (black) or presence of 100 nM GST-RGS16 (orange) or 100 nM GST-
RGS4
S30C (green) are mean ± SEM. from three individual experiments performed.  * 
denotes significantly different from the α2A-adrenoceptor-Gαo1
C351I fusion protein and ** 
denotes significantly different from the α2A-adrenoceptor-Gαo1
C351I fusion protein + 1 µM 
GST-RGS16 (p<0.01). 
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Figure 4.15 Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαi1
C351I 
fusion protein in the absence and presence of GST-RGS16 or GST-RGS16
S30C  
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαi1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured in the absence (black) or presence of 100 nM GST-
RGS16 (orange) or 100 nM GST-RGS16
S30C (green) using 0.5 µM [γ
32P]GTP. Data shown 
are from quadruplicate determinations (mean ± SEM) and are representative of three 
individual experiments performed. 
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Figure 4.16 Comparison of GST-RGS16 or GST-RGS16
S30C on pEC50 values of 
adreanline to stimulate the GTPase activity of the α2A-adrenoceptor-Gαi1
C351I fusion 
protein  
The pEC50 results from Figure 4.15 are presented for comparison of results. The pEC50 in 
the absence (balck) or presence of 100 nM GST-RGS16 (orange) or 100 nM GST-
RGS16
S30C (green) are mean ± SEM. for three individual experiments performed.   
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Figure 4.17 Expression and immunological detection of RGS4-eYFP and RGS4
 S30C-
eYFP 
HEK293T cells were transiently transfected to express RGS4-eYFP (lane 2) or RGS4
S30C-
eYFP (lane 3).  HEK293T cells transfected with pcDNA3 were included as a control (lane 
1).  Cell lysates were resolved by SDS-PAGE and then immunoblotted with anti-GFP 
antiserum.  Results shown are of a single experiment and are representative of three 
experiments performed. 
 
 
 
 
 
Mr (x10
-3) 
75 
50 
35 
  1.            2.             3. 
RGS4-eYFP      130 
 
(A)  (i)              (ii)             (iii)              (iv) 
 
 
 
(B)  (i)              (ii)             (iii)              (iv) 
 
 
 
(C)  (i)              (ii)             (iii)              (iv) 
 
 
 
(D)  (i)              (ii)             (iii)              (iv) 
 
 
 
 
      131 
Figure 4.18  The cellular localisation of RGS4
S30C-eYFP 
HEK293T cells grown on coverslips were transiently transfected with (A) RGS4
S30C-eYFP 
(B) RGS4
S30C-eYFP co-transfected with Gαi1  (C) RGS4
S30C-eYFP co-transfected with the 
α2A-adrenoceptor or (D) RGS4
S30C-eYFP co-transfected with the α2A-adrenoceptor and 
stimulated with 100 µM UK14304 for 30 minutes.  Images were generated using an
 
inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan 
Fluor Apochromat lens and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 
33342 nuclei staining (blue) (ii) RGS4
S30C-eYFP (green) or (iii) WGA-Alexa Fluor 594 
membrane staining (red) (iv) merged images.  Results shown are of a single experiment 
and are representative of three experiments performed. 
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Figure 4.19 Percentage plasma membrane and cytosolic localisation of RGS4
S30C-
eYFP fluorescence  
HEK293T transfected cells were examined for RGS4-eYFP fluorescence or RGS4
S30C-
eYFP intensity at the plasma membrane (open bars) and in the cytoplasm (closed bars). 
Images were deconvolved using an iterative and constrained algorithm (Chapter 2, Section 
2.7.5).  Surface and cytosolic masks were created and superimposed and fluorescence pixel 
intensity values
 corresponding to eYFP located at the plasma membrane and cytoplasm of
 
the cell were quantified from each generated mask. Fluorescence was expressed as a 
percentage of the total fluorescence intensity using a mean of three cells ± SEM.  
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Figure 4.20 Comparison of percentage RGS4-eYFP
 S30C fluorescence at the plasma 
membrane 
HEK293T cells were transiently transfected to express RGS4
S30C-eYFP, RGS4
S30C-eYFP 
co-transfected with Gαi1, RGS4
S30C-eYFP co-transfected with the α2A-adrenoceptor or 
RGS4
S30C-eYFP co-transfected with the α2A-adrenoceptor and stimulated with 100 µM 
UK14304 for 30 minutes.  The membrane fraction was measured for total RGS4
S30C-eYFP 
(defined as 100%) and compared to the percentage eYFP fluorescence of RGS4
S30C-eYFP 
co-expressed with other signalling proteins.  Data shown are from triplicate determinations 
(mean ± SEM.) and are representative of three experiments performed. 
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Figure 4.21 Coomassie Blue staining for purified GST-RGS4
S30A 
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding GST-RGS4
S30A.  
GST-fused protein was induced and purified and equal volumes of each fraction were 
resolved by SDS-PAGE and stained with Coomassie Blue.  Induced cell lysates of 
BL21bacteria before addition of glutathione sepharose beads (lane 1), induced cell lysates 
of BL21after incubation with glutathione sepharose beads (lane 2), elution 1 (lane 3), 
elution 2 (lane 4), elution 3 (lane 5), elution 4 (lane 6). 
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Figure 4.22 Coomassie Blue staining for purified GST-RGS4
S30E 
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding GST-RGS4
S30E.  
GST-fused protein was induced and purified and equal volumes of each fraction were 
resolved by SDS-PAGE and stained with Coomassie Blue.  Induced soluble clarified 
extract of BL21 bacteria before addition of glutathione sepharose beads (lane 1), induced 
soluble clarified extract of BL21 bacteria after incubation with glutathione sepharose beads 
(lane 2), elution 1 (lane 3), elution 2 (lane 4), elution 3 (lane 5), elution 4 (lane 6). 
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Figure 4.23 Coomassie Blue staining for purified GST-RGS4
S30K 
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding GST-RGS4
S30K.  
GST-fused protein was induced and purified and equal volumes of each fraction were 
resolved by SDS-PAGE and stained with Coomassie Blue Marker (lane 1), crude bacterial 
lysate (lane 2), soluble clarified extract before incubation with glutathione sepharose beads 
(lane 3), soluble clarified extract after incubation with glutathione sepharose beads (lane 
4), elution 1 (lane 5), elution 2 (lane 6), elution 3 (lane 7), elution 4 (lane 8). 
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Figure 4.24 Coomassie Blue staining for purified GST-RGS4
S30M 
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding GST-RGS4
S30M.  
GST-fused protein was induced and purified and equal volumes of each fraction were 
resolved by SDS-PAGE and stained with Coomassie Blue Marker (lane 1), crude bacterial 
lysate (lane 2), soluble clarified extract before incubation with glutathione sepharose beads 
(lane 3), soluble clarified extract after incubation with glutathione sepharose beads (lane 
4), elution 1 (lane 5), elution 2 (lane 6), elution 3 (lane 7), elution 4 (lane 8). 
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Figure 4.25 Coomassie Blue staining for purified GST-RGS4
S30F  
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding GST-RGS4
S30F.  
GST-fused protein was induced and purified and equal volumes of each fraction were 
resolved by SDS-PAGE and stained with Coomassie Blue Marker (lane 1), crude bacterial 
lysate (lane 2), soluble clarified extract before incubation with glutathione sepharose beads 
(lane 3), soluble clarified extract after incubation with glutathione sepharose beads (lane 
4), elution 1 (lane 5), elution 2 (lane 6), elution 3 (lane 7), elution 4 (lane 8). 
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Figure 4.26 Coomassie Blue staining for purified GST-RGS4
S30P 
BL21 bacteria were transformed with the plasmid pGEX 6P-1 encoding GST-RGS4
S30P.  
GST-fused protein was induced and purified and equal volumes of each fraction were 
resolved by SDS-PAGE and stained with Coomassie Blue Marker (lane 1), crude bacterial 
lysate (lane 2), soluble clarified extract before incubation with glutathione sepharose beads 
(lane 3), soluble clarified extract after incubation with glutathione sepharose beads (lane 
4), elution 1 (lane 5), elution 2 (lane 6), elution 3 (lane 7), elution 4 (lane 8). 
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Figure 4.27 Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence of GST-RGS4 or GST-RGS4
S30A    
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured in presence of 1 µM GST-RGS4 (red) or 1 µM GST-
RGS4
S30A (purple) using 0.5 µM [γ
32P]GTP.  Data shown are from quadruplicate 
determinations (mean ± SEM) and are representative of three individual experiments 
performed. 
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Figure 4.28 Comparison of pEC50 values of adrenaline to stimulate the GTPase 
activity of the α2A-adrenoceptor-Gαo1
C351I fusion protein in the presence of GST-
RGS4
S30A  
The results from Figure 4.27 are presented in graphical form for comparison of results. The 
pEC50 in the presence of GST-RGS4 (red) or presence of GST-RGS4
S30A (purple) are mean 
± SEM. from three individual experiments performed. * denotes significantly different 
from the α2A-adrenoceptor-Gαo1
C351I fusion protein + 1 µM GST-RGS4 (p<0.05).   
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Figure 4.29 Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence of GST-RGS4
S30E    
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured in presence of 1 µM GST-RGS4 (red) or 1 µM GST-
RGS4
S30E (green) using 0.5 µM [γ
32P]GTP.  Data shown are from quadruplicate 
determinations (mean ± SEM) and are representative of three individual experiments 
performed. 
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Figure 4.30 Comparison of pEC50 values of adrenaline to stimulate the GTPase 
activity of the α2A-adrenoceptor-Gαo1
C351I fusion protein in the presence of GST-
RGS4
S30E    
The results from Figure 4.29 are presented in graphical form for comparison of results.  
The pEC50 in the presence of GST-RGS4 (red) or presence of GST-RGS4
S30E (green) are 
mean ± SEM. from three individual experiments performed. 
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Figure 4.31 Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence of GST-RGS4
S30K   
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured presence of 100 nM GST-RGS4 (red) or 100 nM GST-
RGS4
S30K (mustard) using 0.5 µM [γ
32P]GTP.  Data shown are from quadruplicate 
determinations (mean ± SEM) and are representative of three individual experiments 
performed. 
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Figure 4.32 Comparison of pEC50 values of adrenaline to stimulate the GTPase 
activity of the α2A-adrenoceptor-Gαo1
C351I fusion protein in the presence of GST-
RGS4
S30K    
The pEC50 results from Figure 4.31are presented for comparison of results.  The pEC50 in 
the presence of 100 nM GST-RGS4 (red) or 100 nM GST-RGS4
S30K (mustard) are mean ± 
SEM. from three individual experiments performed.  * denotes significantly different from 
α2A-adrenoceptor-Gαo1
C351I fusion protein + 100 nM GST-RGS4 (p<0.05). 
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Figure 4.33 Adrenaline-stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence of GST-RGS4
S30M   
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured presence of 100 nM GST-RGS4 (red) or 100 nM GST-
RGS4
S30M (pink) using 0.5 µM [γ
32P]GTP.  Data shown are from quadruplicate 
determinations (mean ± SEM) and are representative of three individual experiments 
performed. 
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Figure 4.34 Comparison of pEC50 values of adrenaline to stimulate the GTPase 
activity of the α2A-adrenoceptor-Gαo1
C351I fusion protein in the presence of GST-
RGS4
S30M    
The pEC50 results from Figure 4.33 are presented for comparison of results.  The pEC50 in 
the presence of 100 nM GST-RGS4 (red) or 100 nM GST-RGS4
S30M (pink) are mean ± 
SEM. from three individual experiments performed.   
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Figure 4.35 Adrenaline stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence of GST-RGS4
S30F   
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured presence of 100 nM GST-RGS4 (red) or 100 nM GST-
RGS4
S30F (navy) using 0.5 µM [γ
32P]GTP.  Data shown are from quadruplicate 
determinations (mean ± SEM) and are representative of three individual experiments 
performed. 
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Figure 4.36 Comparison of pEC50 values of adrenaline to stimulate the GTPase 
activity of the α2A-adrenoceptor-Gαo1
C351I fusion protein in the presence of GST-
RGS4
S30F 
The pEC50 results from Figure 4.35 are presented in for comparison of results.  The pEC50 
in the presence of 100 nM GST-RGS4 (red) or 100 nM GST-RGS4
S30F (navy) are mean ± 
SEM. from three individual experiments performed.  Where ** denotes significantly 
different from the α2A-adrenoceptor-Gαo1
C351I fusion protein + 100 nM GST-RGS4 
(p<0.01) 
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Figure 4.37 Adrenaline stimulated GTPase activity of the α2A-adrenoceptor-Gαo1
C351I 
fusion protein in the presence of GST-RGS4
S30P 
HEK293T cells were transiently transfected to express the α2A-adrenoceptor-Gαo1
C351I 
fusion protein.  Cells were treated with P. tox (25 ng/ml for 16 hours) and membranes were 
prepared.  The capacity of varying concentrations of adrenaline to stimulate high-affinity 
GTPase activity was then measured presence of 100 nM GST-RGS4 (red) or 100 nM GST-
RGS4
S30P (brown) using 0.5 µM [γ
32P]GTP.  Data shown are from quadruplicate 
determinations (mean ± SEM) and are representative of three individual experiments 
performed. 
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Figure 4.38 Comparison of pEC50 values of adrenaline to stimulate the GTPase 
activity of the α2A-adrenoceptor-Gαo1
C351I fusion protein in the presence of GST-
RGS4
S30P    
The pEC50 results from Figure 4.37 are presented for comparison of results.  The pEC50 in 
the presence of 100 nM GST-RGS4 (red) or 100 nM GST-RGS4
S30P (brown) are mean ± 
SEM. from three individual experiments performed.   
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pEC50 
 
Amino acid at position 30 
 
Wild-Type RGS4 
 
Mutant 
 
C 
 
6.72 ± 0.08 
 
6.46 ± 0.11* 
 
A 
 
6.80 ± 0.06 
 
6.36 ± 0.2 ** 
 
E 
 
6.80 ± 0.06 
 
6.74 ± 0.09 
 
K 
 
6.48 ± 0.05 
 
6.21 ± 0.04 ** 
 
M 
 
6.48 ± 0.05 
 
6.87 ± 0.17 ** 
 
F 
 
6.48 ± 0.05 
 
6.11 ± 0.24* 
 
P 
 
6.48 ± 0.05 
 
6.45 ± 0.18 
 
Table 4.1 Comparison of pEC50 values in RGS4 serine 30 mutants 
The comparison of pEC50 values for high-affinity adrenaline-stimulated activation of the 
α2A-adrenoceptor-Gαo1
C351I
 for each serine 30 mutant compared to wild-type RGS4.  Data 
shown are the means of three independent experiments ± SEM.  Statistical significance 
was determined using a Student’s t test, * represents p<0.05 and ** represents p<0.005.  It 
should be noted that results for K, M, F and P wild-type controls were produced from the 
same experiment.      153 
 
 
 
 
 
 
 
 
 
 
Figure 4.39 Expression and immunological detection of RGS4-eYFP and RGS4
S30A -
eYFP 
HEK293T cells were transiently transfected to express RGS4-eYFP (lane 2) or RGS4
S30A-
eYFP (lane 3).  HEK293T cells transfected with pcDNA3 were included as a control (lane 
1).  Cell lysates were resolved by SDS-PAGE and then immunoblotted with anti-GFP 
antiserum.  Results shown are from a single experiment and are representative of three 
experiments performed. 
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Figure 4.40 Expression and immunological detection of RGS4-eYFP and RGS4
 S30E -
eYFP 
HEK293T cells were transiently transfected to express RGS4-eYFP (lane 2) or RGS4
S30E-
eYFP (lane 3).  HEK293T cells transfected with pcDNA3 were included as a control (lane 
1).  Cell lysates were resolved by SDS-PAGE and then immunoblotted with anti-GFP 
antiserum.  Results shown are from a single experiment and are representative of three 
experiments performed. 
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Figure 4.41 The cellular localisation of RGS4
S30A-eYFP 
HEK293T cells grown on coverslips were transiently transfected with (A) RGS4
S30A-eYFP 
(B) RGS4
S30A-eYFP co-transfected with Gαi1  (C) RGS4
S30A-eYFP co-transfected with the 
α2A-adrenoceptor or (D) RGS4
S30A-eYFP co-transfected with the α2A-adrenoceptor and 
stimulated with 100 µM UK14304 for 30 minutes.  Images were generated using an
 
inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan 
Fluor Apochromat lens and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 
33342 nuclei staining (blue) (ii) RGS4
S30A-eYFP (green) or (iii) WGA-Alexa Fluor 594 
membrane staining (red) (iv) merged images.  Results shown are from a single experiment 
and are representative of three experiments performed. 
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Figure 4.42 The cellular localisation of RGS4
S30E-eYFP 
HEK293T cells grown on coverslips were transiently transfected with (A) RGS4
S30E-eYFP 
(B) RGS4
S30E-eYFP co-transfected with Gαi1  (C) RGS4
S30E-eYFP co-transfected with the 
α2A-adrenoceptor or (D) RGS4
S30E-eYFP co-transfected with the α2A-adrenoceptor and 
stimulated with 100 µM UK14304 for 30 minutes.  Images were generated using an
 
inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan 
Fluor Apochromat lens and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 
33342 nuclei staining (blue) (ii) RGS4
S30E-eYFP (green) or (iii) WGA-Alexa Fluor 594 
membrane staining (red) (iv) merged images.  Results shown are from a single experiment 
and are representative of three experiments performed. 
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Figure 4.43 The cellular localisation of RGS4
S30K-eYFP 
HEK293T cells grown on coverslips were transiently transfected with (A) RGS4
S30K-eYFP 
(B) RGS4
S30K-eYFP co-transfected with Gαi1  (C) RGS4
S30K-eYFP co-transfected with the 
α2A-adrenoceptor or (D) RGS4
S30K-eYFP co-transfected with the α2A-adrenoceptor and 
stimulated with 100 µM UK14304 for 30 minutes.  Images were generated using an
 
inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan 
Fluor Apochromat lens and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 
33342 nuclei staining (blue) (ii) RGS4
S30K-eYFP (green) or (iii) WGA-Alexa Fluor 594 
membrane staining (red) (iv) merged images.  Results shown are from a single experiment 
and are representative of three experiments performed. 
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(A)  (i)              (ii)             (iii)              (iv) 
 
 
 
(B)  (i)              (ii)             (iii)              (iv) 
 
 
 
(C)  (i)              (ii)             (iii)              (iv) 
 
 
 
(D)  (i)              (ii)             (iii)              (iv) 
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Figure 4.44 The cellular localisation of RGS4
S30M-eYFP 
HEK293T cells grown on coverslips were transiently transfected with (A) RGS4
S30M-eYFP 
(B) RGS4
S30M-eYFP co-transfected with Gαi1  (C) RGS4
S30M-eYFP co-transfected with the 
α2A-adrenoceptor or (D) RGS4
S30M-eYFP co-transfected with the α2A-adrenoceptor and 
stimulated with 100 µM UK14304 for 30 minutes.  Images were generated using an
 
inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan 
Fluor Apochromat lens and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 
33342 nuclei staining (blue) (ii) RGS4
S30M-eYFP (green) or (iii) WGA-Alexa Fluor 594 
membrane staining (red) (iv) merged images.  Results shown are from a single experiment 
and are representative of three experiments performed. 
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(A)  (i)              (ii)             (iii)              (iv) 
 
 
 
(B)  (i)              (ii)             (iii)              (iv) 
 
 
 
(C)  (i)              (ii)             (iii)              (iv) 
 
 
 
(D)  (i)              (ii)             (iii)              (iv) 
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Figure 4.45 The cellular localisation of RGS4
S30F-eYFP 
HEK293T cells grown on coverslips were transiently transfected with (A) RGS4
S30F-eYFP 
(B) RGS4
S30F-eYFP co-transfected with Gαi1  (C) RGS4
S30F-eYFP co-transfected with the 
α2A-adrenoceptor or (D) RGS4
S30F-eYFP co-transfected with the α2A-adrenoceptor and 
stimulated with 100 µM UK14304 for 30 minutes.  Images were generated using an
 
inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan 
Fluor Apochromat lens and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 
33342 nuclei staining (blue) (ii) RGS4
S30F-eYFP (green) or (iii) WGA-Alexa Fluor 594 
membrane staining (red) (iv) merged images.  Results shown are from a single experiment 
and are representative of three experiments performed. 
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(A)  (i)              (ii)             (iii)              (iv) 
 
 
 
(B)  (i)              (ii)             (iii)              (iv) 
 
 
 
(C)  (i)              (ii)             (iii)              (iv) 
 
 
 
(D)  (i)              (ii)             (iii)              (iv) 
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Figure 4.46 The cellular localisation of RGS4
S30P-eYFP 
HEK293T cells grown on coverslips were transiently transfected with (A) RGS4
S30P-eYFP 
(B) RGS4
S30P-eYFP co-transfected with Gαi1  (C) RGS4
S30P-eYFP co-transfected with the 
α2A-adrenoceptor or (D) RGS4
S30P-eYFP co-transfected with the α2A-adrenoceptor and 
stimulated with 100 µM UK14304 for 30 minutes.  Images were generated using an
 
inverted Nikon TE2000-E microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan 
Fluor Apochromat lens and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 
33342 nuclei staining (blue) (ii) RGS4
S30P-eYFP (green) or (iii) WGA-Alexa Fluor 594 
membrane staining (red) (iv) merged images.  Results shown are from a single experiment 
and are representative of three experiments performed. 
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4.3  Discussion 
In this study, the GOF properties of RGS4
S30C, initially identified in a yeast based screen, 
are confirmed in an in vitro high-affinity GTPase assay.  RGS4
S30C demonstrated an 
enhanced α2A-adrenoceptor-activated increase in high-affinity GTPase activity of Gαo1 
compared to wild-type RGS4.  This increased GTPase activity was accompanied by a 
concurrent decrease in the potency of the adrenoceptor agonists adrenaline and UK14304 
to stimulate high-affinity GTPase activity compared to wild-type RGS4.  This serine 
residue is conserved in other members of the B/R4 family of RGS proteins and the 
conversion of serine 30 to cysteine in RGS16 also demonstrated an increase in high-
affinity GTPase activity and decrease in agonist potency compared to wild-type RGS16.  
These results suggest that the conserved serine residue in the B/R4 subfamily of RGS 
proteins is important for the GAP activity of these proteins.  Interestingly, the only other 
GOF mutation identified in an RGS protein was identified in S. cerevisiae and was also 
located in the N terminus of this protein at position 20 (SST2
P20L) (Dohlman et al., 1995).  
Serine 30 in RGS4 is positioned in the N-terminal amphipathic helix suggesting perhaps 
that this residue could be implicated in the ability of RGS4 to directly interact with GPCRs 
(Srinivasa et al., 1998;Riddle et al., 2005;Itoh et al., 2006).  The N-terminus, and in 
particular, residue 30 may help correctly position RGS4 at the receptor where it can 
optimally inactivate the G protein α subunit via the GAP activity of the RGS domain.  
Mutation of this residue may serve to change the orientation of RGS4 and subsequently the 
GAP activity of the RGS domain. 
To compare the GTPase activity of the RGS proteins studied, GST-RGS proteins were 
expressed and purified using previously published techniques (Hoffmann et al., 2001).  A 
high-affinity GTPase assay using a fixed concentration of agonist (100 µM) and increasing 
concentrations of RGS4 revealed that addition of 1 µM purified RGS4, as previously used 
by Cavalli et al., (Cavalli et al., 2000) gave sufficient activity to effectively measure 
enhanced GTPase activity of the G protein. Purification of RGS16 and RGS16
S30C 
however, was experimentally more difficult than RGS4.  In this study, maximal GTPase 
activity of RGS4 and RGS16 are never directly compared, therefore it was possible to 
lower the concentration of purified RGS16 added to high-affinity GTPase assays to 100 
nM.  In the current studies, 10 µL of each purified RGS protein was manually added to 
each assay plate, perhaps future experiments could make use of an automated liquid 
handling device to precisely transfer a smaller volume of purified RGS protein from a      168 
microplate to the assay plate allowing the final concentration of difficult to purify RGS 
proteins to be increased and perhaps ultimately enabling total assay volume to be reduced.  
In addition to an increase in the maximal high-affinity GTPase activity of Gαo1, both RGS4 
and RGS16 caused a simultaneous significant decrease in potency of the adrenoceptor 
agonist.  These observed decreases in potency are in accordance with other published 
results for the addition of RGS proteins to high-affinity GTPase assays (Ward and 
Milligan, 1999;Cavalli et al., 2000).  Hoffmann et al., compared the capacity of RGS16, 
RGS1 and GAIP to regulate GTP hydrolysis by Gαo1 following its activation by a range of 
agonists at the α2A-adrenoceptor (Hoffmann et al., 2001).  RGS16 was the most active 
RGS protein and concomitantly reduced the potency of adrenaline (pEC50 6.0 ± 0.1). 
Marked differences of the three different RGS proteins to alter the efficacy and the potency 
of the α2A-adrenoceptor-Gαo1 following agonist activation provided evidence that RGS 
proteins must interact with receptors.  If the RGS proteins were to interact only with the G 
proteins the agonist binding site would remain unchanged and no effect would be expected 
in the potency of the agonist 
In this study, the potency of adrenaline to stimulate the α2A-adrenoceptor high-affinity 
GTPase activity of Gαo1 on addition of purified RGS16 (pEC50 5.68 ± 0.3) was lower on 
the addition of RGS4 (pEC50 6.72 ± 0.08).  This perhaps provides yet further evidence for 
the selective interactions between RGS protein and GPCRs.  RGS4 and RGS16 must 
interact with the α2A-adrenoceptor, altering the conformation of the receptor.  These closely 
related RGS proteins do not function equally and the specificity of the interaction is 
perhaps fundamental to the GAP activity of the RGS protein and the ability to control 
biological functions. Indeed, previous evidence has suggested regions of RGS proteins 
outwith the RGS domain are particularly important for the selective interaction with 
GPCRs.  Interactions between RGS proteins and GPCRs are thought to be promoted 
through the N-terminal of the RGS protein.  Co-immunoprecipitation studies have 
demonstrated that the N-terminus of RGS2 binds to the third intracellular loop of the M3 
muscarinic receptors.  This binding was also seen for another member of the B/R4 family 
of RGS proteins, RGS16, but not for a further member of this family, RGS1 (Bernstein et 
al., 2004).  Also of interest are previous studies in an oocyte expression system which have 
suggested that the N-terminal of RGS8 is responsible for its ability to inhibit signalling by 
either the M1 muscarinic receptors or the substance P receptors but not the M3 muscarinic 
receptors (Itoh et al., 2006).  It is therefore conceivable that perhaps residues within the N-     169 
terminal of RGS4 and RGS16, are important for the alteration in potency of adrenaline to 
stimulate the α2A-adrenoceptor high-affinity GTPase activity of Gαo1. 
High-affinity GTPase assays using the α2A-adrenoceptor-Gαi1 fusion protein revealed that 
the GTPase enhancing activity of RGS4 and RGS16 are selective for Gαo1 over Gαi1.  
Addition of purified RGS4 or RGS16 to high-affinity GTPase assays did not increase 
maximal GTPase activity for Gαi1, but did, however, decrease the potency for adrenaline to 
stimulate high-affinity GTPase activity.  These conflicting results could suggest that the 
Gαi1 protein is working at maximal capacity in this assay system, and presence of 
additional exogenous RGS proteins interacts with the α2A-adrenoceptor but cannot further 
increase this maximal GTPase activity.  However, it has previously been established that 
the B/R4 subfamily of RGS proteins show selectivity for Gαo1 over Gαi1 (Cavalli et al., 
2000;Riddle et al., 2005), so perhaps, both RGS4 and RGS16 can interact with the α2A-
adrenoceptor but are not able to act as  efficient GAP proteins for Gαi1.   
Previously, residues involved in RGS4-Gα interaction were identified by examining the 
crystal structure of the RGS domain of RGS4 complexed with Gαi1 (Tesmer et al., 1997). 
Due to the globular nature of the N-terminal of RGS4, this region could not be crystallised 
and residues identified in the RGS-Gαi1 interaction were all within the RGS-fold of RGS4.  
Residues important for Gα selectivity within the N-terminus of RGS4 may have been 
unwittingly overlooked.  Future advances in crystallisation may allow the crystallisation of 
the full-length of RGS4-Gαo1 and reveal resides within the N-terminus important for this 
interaction.   
In this study, addition of purified RGS4
S30C or RGS16
S30C to high-affinity GTPase assays 
did not increase maximal GTPase activity for Gαi1.  However, RGS4
S30C and RGS16
S30C 
decreased the potency for adrenaline to stimulate high-affinity GTPase activity compared 
to basal activity.  This decrease in potency, unlike Gαo1, was not significantly different to 
the wild-type RGS protein.  These results suggest that, like their equivalent wild-type 
counterparts, these RGS proteins interact with the α2A-adrenoceptor and alter the 
conformation of the receptor despite the Gα subunit fused to the C-terminal.  RGS4 and 
RGS16 are also known to selectively interact with Gαi2 (Cavalli et al., 2000;Hoffmann et 
al., 2001). It would now be of interest to investigate the α2A-adrenoceptor-Gαi2 high-
affinity GTPase activity to reveal further selectivity of the B/R4 subfamily of RGS proteins 
using high-affinity GTPase assays.        170 
An increase in the membrane attachment of RGS4
S30C in HEK293T cells would orientate 
the mutated RGS protein in closer proximity to G proteins and therefore could be 
responsible for the enhanced GTPase activity of the protein.  Mutation of residue 30 to 
cysteine may have allowed palmitoylation of this residue.  Palmitoylation is the post-
translational, reversible addition of palmitate to cysteine residues that can alter both 
subcellular localisation and GAP activity of the modified protein.  Indeed, palmitolyation 
of cysteine residues at position 2 and 12 and 95 of RGS4 have already been reported (Tu et 
al., 1999).  It may therefore be plausible that further palmitolyation of cysteine at residue 
30 of RGS4 could also occur.  The cytosolic and membrane localisation of RGS4
S30C was 
comparable to wild-type RGS4 in both unstimulated and stimulated cells.  However, the 
cellular localisation of RGS4
S30C co-expressed with G proteins was conducted using Gαi1.  
At this point, high-affinity GTPase results in this study show selectivity for Gαo1 over Gαi1, 
and it would therefore be of more interest if Gαo1 had been selected for co-expression and 
perhaps future localisation studies of RGS4 should take this into account.   
It was also conceivable that an increase in the level of cellular expression of RGS4
S30C 
compared to wild-type RGS4 was responsible for the GOF properties of the mutant.  
However, detection of cell lysates transiently expressing RGS4-eYFP or RGS4
S30C-eYFP 
with an antiserum directed against GFP showed bands of equal intensity suggesting equal 
levels of expression of the two proteins.  However, the transient over-expression of both 
RGS4-eYFP and RGS4
S30C-eYFP could perhaps have concealed any differences in 
subcellular localisation or expression levels of the RGS4
S30C mutant.    
This transient over-expression of RGS4-eYFP or RGS4
S30C-eYFP could also have 
concealed differences in the inhibition of single cell [Ca
2+]i mobilisation from agonist 
activated HEK293T cells transiently expressing the α1b-adrenoceptor-Gα11 fusion protein.  
Addition of phenylephrine to these cells transiently expressing the α1b-adrenoceptor-Gα11 
fusion protein and RGS4
S30C-eYFP did not demonstrate any further inhibition or change in 
the kinetics of the downstream signalling response compared to cells expressing the α1b-
adrenoceptor-Gα11 fusion protein and wild-type RGS4-eYFP.  The transient expression of 
the eYFP tagged RGS protein routinely allowed individual cells to be selected for analysis 
that were the most highly fluorescent and therefore cells that were unequivocally 
expressing the RGS4 protein.  It is therefore reasonable to suggest that the inhibition of 
[Ca
2+]i release by RGS4 was near maximum capacity for the system and identification of 
further inhibition by an RGS4 GOF mutation would be difficult to detect.        171 
Mutating serine 30 to a range of other amino acids established the importance of this 
particular residue on the effect on the α2A-adrenoceptor-activated high-affinity GTPase 
activity.  Amino acids were selected for mutational analysis by the properties of their side 
chains.  The mutation of serine 30 to alanine, lysine, or phenylalanine resulted in a similar 
increase in α2A-adrenoceptor-Gαo1 activated high-affinity GTPase activity to RGS4
S30C.  As 
predicted for GOF mutants, all the mutants also caused a concomitant decrease in potency 
of the adrenoceptor agonist adrenaline.  It is interesting to note that RGS4
S30F and 
RGS4
S30K were also the most active mutants in Sz. pombe (Hill et al., personal 
communication).  As amino acids other than cysteine also diplay GOF activity, it is 
therefore unlikely that palmitoylation is responsible for the increase in RGS activity.  Other 
chemical properties shared by all GOF mutants are more likely to be responsible.  
Crucially, the hydroxyl group of serine at position 30 seems to be important to maintain 
wild-type activity of RGS4.  Future experiments mutating residue 30 to tyrosine or 
threonine would allow further examination of this hypothesis.  
Interestingly, conversion of residue 30 to glutamic acid or proline decreased the activity of 
RGS4 against Gαo1 in high-affinity GTPase assays. Surprisingly, both of these mutants 
demonstrated no alteration in the potency of adrenaline to stimulate high-affinity GTPase 
activity. This perhaps suggests that the presence of glutamic acid or proline alters the 
conformation of the RGS amphiphatic helix such that the RGS now no longer interacts 
with α2A-adrenoceptor.  The side chain dimensions of the two most active mutants, 
phenylalanine and lysine, are comparably large.  However, the amino acids cysteine and 
alanine at position 30 in RGS4 also demonstrated GOF properties, but the dimensions of 
these amino acids are not bigger than the least active, proline.  It is, therefore, most likely 
that chemical properties of the side chains are contributing to the GTPase activity 
alterations.  However, noticeable differences in the chemical properties between the most 
active mutants and least active RGS4
S30X mutants are difficult to detect.   
It has been determined that two members of the B/R4 subfamily of RGS proteins, RGS5 
and RGS18 contain proline at the amino acid corresponding to residue 30 in RGS4.  Since 
RGS4
S30P resulted in a reduction in RGS activity, it would be interesting to compare 
RGS5
P30S and RGS18
P30S with RGS4
S30P and further elucidate the role of proline in the 
orientation and interaction of Gα subunits with RGS proteins. 
Despite serine 30 being outwith the predicted RGS domain in RGS4 and RGS16, mutation 
of this residue can directly affect its ability to enhance GTPase activity.  This discovery      172 
may have many future therapeutic implications as alterations in RGS signalling play a role 
in many disease states.  An RGS GOF mutation could be used directly to decrease a 
signalling pathway or current small molecule inhibitors (Ingi et al., 1998) could be tested 
to examine their ability to inhibit the enhanced RGS activity of these mutants. The 
specificity of both RGS4 and RGS16 for Gαo1 is an important aspect of future therapeutics.  
This selectivity allows novel inhibitors to be designed to act on selective Gαo1 signalling 
pathways of interest. 
This study describes the GOF properties of RGS4
S30C in a α2A-adrenoceptor high-affinity 
GTPase assay. Mutation of a single amino acid in the N-terminus of this protein to enhance 
the RGS activity was transposed to another B/R4 family member, RGS16. The 
demonstrated Gα selectivity of both wild-type and mutant proteins has important future 
therapeutic implications for many signalling pathways regulated by RGS proteins.     173 
5  Chapter 5 
5.1  Introduction 
RGS proteins increase the intrinsic rate of GTP hydrolysis on Gα subunits.  It has been 
suggested that RGS proteins increase this hydrolysis by at least 40-fold by stabilising the 
transition state of the GTPase complex (Watson et al., 1996;Druey and Kehrl, 1997).  The 
highly conserved nine-helix bundle of the RGS domain is predicted to directly contact the 
Gα subunit at three switch regions.  These switch regions undergo a conformational change 
during the GTPase cycle and specific amino acids within the RGS domain have been 
identified that, through non-covalent interactions, contribute to stabilising this 
conformational change. 
Biochemical studies have shown that RGS proteins have little or no affinity for Gα-GDP 
complexes, and therefore do not alter the rate of GDP release.  Instead, RGS proteins bind 
to the GTP-bound forms of Gα subunits and stimulate GTP hydrolysis.  Interestingly, RGS 
proteins had higher affinity for Gαi1 bound to GDP and AlF4
-, a complex proposed to 
mimic the transition state of the GTPase reaction, indicating that RGS proteins act by 
stabilising the transition state (Watson et al., 1996;Berman et al., 1996b). The Ras family 
are also weak GTPases and data from p120GAP binding to, and accelerating the GTP 
hydrolysis of p21
ras, provided evidence that p120GAP introduced residues into the Ras 
active site that directly participate in the catalysis of GTP hydrolysis (Gideon et al., 
1992;Mittal et al., 1996;Scheffzek et al., 1996).  Crystallisation of RGS4 complexed with 
Gαi1 bound to GDP, AlF4
- and Mg
2+, showed only the RGS domain of RGS4 visible in the 
crystal.  However, due to the highly conserved nature of the RGS domain, the data from 
the crystallisation revealed features important for all members of the RGS family (Tesmer 
et al., 1997).  In contrast to the Ras family proteins, RGS proteins show no structural 
similarity to p120GAP, and appear not to contribute catalytical residues to the stimulation 
of GTP hydrolysis. 
Mutagenesis of residues identified from the crystallisation complex has revealed residues 
essential for normal function of RGS4.  In particular, asparagine
128 has been suggested as a 
key amino acid for the GAP action of RGS4.  It has been demonstrated that RGS4
N128A and 
RGS4
N88S,N128A have impaired GAP activity against the α2A-adrenoceptor-Gαo1 fusion 
protein (Bahia et al., 2003).  Interestingly, it was also shown that RGS4
N88S was both able      174 
(Cavalli et al., 2000) and unable (Bahia et al., 2003) to act as an effective GAP for Gαo1.  
The aim of this chapter was to investigate these RGS4 mutants using western blotting, 
microscopy and agonist-activated [Ca
2+]i mobilisation.   By adding eYFP to the C-terminal 
of RGS4
N88S, RGS4
N128A and RGS4
N88S,N128A, these techniques were used to examine the 
GAP activity of these RGS4 mutants against Gα11. 
5.2  Results 
Mutations previously introduced into RGS4 to explore the functionality of the protein as a 
GAP, were C-terminally tagged with eYFP.  This fluorescent tag was introduced to RGS4 
in which asparagine residues 88 and 128 were mutated to serine and alanine respectively.  
In addition, eYFP was also introduced to the C-terminal of RGS4
N88S and RGS4
N128A to 
investigate the importance of each single mutation.  Figure 5.1 shows the structure of these 
amino acids for comparison. 
5.2.1  Expression of aspargine RGS4 mutants 
To investigate the effect of mutating residues 88 and 128 in RGS4 on the expression level 
of the protein, RGS4-eYFP and RGS4
N88S,N128A-eYFP were individually transiently 
expressed in HEK293T cells and cell lysates were separated by SDS-PAGE (Figure 5.2).  
HEK293T cells transfected with pcDNA3 were included as a control (lane 1).  Proteins 
were detected by western blotting using an anti-GFP antiserum that recognises eYFP.  
Bands corresponding to RGS4-eYFP (lane 2) and RGS4
N88S,N128A-eYFP (lane3) at ~50kDa 
were of comparable intensity indicating equal expression of the two proteins.  No 
immunoreactivity was observed at ~50kDa in the control sample.  However, 
immunoreactivity of a non-specific protein in all lanes at ~70kDa demonstrates equal 
loading of all three protein samples. 
This protocol was repeated to investigate the expression level of RGS4
N88S-eYFP.  Bands 
of equal intensity corresponding to RGS4-eYFP and RGS4
N88S-eYFP were observed 
suggesting equivalent expression of the two proteins by HEK293T cells (Figure 5.3).  As 
observed previously, no immunoreactivity at ~50kDa, the predicted molecular weight for 
an eYFP-tagged RGS4, was observed in lane 1 in which cells were transfected only with 
pcDNA3.  Again, a non-specific band at ~70kDa was observed in all three samples, 
suggesting identical total protein concentrations were present.      175 
This protocol was again repeated to compare the expression levels of RGS4
N128A-eYFP to 
wild-type RGS4-eYFP.  Cell lysates of transfected HEK293T cells separated by SDS-
PAGE and immunoblotted by an anti-GFP antiserum demonstrated equal expression of 
both the wild-type and the mutant RGS4 protein (Figure 5.4). 
5.2.2  Functional activity of asparagine RGS4 mutants 
As previously described, following expression of the α1b-adrenoceptor-Gα11 fusion protein, 
agonist activation causes an elevation in [Ca
2+]i (Chapter 5, Section 1.22) (Stevens et al., 
2001).  In HEK293T cells, Gα11 activates PLCβ which in turn hydrolyses PIP2 and 
produces IP3 and DAG, leading to activation of downstream effector molecules and a rise 
in [Ca
2+]i.  The amplification of this signal is limited by the return of the Gα subunit to the 
inactive GDP-bound state by GTPase activity.  Therefore, increasing the rate of GTP 
hydrolysis by the GAP action of RGS proteins should further limit this amplification.  
Expression of RGS4 with a fluorescent tag attached allows the visual identification of cells 
positively transfected with RGS4.  Expression of RGS4-eYFP negatively regulates [Ca
2+]i 
mobilisation by agonist-stimulated α1b-adrenoceptor-Gα11 fusion protein (Figure 5.5).   
The co-expression of the α1b-adrenoceptor-Gα11 fusion protein with an RGS mutant that 
has impaired GAP activity would be anticipated to limit the effect on [Ca
2+]i mobilisation.  
Indeed, co-expression of RGS4
N88S-eYFP, RGS4
N128A-eYFP and RGS4
N88S,N128A-eYFP 
with the α1b-adrenoceptor-Gα11 fusion protein had no effect on agonist-mediated elevation 
of [Ca
2+]i (Figure 5.6). 
The consistency of these results was demonstrated by repeating this protocol using the 
thyrotropin-releasing hormone receptor (TRHR-1)-Gα11 fusion protein.  Co-expression of 
this receptor-G protein fusion with RGS4-eYFP also demonstrated reduced amplification 
of [Ca
2+]i (Figure 5.7).  However, co-expression of RGS4
N88S-eYFP, RGS4
N128A-eYFP and 
RGS4
N88S,N128A-eYFP with the TRHR-1-Gα11 fusion protein did not affect the maximal 
[Ca
2+]i mobilisation,  suggesting that all three RGS4 mutants have ablated GAP activity 
with no additive effect following expression of the double mutant (Figure 5.8). 
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Figure 5.1 Amino acids selected for substitution of asparagine 88 and 128 in RGS4 
Asparagine residues in RGS4 were selected for site directed mutagenesis.  Asparagine at 
position at 88 was mutated to serine and asparagine at position 128 was mutated to alanine 
to produce three constructs, RGS4
N88S-eYFP, RGS4
N128A-eYFP and RGS4
N88S,N128A-eYFP. 
.  
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Figure 5.2 Expression and immunological detection of RGS4-eYFP and 
RGS4
N88S,N128A-eYFP 
HEK293T cells were transiently transfected to express RGS4-eYFP (lane 2) or 
RGS4
N88S,N128A-eYFP (lane 3).  HEK293T cells transfected with pcDNA3 were included as 
a control (lane 1).  Cell lysates were resolved by SDS-PAGE and then immunoblotted with 
anti-GFP antiserum.  Results shown are of a single experiment and are representative of 
three experiments performed. 
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Figure 5.3 Expression and immunological detection of RGS4-eYFP and RGS4
N88S-
eYFP 
HEK293T cells were transiently transfected to express RGS4-eYFP (lane 2) or RGS4
N88S-
eYFP (lane 3).  HEK293T cells transfected with pcDNA3 were included as a control (lane 
1).  Cell lysates were resolved by SDS-PAGE and then immunoblotted with anti-GFP 
antiserum.  Results shown are of a single experiment and are representative of three 
experiments performed. 
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Figure 5.4 Expression and immunological detection of RGS4-eYFP and RGS4
N128A-
eYFP 
HEK293T cells were transiently transfected to express RGS4-eYFP (lane 2) or RGS4
N128A-
eYFP (lane 3).  HEK293T cells transfected with pcDNA3 were included as a control (lane 
1).  Cell lysates were resolved by SDS-PAGE and then immunoblotted with anti-GFP 
antiserum.  Results shown are of a single experiment and are representative of three 
experiments performed. 
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Figure 5.5 RGS4-eYFP reduces phenylephrine stimulation of [Ca
2+]i  via the α1b-
adrenoceptor-Gα11
  fusion protein  
HEK293T cells were transfected to express the α1b-adrenoceptor-Gα11 fusion protein 
(black line) or the α1b-adrenoceptor-Gα11
 fusion protein and RGS4-eYFP (green line).  
Cells were loaded with Fura-2/AM and [Ca
2+]i levels imaged before and after 3 µM 
phenylephrine was perfused over the cells for 60 seconds.  Data represents means ± SEM. 
from 15 (α1b-adrenoceptor-Gα11), and 17 (α1b-adrenoceptor-Gα11
 and RGS4-eYFP) cells 
from 3 individual experiments performed. 
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Figure 5.6 Mutation of asparagine 88 or 128 in RGS4 eliminates GAP activity against 
phenylephrine-stimulation of [Ca
2+]i  via the α1b-adrenoceptor-Gα11
 fusion protein 
HEK293T cells were transfected to express the α1b-adrenoceptor-Gα11 fusion protein 
(black line), the α1b-adrenoceptor-Gα11
 fusion protein and RGS4
N88S-eYFP (pink), the α1b-
adrenoceptor-Gα11
 fusion protein and RGS4
N128A-eYFP (orange), or the α1b-adrenoceptor-
Gα11
 fusion protein and RGS4
N88S,N128A-eYFP (brown).  Cells were loaded with Fura-
2/AM and [Ca
2+]i levels imaged before and after 3 µM phenylephrine was perfused over 
the cells for 60 seconds.  Data represents means ± SEM. from 15 (α1b-adrenoceptor-Gα11), 
27 (α1b-adrenoceptor-Gα11
 and RGS4
N88S-eYFP), 9 (α1b-adrenoceptor-Gα11
 and 
RGS4
N128A-eYFP), and 20 (α1b-adrenoceptor-Gα11
 and RGS4
N88S,N128A-eYFP) cells from 3 
individual experiments performed. 
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Figure 5.7 RGS4-GFP
2 reduces TRH stimulation of [Ca
2+]i  via theTRHR–1-Gα11  
fusion protein 
HEK293T cells were transfected to express the TRHR-1-Gα11 fusion protein (black line) 
or the TRHR-1
 and RGS4-GFP
2 (green line).  Cells were loaded with Fura-2/AM and 
[Ca
2+]i levels imaged before and after 10 µM thyrotropin-releasing hormone (TRH) was 
perfused over the cells for 60 seconds.  Data represents means ± SEM. from 12 (TRHR-1) 
and 9 (TRHR-1and RGS4-GFP
2) cells from 3 individual experiments performed. 
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Figure 5.8 Mutation of asparagine  88 or 128 in RGS4 elimanes GAP activity against 
TRH stimulation of [Ca
2+]i  via  the TRHR–1-Gα11  fusion protein   
HEK293T cells were transfected to express the TRHR-1 (black line), the TRHR-1
 and 
RGS4
N88S-eYFP (pink line), the TRHR-1
 and RGS4
N128A-eYFP (orange line), or the 
TRHR-1 and RGS4
N88S,N128A-eYFP (brown) line.
  Cells were loaded with Fura-2/AM and 
[Ca
2+]i levels imaged before and after 10 µM TRH was perfused over the cells for 60 
seconds.  Data represents means ± SEM. from 12 (TRHR-1), 13 (TRHR-1and RGS4
N88S-
eYFP), 17 (TRHR-1and RGS4
N128S-eYFP), 15 (TRHR-1and RGS4
N88S,N128A-eYFP) cells 
from 3 individual experiments performed. 
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5.3  Discussion 
Mutational analysis of RGS proteins previously identified specific amino acids important 
for the GAP activity of these proteins.  Changing specific single amino acids at the Gαi1-
RGS4 binding interface can result in impaired GAP activity of RGS4.  The structure of 
RGS4-Gαi1 complexed in the transition state suggests that RGS4 could stimulate GTP 
hydrolysis by contributing to the overall stability of the transition state complex.   
The importance of asparagine
88 and asparagine
128 to the GAP activity of RGS4 has 
previously been reported and was further investigated in this study.  Mutation of both 
residue 88 and residue 128 to serine and alanine respectively, resulted in ablated GAP 
activity RGS4 towards Gα11, a previously unknown detail.  In addition, the importance of 
each individual mutation was also studied.  Both RGS4
N88S and RGS4
N128A demonstrated 
ablated GAP activity, showing there was no additive effect of the double mutant.  These 
RGS4 mutants were selected for use in this study due to their previous successful 
application to show impaired GAP activity.  However, no previous study has demonstrated 
the use of these RGS4 mutants towards Gα11. 
Introduction of a mutation can often cause an alteration in expression of the protein.  
However, no differences in protein size or expression levels were observed among the 
aspragine RGS4 mutant proteins.  This suggests that the impaired GAP activity of the 
RGS4 mutants was caused by disruption of the binding interface between the Gα subunit 
and RGS4. 
Structural data shows that the three switch regions of Gαi1 interact with the most highly 
conserved regions of RGS4 (Tesmer et al., 1997). Threonine
182 of switch region I interacts 
exclusively with seven highly conserved residues of RGS4, including asparagine
88.  It 
could therefore be anticipated that when asparagine
88 was mutated to serine, the loss of an 
amide and a carbonyl group would disrupt the interaction between switch region I and 
RGS4, causing impaired GAP activity.  A previous study has investigated the mutation of 
asparagine
88 to alanine (Srinivasa et al., 1998).  The alanine substitution also demonstrated 
diminished GAP activity of RGS4 and was proposed to disrupt the binding pocket in 
RGS4 in which theronine
182 of the G protein binds.  In this way, serine at position 88 in 
RGS4 would also cause a change in the amino acid side chains contributing to the binding 
pocket, and a loss of hydrogen bonding to the Gα subunit.  Further evidence has also 
suggested that asparagine
88 interacts co-operatively with the neighbouring amino acid,      185 
glutamic acid
77.  A double mutant in which both these amino acids were mutated to alanine 
had a much stronger defect in GAP activity than either single mutation (Srinivasa et al., 
1998).   However, a study using a RGS4
N88S fused in-frame to the α-adrenoceptor 
demonstrated that this fusion protein was both able to stimulate and then deactivate Gαo1 
(Bahia et al., 2003).  In the present study, asparagine
88 was functionally important in the 
regulation of [Ca
2+]i amplification.  RGS4
N88S demonstrated a loss of GAP activity by the 
inability to inhibit signalling by activated Gα11 in HEK293T cells.  It could therefore be 
reasoned that aspargine
88 of RGS4 also interacts with the equivalent theronine in Gα11, 
Gα11
T186. 
Also in switch region I, lysine
180 of Gαi1 forms extensive van der Waals contacts with 
asparagine
128 of RGS4.  Although a transient, weak electrical attraction of one atom for 
another, a number of van der Waals forces can provide an important component of protein 
structure.  The force arises from the transient attraction between the nucleus of one atom 
and the electron cloud of a neighbouring atom. When asparagine is mutated to alanine, the 
loss of a carbonyl group and a hydroxyl group could be anticipated to affect the spatial 
distance between the molecules.  The attraction between atoms can only operate over a 
short distance and if two atoms move closer together then severe repulsion between the 
two nuclei of the atoms can occur. If the atoms move further apart the weak attractions will 
be broken. The presence of alanine at position 128 could therefore disrupt this bonding and 
reduce the contact of RGS4 and Gαi1, weakening the ability of RGS4 to stabilise the 
transition state of the GTPase cycle. 
Switch region I and II of Gαi1 also interact with asparagine
128 in RGS4 (Tesmer et al., 
1997).  The importance of asparagine
128 to the function of RGS4 is highlighted by the 
almost complete conservation of this residue within the RGS family.  The only natural 
substitution is for serine in some RGS proteins such as GAIP (Vries et al., 1995;Berman et 
al., 1996b;Popov et al., 1997;Posner et al., 1999).  Natochin et al., mutated aspargine
128 in 
RGS4 to serine to and demonstrated that serine proves to be the best substitution for 
asparagine in regards to preserving the GAP activity of the protein (Natochin et al., 1998).  
Asparagine
128 is the only RGS4 residue that projects into the active site of Gαi1 and 
together with its location at the binding interface and interaction with three Gαi1 residues at 
the active site (glutamine
204, glutamic acid
207 and lysine
180) further underline the 
importance of asparagine
128 to the GAP activity of RGS4.      186 
Previous results from mutating asparagine
128 in RGS4 to several other amino acids have 
indicated that some GAP activity of RGS4 can be retained (Natochin et al., 1998).   
However, all results using RGS4
N128A suggested that the alanine mutant had low GAP 
activity (Natochin et al., 1998;Srinivasa et al., 1998;Posner et al., 1999;Bahia et al., 2003). 
Although now disputed (Srinivasa et al., 1998), asparagine
128 has previously been 
suggested to be critical in orientating and polarising a hydrolytic water molecule in the 
transition state of GTP hydrolysis (Posner et al., 1999).  Replacing asparagine
128 with the 
hydrophobic amino acid alanine would prevent any interaction with a water molecule and 
the RGS protein would be unable to stabilise conformational changes in the GTPase cycle. 
This study demonstrated that RGS4
N88S,N128A displayed loss of GAP activity towards Gα11. 
Both RGS4
N88S and RGS4
N128A also displayed no functional GAP activity towards Gα11 
with no apparent change in GAP activity following expression of a single asparagine 
mutation.  Following transfection, single cells were selected that were fluorescent, a 
marker for cells positively transfected with RGS4-eYFP.  In a field of view, cells 
invariably show a range of fluorescence expression and to allow reliable comparison 
between mutants, only the brightest fluorescent cells were selected.  It is possible, 
therefore, that in using agonist-activated [Ca
2+]i amplification to measure GAP activity, 
small differences in GAP activity between mutants may have been concealed. It would 
perhaps been hypothesised that RGS4
N88S and RGS4
N128A could have retained some GAP 
activity, compared to the double mutant.  As previously mentioned, structural and 
functional data suggest that RGS4 stimulates GTP hydrolysis by stabilising the transition 
state conformation.  The additive effect of disrupting two areas of the binding interface 
between RGS4 and Gα11 would be anticipated to further impair the GAP activity of RGS4.  
However, these single amino acid mutations seem able to totally disrupt the GAP activity 
of the protein, perhaps being sufficient to achieve a global conformational change of the 
complex. 
Finally, the identity of Gα subtype may play a role in determining the GAP activity of RGS 
proteins.   The loss of GAP activity of the asparagine RGS4 mutants in this study is 
consistent with other studies, when the Gα substrate was Gαo and Gαi1 (Druey and Kehrl, 
1997;Bahia et al., 2003).  The amino acids of Gα subunit proposed to be involved in 
binding to residues 88 and 128 of RGS4 are highly conserved, although Posner et al., 
demonstrated RGS4
N128F differentially decreased the GAP activity towards Gαi1 compared 
to Gαq.  This mutation was suppressed by mutating the residue in Gαi to that found in Gαq 
(
K180P) (Posner et al., 1999).  The identity of the Gα subunit may alter the function of      187 
asparagine
128 and perhaps comparing the agonist-activated [Ca
2+]i mobilisation by the α1b-
adrenoceptor fused to Gαq would have been informative. 
The lifetime of the RGS-Gα complexes determines the GAP activity of RGS proteins for 
plasma membrane-associated heterotrimeric G proteins and determines the signal strength 
and regulates activity of effectors.  Certainly, RGS4 may also interact with the receptor and 
the Gβγ subunit to further stabilise the signalling complex but the total loss of all GAP 
activity in such mutant RGS proteins could prove useful in future drug discovery.  Small 
molecules which inhibit RGS-Gα interaction have been proposed as novel drugs which 
could be used to treat numerous disease states.  As such, the model of these mutant 
aspargine resides in RGS4 could be crucial to novel drug development.     188 
6  Chapter 6 
6.1  Introduction 
Genetic and biochemical studies have demonstrated that RGS proteins interact directly 
with Gα subunits (Berman et al., 1996b). This physical association allows RGS proteins to 
increase the rate of hydrolysis of GTP to GDP on the Gα subunit and negatively regulate 
signalling. Multiple RGS proteins are known to interact with each Gα subtype and 
establishing the contribution of endogenous RGS proteins to signal transduction in vivo 
was initially thought to require construction of specific knockout mutants. However, the 
identification and characterisation of a Gα subunit mutant that specifically disrupts the 
interaction with RGS proteins provided a new approach to study the endogenous function 
of RGS proteins (DiBello et al., 1998). A single amino acid change in the Gα subunit 
produced a G protein insensitive to RGS action.   
This point mutation in the Gα subunit was originally identified in S. cervisiae in a screen 
for yeast strains that were supersensitive to pheromone.  One such strain had a single 
glycine to serine mutation in the yeast Gα subunit, Gpa1, which escaped regulation by the 
RGS protein, Sst2.  This glycine residue was shown to be conserved in the mammalian Gα 
subunits and subsequent studies have shown that the corresponding mutation in Gαq, Gαi1 
and Gαo also produces RGS-insensitivity. These mutant Gα subunits have become 
important tools for studying the endogenous role of RGS proteins. Indeed, with multiple 
RGS proteins being able to interact with each Gα subtype, inactivating every one of these 
endogenous RGS proteins would be difficult.  Instead, the use of a single mutant Gα 
subunit can be used to ascertain the combined role of endogenous RGS proteins on the 
function of a particular Gα subunit. 
Transient over-expression of RGS proteins, or more usually, epitope-tagged RGS proteins, 
produces an unnatural system and could lead to invalid conclusions.  However, most 
previous studies have used transient over-expression to determine RGS function and 
overcome the low natural abundance of endogenous RGS proteins.  As an alternative, 
transiently expressing a Gα subunit insensitive to RGS proteins could elucidate 
endogenous RGS function.  This study determines if the previously identified RGS-
insensitive mutation can be effectively transferred into Gα11.  Gαq and Gα11 share 98% 
homology and examination of mammalian Gαq
G188S in cells co-transfected with the 5HT2C      189 
receptor has previously revealed that, compared to wild-type mammalian Gαq, the response 
of Gαq
G188S was not inhibited by RGS7 (DiBello et al., 1998).  However, it has now been 
determined that some RGS proteins can discriminate between the two highly related Gαq 
family subunits (Ladds et al., 2007) and the aim of this study was to investigate signal 
transduction of a potentially RGS-insensitive Gα11 (Gα11
G188S
). 
Agonist-activation of receptors linked to the Gαq subfamily of G proteins produce 
amplification of the second messenger, calcium.  The intracellular Ca
2+ response produced 
in single cells was used to investigate the role of Gα11
G188S
.  Thus, the use of mouse 
embryonic fibroblast cells (EF88) derived from a combined Gαq and Gα11 knockout mouse 
was crucial in this study.  The Gα11
G188S protein was fused in-frame to the C-terminal of 
the α1b-adrenoceptor.   Following agonist occupation, the rise in [Ca
2+]i mediated by a wild-
type α1b-adrenoceptor-Gα11 fusion protein (Stevens et al., 2001) was compared to the rise 
in [Ca
2+]i mediated by the α1b-adrenoceptor-Gα11
G188S fusion protein in EF88 cells.  The 
generality of agonist-activated [Ca
2+]i mediated by Gα11
G188S  was demonstrated by 
transferring the 
G188S mutation to the Gα11 protein fused in-frame to the C-terminal of the 
TRHR-1.  The level of [Ca
2+]i produced upon activation of the TRHR-1-Gα11
G188S fusion 
protein was then compared to the wild-type TRHR-1-Gα11 fusion protein. 
Biochemical studies have previously suggested that the RGS-insensitive Gα subunits 
display a reduced affinity for RGS4 (Lan et al., 1998). G proteins, unable to be regulated 
by RGS proteins, have also been reported conflictingly to be both able (Druey et al., 1998) 
and unable (Roy et al., 2003) to translocate RGS4 to the plasma membrane.  Both the α1b-
adrenoceptor and the TRHR-1-G protein fusion proteins were used to study the subcellular 
localisation of RGS4-eYFP in receptor-activated HEK293T cells. 
The [
35S]GTPγS binding assay was used to measure the level of G protein activation of 
Gα11
G188S
.   The binding of the non-hydrolysable analogue [
35S]GTPγS  to the Gα subunit 
of the α1b-adrenoceptor-Gα11 fusion protein was compared to the α1b-adrenoceptor-
Gα11
G188S fusion protein.  The only reported effect of the RGS-insensitive mutation is to 
prevent RGS action on Gα.  However, using these methods, additional novel roles for the 
RGS insensitive mutation, 
G188S in Gα11 became apparent. 
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6.2  Results 
6.2.1  Translocation of RGS4 in the presence Gα11
G188S 
The intracellular translocation of RGS4 was previously examined in this study by 
transfection of HEK293T cells with C-terminally eYFP-tagged RGS4 (Chapter 3, Section 
3.2.3). In agreement with previous studies, the vast majority of transiently transfected 
RGS4-eYFP in HEK293T cells was localised within the cytoplasm (Druey et al., 
1998;Chatterjee and Fisher, 2000).  It was also demonstrated that over-expressing agonist 
activated receptor promoted the translocation RGS4-eYFP from the cytoplasm to the 
plasma membrane in HEK293T cells (Chapter 3, Section 3.2.5).  
In order to investigate the subcellular localisation of RGS4 in the presence of an agonist-
activated receptor fused to an RGS-insensitive G protein, HEK293T cells were transiently 
co-transfected with either (A) the α1b-adrenoceptor-Gα11 fusion protein and RGS4-eYFP or 
(B) the α1b-adrenoceptor-Gα11
G188S fusion protein and RGS4-eYFP (Figure 6.1).  Using 
microscopy, the localisation of RGS4-eYFP in fixed cell samples was determined.  As 
before, the blue colour (i) represents Hoechst 33342 DNA staining that was used to 
identify the nuclei in these cells. The green colour (ii) represents eYFP fluorescence from 
expressed RGS4-eYFP and the red colour (iii) represents WGA-Alexa Fluor 594 used to 
label the plasma membrane.  To identify any RGS4-eYFP localised at the plasma 
membrane, an overlay image is also shown (iv).  In these overlay images yellow colour 
represents any RGS4-eYFP that is co-localised with WGA-Alexa Fluor 594 at the plasma 
membrane.  Figure 6.1 demonstrates that some RGS4-eYFP in HEK293T cells transiently 
co-transfected with the α1b-adrenoceptor-Gα11 fusion protein and stimulated with 100 µM 
phenylephrine, was located at the plasma membrane.  In contrast, RGS4-eYFP in 
HEK293T cells transiently co-transfected with the α1b-adrenoceptor-Gα11
 G188S
 fusion 
protein and stimulated with 100 µM phenylephrine, was predominantly localised within the 
cytoplasm.  Agonist activation of the α1b-adrenoceptor-Gα11
 G188S
 fusion protein therefore 
did not promote detectable translocation of RGS4-eYFP in HEK293T cells. 
The subcellular localisation and translocation pattern of RGS4-eYFP co-expressed with 
Gα11
G188S was also confirmed by determining the percentage fluorescence of RGS4-eYFP 
in the plasma membrane of these co-transfected HEK293T cells (Figure 6.2).  The 
percentage of RGS4-eYFP fluorescence in the plasma membrane of cells co-transfected 
with the α1b-adrenoceptor-Gα11 fusion protein (defined as 100%) was directly compared to      191 
the percentage of RGS4-eYFP fluorescence in the plasma membrane of these cells 
stimulated with 100 µM phenylephrine. In these cells, agonist-stimulation translocated 
RGS4-eYFP to the plasma membrane (159 ± 2%). In contrast, agonist-stimulation did not 
translocate RGS4-eYFP to the plasma membrane when cells were co-transfected with the 
α1b-adrenoceptor-Gα11
G188S
 fusion protein (100 ± 1%).  This further confirmed that the 
predicted RGS-insensitive Gα11 mutation must indeed directly influence the interaction of 
the Gα subunit and RGS4. 
A similar pattern of RGS4-eYFP translocation was demonstrated when HEK293T cells 
were transiently co-transfected with the TRHR-1-Gα11 fusion protein and challenged with 
the TRHR-1 selective agonist TRH (Figure 6.3).  Microscopy revealed that RGS4-eYFP 
was still predominantly localised in the cytoplasm in cells co-transfected with the TRHR-
1-Gα11
G188S
 fusion protein and stimulated with TRH (Figure 6.3(B)).  In contrast, the 
presence of the agonist-stimulated TRHR-1-Gα11 fusion protein showed co-localisation of 
RGS4-eYFP and the plasma membrane marker WGA-Alexa Fluor 594 (Figure 6.3 (A)).  
As before, the percentage of RGS4-eYFP fluorescence in the plasma membrane in cells co-
transfected with the TRHR-1-Gα11 fusion protein or the TRHR-1-Gα11
G188S
 fusion protein 
was also examined (Figure 6.4).  The TRHR-1-Gα11
G188S
 fusion protein did not translocate 
RGS4-eYFP to the plasma membrane.  The direct effect of the predicted RGS-insensitive 
Gα11 mutation on the interaction to RGS4 is therefore not restricted to the action of a single 
receptor. 
6.2.2  [
35S]GTPγS binding to the α1b-adrenoceptor-Gα11
G188S fusion 
protein 
In order to investigate the expression levels of the α1b-adrenoceptor-Gα11
G188S fusion 
protein, membranes transiently expressing the α1b-adrenoceptor-Gα11 fusion proteins, were 
subjected to radioligand binding.  Specific binding of the α1b-adrenoceptor antagonist 
[
3H]prasozin  was determined by subtracting the level of binding observed in the presence 
of the non-specific antagonist phentolamine (100 µM) (Figure 6.5).  Levels of expression 
(Bmax) of the receptor-G protein fusion proteins varied between individual transfections, 
but importantly the affinity (Kd) of the α1b-adrenoceptor-Gα11 (0.54 ± 0.01 nM) and of the 
α1b-adrenoceptor-Gα11
G188S (0.49 ± 0.01 nM) for [
3H]prasozin was not affected by the 
G188S 
mutation in Gα11.        192 
From these binding studies, HEK293T cell membranes with equivalent amounts of each 
transfected fusion protein were added to [
35S]GTPγS binding assays.  A maximally 
effective concentration of phenylephrine increased
 the level of bound [
35S]GTPγS to the 
α1b-adrenoceptor-Gα11 fusion protein.  However, the specific effectiveness of 
phenylephrine to stimulate [
35S]GTPγS binding to the α1b-adrenoceptor-Gα11
G188S fusion 
protein was significantly reduced by 90.2 ± 0.85 % (p<0.01) (Figure 6.6).  Employing a 
range of concentrations of
 phenylephrine revealed that this difference could be attributed to 
the efficacy of the G protein to bind [
35S]GTPγS, as the reduction in the ability of 
phenylephrine to stimulate [
35S]GTPγS binding to the α1b-adrenoceptor-Gα11
G188S
  fusion 
protein was not accompanied by a reduction in potency of the agonist (Figure 6.7).  The 
pEC50 of phenylephrine for the α1b-adrenoceptor-Gα11 fusion protein (pEC50 6.14 ± 0.09) 
and the α1b-adrenoceptor-Gα11
G188S (pEC50 6.35 ± 0.06) remained unchanged (p>0.05) 
(Figure 6.7 (B)). 
Binding of [
35S]GTPγS  to the α1b-adrenoceptor-Gα11  fusion protein was determined by 
immunoprecipitation with an antiserum (CQ) which identifies the C-terminal decapeptide 
of
 Gα11.  To ensure that the reduction in the effectiveness of phenylephrine to stimulate 
[
35S]GTPγS binding on the α1b-adrenoceptor-Gα11
G188S fusion protein was not due to the 
antiserum CQ being unable to recognise the mutated G protein, membranes expressing 
equal levels of receptor-Gα protein fusion, used in the [
35S]GTPγS  binding assay, were 
treated with N-Glycosidase F, separated by SDS-PAGE and detected with the antiserum, 
CQ (Figure 6.8).  Previously, western blot analyses of the α1b-adrenoceptor-Gα11 fusion 
demonstrated distinct doublets (at approximately 90 kDa and 110 kDa) that probably 
reflected differential
 glycosylation of the receptor (Liu et al., 2002).  Pre-treatment of 
membranes with N-Glycosidase F released all common classes of N-glycans from the 
protein backbone and produced a single comparable band for each fusion protein.  Bands 
corresponding to α1b-adrenoceptor-Gα11 (lane 1) and α1b-adrenoceptor-Gα11
G188S (lane 2) 
were of comparable intensity, indicating similar reactivity of the two fusion proteins to the 
antiserum CQ.  Decreased reactivity to the antiserum CQ of the α1b-adrenoceptor-Gα11
G188S 
fusion protein is therefore not responsible for the reduction in the effectiveness of 
phenylephrine to stimulate [
35S]GTPγS binding.      193 
6.2.3  Intracellular Ca
2+ mobilisation following expression of the α1b-
adrenoceptor-Gα11
G188S fusion protein 
To investigate the effect of Gα11
G188S on downstream signalling, the ability of the α1b-
adrenoceptor-Gα11 fusion protein and the α1b-adrenoceptor-Gα11
G188S fusion protein to 
elevate [Ca
2+]i in response to phenylephrine was compared.  To investigate the effect of the 
mutated Gα11 subunit it was imperative to use a cell line with no endogenous wild-type 
Gα11.  Presence of any wild-type Gα11 would produce a response that could not be 
exclusively attributed to the presence of a mutation.  To verify the constitutive knockout of 
endogenous Gαq and Gα11 in EF88 cells, cell lysates of EF88 cells were separated by SDS-
PAGE and probed with the antiserum CQ (Figure 6.9 (lane3)).  As a positive control, EF88 
cells transfected with Gα11 (lane1) or Gα11
G188S (lane2) were included.  Bands 
corresponding to Gα11 at ~37 kDa in lane 1 and lane 2, but not in lane 3 confirmed that no 
endogenous Gαq/Gα11 are expressed in EF88 cells and that the transfection of cells was 
effective.  This immunoblot also further confirms the reactivity of the RGS-insensitive Gα 
subunit with the antiserum CQ. 
Thus, the EF88 cells used in this study do not express endogenous Gαq/Gα11 and, when 
introduced transiently, both the Gα11 and the Gα11
G188S proteins were equally expressed by 
these cells.  The effect of the 
G188S mutation in Gα11 on the activity of downstream 
signalling could now be investigated.  Expression of RGS4 with GFP
2 fused to the C 
terminal, allowed the identification of positively transfected fibroblasts.  Following co-
transfection of the α1b-adrenoceptor-Gα11 fusion protein and RGS4-GFP
2, there was a 
decrease in the maximal agonist-mediated elevation of [Ca
2+]i compared to expression of 
the α1b-adrenoceptor-Gα11 fusion protein alone (Figure 6.10).  The α1b-adrenoceptor-
Gα11
G188S fusion protein was transfected as before and compared to EF88 cells co-
transfected with the α1b-adrenoceptor-Gα11
G188S fusion protein (Figure 6.11).  Surprisingly, 
expression of the α1b-adrenoceptor-Gα11
G188S fusion protein almost eliminated the agonist-
mediated elevation of [Ca
2+]i.  Co-expression of RGS4-GFP
2 did not alter the [Ca
2+]i. 
mobilisation in these cells. 
The [Ca
2+]i  response in EF88 cells transiently transfected with the TRHR-1-Gα11
G188S
 
fusion protein and stimulated with TRH (10 µM) also demonstrated virtually no [Ca
2+]i  
mobilisation compared to the agonist activated wild-type TRHR-1-Gα11 fusion protein 
(Figure 6.12).  The reduction in [Ca
2+]i  elevation of the 
G188S mutation in Gα11 is not 
restricted to the action of the α1b-adrenoceptor.      194 
  
(A)  (i)               (ii)              (iii)              (iv) 
 
 
 
 
(B)  (i)                 (ii)                (iii)              (iv) 
 
 
 
 
Figure 6.1 The cellular localisation of RGS4-eYFP co-expressed with the α α α α1b-
adrenoceptor-Gα α α α11 fusion protein or the α1b-adrenoceptor-Gα11
G188S fusion protein 
and stimulated with phenylephrine 
HEK293T cells grown on coverslips were transiently co-transfected with (A) RGS4-eYFP 
and the α1b-adrenoceptor-Gα11 and stimulated with 100 µM phenylephrine for 30 minutes 
or  (B)  RGS4-eYFP and α1b-adrenoceptor-Gα11
 G188S
  and stimulated with 100 µM 
phenylephrine for 30 minutes.  Images were generated using an
 inverted Nikon TE2000-E 
microscope equipped with a 60 x, (NA=1.4), oil-immersion Plan Fluor Apochromat lens 
and a cooled digital Cool Snap-HQ CCD camera. (i) Hoechst 33342 nuclei staining (blue) 
(ii) RGS4-eYFP (green) or (iii) WGA-Alexa Fluor 594 membrane staining (red) (iv) 
merged images.  Results shown are of a single experiment and are representative of three 
individual experiments performed. 
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Figure 6.2 Comparison of percentage RGS4-eYFP fluorescence at the plasma 
membrane when co-expressed with the α1b-adrenoceptor-Gα11 fusion protein or the 
α α α α1b-adrenoceptor-Gα α α α11
G188S fusion protein  
HEK293T cells were transiently transfected to express RGS4-eYFP and co-transfected 
with the α1b-adrenoceptor-Gα11 fusion protein or the α1b-adrenoceptor-Gα11
G188S fusion 
proteins and stimulated with 100 µM phenylephrine for 30 minutes.  The membrane 
fraction of cells co-expressing the fusion proteins was measured for total RGS4-eYFP 
fluorescence (defined as 100%) and compared to cells not stimulated with phenylephrine.  
Data shown are from triplicate determinations (mean ± SEM.) and are representative of 
three experiments performed. 
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(A)  (i)              (ii)             (iii)              (iv) 
 
 
 
(B)  (i)              (ii)             (iii)              (iv) 
 
 
 
 
Figure 6.3 The cellular localisation of RGS4-eYFP co-expressed with the TRHR-1-
Gα11 fusion protein or the TRHR-1-Gα11
G188S fusion protein and stimulated with TRH 
HEK293T cells grown on coverslips were transiently co-transfected with (A) RGS4-eYFP 
and the TRHR-1-Gα11 fusion protein and stimulated with 10 µM TRH for 30 minutes  or  
(B) RGS4-eYFP and  the TRHR-1-Gα11
G188S
  fusion protein and stimulated with 10 µM 
TRH 30 minutes.  Images were generated using an
 inverted Nikon TE2000-E microscope 
equipped with a 60 x, (NA=1.4), oil-immersion Plan Fluor Apochromat lens and a cooled 
digital Cool Snap-HQ CCD camera. (i) Hoechst 33342 nuclei staining (blue) (ii) RGS4-
eYFP (green) or (iii) WGA-Alexa Fluor 594 membrane staining (red) (iv) merged images.  
Results shown are of a single experiment and are representative of three experiments 
performed. 
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Figure 6.4 Comparison of percentage RGS4-eYFP fluorescence at the plasma 
membrane when co-expressed with the TRHR-1-Gα11 fusion protein or the TRHR-1-
Gα11
 G188S fusion protein 
HEK293T cells were transiently transfected to express RGS4-eYFP and co-transfected 
with the TRHR-1 -Gα11 fusion protein or the TRHR-1-Gα11
G188S fusion protein and 
stimulated with 10 µM TRH for 30 minutes.  The membrane fraction of cells co-expressing 
the fusion protein was measured for RGS4-eYFP fluorescence (defined as 100%) and 
compared to cells not stimulated with TRH.  Data shown are from triplicate determinations 
(mean ± SEM, very small and therefore cannot be seen.) and are representative of three 
experiments performed. 
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(A) 
 
 
 
 
 
 
(B) 
 
 
 
 
 
Figure 6.5  Binding of [
3H]prasozin to the α1b-adrenoceptor-Gα11 fusion protein or the 
α1b-adrenoceptor-Gα11
G188S fusion protein 
HEK293T cells were transfected to express (A) the α1b-adrenoceptor-Gα11 fusion protein 
or (B) the α1b-adrenoceptor-Gα11
G188S fusion protein.   2 µg of each membrane preparation 
was used to measure the binding (blue) of [
3H]prasozin (0-3.4 nM).  Non-specific binding 
(red) was determined in the presence of phentolamine (100 µM).  Data shown are from 
triplicate determinations (mean ± SEM.) and are representative of three individual 
experiments performed. 
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Figure 6.6 Maximally effective concentration of phenylephrine-stimulated 
[
35S]GTPγ γ γ γS binding to the α1b-adrenoceptor-Gα11 fusion protein or the α1b-
adrenoceptor-Gα11
G188S fusion protein  
Membranes expressing 90 fmol of the α1b-adrenoceptor-Gα11 fusion protein (left) or the 
α1b-adrenoceptor-Gα11
G188S
  fusion protein (right) were added to [
35S]GTPγS binding assays 
in the absence (filled bars) or presence of a single concentration of phenylephrine (100 
µM) (open bars).  Prior to scintillation counting samples were subsequently 
immunoprecipitated with an anti-Gαq/11 antiserum CQ.  Data shown are from triplicate 
determinations (mean ± SEM.) and are representative of three individual experiments 
performed. 
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Figure 6.7 A range of concentrations of phenylephrine-stimulated [
35S]GTPγ γ γ γS 
binding to the α1b-adrenoceptor-Gα11 fusion protein or the α1b-adrenoceptor-
Gα11
G188S fusion protein
 
(A) Membranes expressing 90 fmol of the α1b-adrenoceptor-Gα11 fusion protein (filled 
symbols) or the α1b-adrenoceptor- Gα11
G188S
  fusion protein (open symbols) were added to 
[
35S]GTPγS binding assays in the presence of a range of concentrations of phenylephrine 
(3 nM – 3 mM).  Samples were subsequently immunoprecipitated with an anti-Gαq/11 
antiserum and counted.  Data shown are from triplicate determinations (mean ± SEM.) and 
are representative of three individual experiments performed. 
(B) The potency of phenylephrine to stimulate [
35S]GTPγS binding in the α1b-
adrenoceptor-Gα11
G188S
  fusion protein compared to the wild-type fusion protein.  pEC50 of 
phenylephrine for the α1b-adrenoceptor- Gα11 fusion protein (pEC50 6.14 ± 0.09) and the 
α1b-adrenoceptor-Gα11
G188S  (pEC50 6.35 ± 0.06) remains unchanged (p>0.05).  Data shown 
are mean ± SEM of three individual experiments performed. 
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Figure 6.8 Expression and immunological detection of the α1b-adrenoceptor-Gα11 
fusion protein and the α1b-adrenoceptor-Gα11
G188S fusion protein  
HEK293T cells were transfected to transiently express the α1b-adrenoceptor-Gα11 fusion 
protein (lane 1) or the α1b-adrenoceptor- Gα11
G188S fusion protein (lane 2).  Cell 
membranes containing 90 fmol of fusion protein, as calculated from [
3H]prazosin binding 
studies,  were treated with N-glycosidase F and resolved by SDS-PAGE and then 
immunoblotted with an anti-Gαq/11 antiserum CQ.  Results shown are of a single 
experiment and are representative of three individual experiments performed. 
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Figure 6.9 Expression and immunological detection of Gα11 and Gα11
G188S  
EF88 cells were transfected, using the Amaxa nucleofection kit, to transiently express 
Gα11 (lane 1) or Gα11
G188S (lane 2). EF88 cells transfected with pcDNA3 were included as 
a control (lane 3).  Cell lysates were resolved by SDS-PAGE and then immunoblotted with 
the anti-Gαq/11 antiserum CQ.  Results shown are of a single experiment and are 
representative of three individual experiments performed. 
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Figure 6.10 RGS4-GFP
2 reduces phenylephrine-stimulated [Ca
2+]i  from the α1b-
adrenoceptor-Gα11  fusion protein   
EF88 cells were transfected to express the α1b-adrenoceptor-Gα11 fusion protein (black) or 
the α1b-adrenoceptor-Gα11
 fusion protein and RGS4-GFP (blue).  Cells were loaded with 
Fura-2/AM and [Ca
2+]i levels imaged before and after 3 µM phenylephrine was perfused 
over the cells for 60 seconds.  Data represents means ± SEM. from 13 (α1b-adrenoceptor-
Gα11) and 11 (α1b-adrenoceptor-Gα11
 and RGS4-GFP
2) cells from 3 individual 
experiments. 
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Figure 6.11 Mutation of glycine 188 of Gα11 prevents phenylephrine-stimulated 
[Ca
2+]i  from the α1b-adrenoceptor fusion protein 
EF88 cells were nucleofected to express the α1b-adrenoceptor-Gα11
G188S fusion protein 
(green) or the α1b-adrenoceptor-Gα11
G188S fusion protein and RGS4-GFP (red).  Cells were 
loaded with Fura-2/AM and [Ca
2+]i levels imaged before and after 3 µM phenylephrine 
was perfused over the cells for 60 seconds.  Data represents means ± SEM. from 17 (α1b-
adrenoceptor-Gα11
G188S) and 8 (α1b-adrenoceptor-Gα11
G188S and RGS4-GFP) cells from 3 
individual experiments. 
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Figure 6.12 Mutation of glycine 188 of Gα11 prevents TRH stimulated [Ca
2+]i  from 
the TRHR- Gα11 fusion protein 
EF88 cells were transfected to transiently express the TRHR-1-Gα11
 fusion protein (black) 
or the TRHR-1-Gα11
G188S fusion protein (grey).  Cells were loaded with Fura-2/AM and 
[Ca
2+]i levels imaged before and after 10 µM TRH was perfused over the cells for 60 
seconds. Green fluorescent protein was co-expressed as a marker of positively transfected 
cells.  Data represents means ± SEM. from 19 (TRHR-1-Gα11
G188S) and 15 (TRHR-1-
Gα11
G188S) cells from 3 individual experiments. 
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Figure 6.13 Structure of Gαi1-RGS4 complex and modelling of the glycine to serine 
mutation in Gαi1 
(A) The ribbon structure of Gαi1-RGS4.  Gα is shown in green, and RGS4 is shown in 
blue.  The position of Gαi1
G183 (corresponds to Gα11
G188) is indicated by the space filled 
atoms. (B) The Connolly diagram of the switch region I of wild-type Gαi1-RGS4 complex.  
Residues in Gαi1 (glycine 183, theronine 182) and RGS4 (glutamic acid 83) are indicated.  
(C) Switch region I with Gαi1
G183S substitution.  In this area, the hydroxyl group of serine is 
less than 1 Å from the backbone of the carbonyl of the glutamic acid 83 of RGS4 (taken 
from DiBello et al., 1998). 
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6.3  Discussion 
The specific functions of endogenous RGS proteins have, in the past, been poorly defined.  
However, a single point mutation in Gα subunits, has been suggested to render the mutant 
Gα protein insensitive to RGS proteins, without a change in GDP release, GTPγS binding 
or intrinsic GTP hydrolysis (Berman et al., 2004).  The structure of RGS4 complexed with 
Gαi1, revealed the residue producing RGS-insensitivity (
G183S in Gαi1) indicated steric and 
electrostatic interactions between this residue and RGS4 (Figure 6.13) (Tesmer et al., 
1997;DiBello et al., 1998).  This mutation was transferred into Gα11 and investigated in the 
present study.  Results from RGS-insensitive and –sensitive Gα11 subunits fused to GPCRs 
demonstrated that this mutation in Gα11 must also affect other components of signal 
transduction. 
Unlike the constitutively active Gα subunit (Gαi1
Q204L, Chapter 3 Section 3.2.4), the effects 
of RGS-insensitive mutations are still under control of receptors to enhance the overall 
efficacy of the G protein cycle in a more physiological pattern. The physiological roles of 
some RGS proteins (including RGS1, RGS2, RGS4 and RGS9) have been investigated 
using RGS knockouts.  For example, the engineering of Rgs2
-/- mutant mice allowed the 
endogenous role of RGS2 in developmental, behavioural and physiological tests to be 
explored.  Symptoms recorded included only subtle behavioural and immunological 
differences, although subsequently, these mutant mice were found to be severely 
hypertensive (Heximer et al., 2003).  The RGS4 knockout was also initially reported to 
have only subtle differences.  Mutant mice displayed lower weight and poorer sensory 
motor coordination.  Surprisingly, more serious defects were never displayed. There was 
no alteration in neuronal differentiation or opioid signalling as mutant mice had normal 
tolerance to pain compared to wild-type (Grillet et al., 2005).  Perhaps future studies 
should compare these knockout mice with knockdown animal models. Compensation 
during development may take place in knockout animals and these future experiments may 
reveal differences so far undiscovered.   
Perhaps standard knockout or knockdown strategies targeted towards a single RGS would 
also underestimate the overall function of RGS proteins. The use of the RGS-insensitive 
Gα subunits could therefore determine the full contribution of RGS proteins mediated by a 
particular Gα subunit.  Most of what is known about endogenous RGS proteins has been 
learned through the use of RGS-insensitive mutants of Gαi/o (Chen and Lambert, 
2000;Jeong and Ikeda, 2000).  In this way, endogenous RGS proteins have been shown to      210 
have a negative effect on signalling and show that the GAP activity of RGS
 proteins 
provides a control that regulates
 potency and maximal response of agonist-activated 
signalling.  Few studies have applied this strategy to Gαq/11-mediated signalling, as the 
GTPase activity of Gαq/11 proteins can be accelerated not only by RGS proteins but also by 
the effector molecule PLCβ.  RGS proteins could negatively regulate Gαq/11 signals by 
serving as effector antagonists, competing with PLCβ for binding to active G-proteins 
(Hepler et al., 1997).  Thus, it is not clear to what extent RGS proteins are essential for 
terminating transient Gαq/11-mediated signals and it is important to consider the possibility 
that the RGS-insensitive mutation introduced to Gαq/11 may have caused an altered kinetic 
response of PLCβ. 
In the present work, the α1b-adrenoceptor-Gα11 fusion protein was used as a starting point 
to explore the effects of the presumed RGS-insensitive mutation on Gα11 on cell signalling 
in response to agonist (Stevens et al., 2001;Fu et al., 2004).  It has previously been 
demonstrated that the α1b-adrenoreceptor-Gα11 fusion protein is able to bind [
35S]GTPγS in 
response to phenylephrine (Carrillo et al., 2002). Mutations frequently alter the expression 
levels
 of a polypeptide, and therefore the use of receptor-G protein fusion constructs 
allowed the expression levels of not only the receptor but also of the Gα subunit to be 
determined.  Expression of each fusion construct was determined by [
3H]prasozin assays to 
allow the same amount
 of each construct to be added to [
35S]GTPγS binding
 studies.  Both 
fusion proteins bound the [
3H]prazosin with the same high-affinity.   
To isolate and enrich the [
35S]GTPγS-bound
 α1b-adrenoreceptor-Gα11 fusion proteins, after 
incubating [
35S]GTPγS with the membrane fraction of transfected cells, Gα11 in the 
reactions was solubilised
 by detergents and immunoprecipitated using an anti-Gαq/11 
antiserum, CQ and counting the radioactivity.  In concert with [
35S]GTPγS binding studies, 
membrane preparations were also separated by SDS-PAGE and immunoblotted with the 
anti-Gαq/11 antiserum to confirm that equivalent number of expressed receptor-G-protein 
fusion proteins were present in the assay, and also, despite the 
G188S mutation, that the anti-
Gαq/11 antiserum
 was equally effective in identifying each fusion protein  
It was therefore of considerable interest to note that the α1b-adrenoceptor-Gα11
G188S fusion 
protein displayed reduced ability to bind to [
35S]GTPγS in response to the α1-adrenoceptor 
agonist, phenylephrine.  GTPγS is a poorly-hydrolysed analogue of GTP, and therefore any 
alteration in [
35S]GTPγS binding is independent of GAP activity of RGS proteins on the 
Gα subunit.  The RGS-insensitive mutant in this assay was anticipated to have no effect on      211 
[
35S]GTPγS binding compared to the wild-type fusion protein.  It therefore appears that the 
G188S mutation in Gα11 reduces the ability of [
35S]GTPγS to bind to Gα11.  However, some 
previous biochemical studies have suggested that the equivalent RGS-insensitive mutation 
preserves the kinetics of GTPγS binding in Gαo and Gαi (Lan et al., 1998).  The structural 
data for GTPγS binding to Gα11 is not available but differences in GTPγS binding between 
Gαq and Gαi/o may be understandable due to the differences in their primary structure.  
Therefore, it is reasonable to conclude that the 
G188S mutation in Gα11 could reduce the 
ability of [
35S]GTPγS to bind to Gα11.  
Boutet-Robinet et al., (Boutet-Robinet et al., 2003) investigated the role of endogenous 
RGS proteins on dopaminergic D2S receptor signalling in Chinese hamster ovary cells 
using a RGS- and P.tox-insenstive Gαo protein.  Dopamine-mediated [
35S]GTPγS binding 
in these cells was attenuated by more that 60% compared to cells co-expressing the D2S 
receptor and the wild-type P.tox-insensitive Gαo protein.  It was reasoned that if Lan et al., 
(Lan et al., 1998) were correct in reporting that the RGS-insensitive mutation does not 
modify GTP binding characteristics of the Gα subunit, the observed decrease in coupling 
was likely due to RGS proteins increasing the pool of Gαo proteins available for this 
activation.  As in the present study, the use of a fusion protein between the GPCR and the 
G protein α subunit would give a 1:1 stoichiometry of the GPCR to the Gα subunit.  
Experiments using D2S receptor fused in-frame to the N-terminal of either Gαo or Gαo
G184S 
would validate the interpretation of these results. 
More recently, Shi et al., (Shi et al., 2006) investigated the effects of over-expression of 
RGS-insensitive Gαq on 5HT2A receptor signalling in transgenic rats.  GTPγS-stimulated 
PLC activity was higher in rats over-expressing wild-type Gαq compared to Gαq
G188S.  
Importantly, these researchers also speculated that the point mutation on Gαq (
G188S) might 
reduce the ability of GTPγS to bind and activate the PLC.  However, it was also suggested 
that RGS proteins might favour G protein cycling by allowing the activation and 
deactivation of the G protein without receptor dissociation.  Therefore, the absence of RGS 
binding in these transgenic rats may lead to a decrease in G protein signalling and 
ultimately a decrease in receptor mediated GTPγS loading (Ross and Wilkie, 2000).  
Downstream signal transduction was also investigated in the present study to demonstrate 
the effect of the predicted RGS-insensitive Gα11 subunit on agonist-mediated elevated 
[Ca
2+]i.  The co-expression of RGS4 with the α1b-adrenoceptor-Gα11 fusion protein in EF88 
cells reduced agonist-stimulated [Ca
2+]i.  Absence of RGS activity on Gα11
G188S was      212 
hypothesised to have a positive effect on Gα subunit activation and increase agonist-
mediated [Ca
2+]i.  However, compared to the wild-type fusion protein, phenylephrine-
stimulated [Ca
2+]i  was diminished in EF88 cells expressing the α1b-adrenoceptor-Gα11
G188S 
fusion protein.  A similar result was observed in EF88 cells expressing the TRHR-1R-
Gα11
G188S fusion protein, indicating a genuine effect of Gα11
G188S to abolish agonist-
mediated [Ca
2+]i signalling.  
In EF88 cells the agonist-mediated elevation of [Ca
2+]i is a measure of Gβγ release and 
function (Stevens et al., 2001).  Co-expression of α-transducin, which is an effective Gβγ 
sequestering agent, resulted in blocking of the agonist activated elevation of [Ca
2+]i (Liu et 
al., 2002).  It could therefore be speculated that Gα11
G188S has a reduced ability to release 
Gβγ.  Expression of a Gα mutant with a deficiency in Gβγ release would result in a 
construct unable to elevation [Ca
2+]i in EF88 cells.  Indeed, the reduced binding of 
[
35S]GTPγS to Gα11
G188S in the present study could also be due to the reduced ability of the 
mutated Gα subunit to release Gβγ.  If Gα11
G188S was less able to release the Gβγ subunit, 
then binding of GTPγS would also subsequently be reduced. 
Mutant forms of Gα11 have previously been demonstrated to poorly elevate [Ca
2+]i in EF88 
cells (Liu et al., 2002). Mutations of the corresponding residues in Gαq had already been 
inferred to lack the capacity to bind Gβγ effectively (Evanko et al., 2000).  Lui et al., 
therefore used co-immunoprecipitation studies, and clearly showed that the α1b-
adrenoceptor fused to the wild-type Gα11 subunit associated with co-expressed β1, but only 
small amounts of β1 were present along with the mutant Gα11 containing-fusion proteins. It 
was reasoned that this alteration was a reflection of the reduced effectiveness of Gβγ 
binding to the mutant Gα11 (Liu et al., 2002).  Fusion proteins containing a mutation in the 
α1b-adrenoceptor, which generated constitutive activity of the receptor, with reduced ability 
to bind [
35S]GTPγS have also been described (Carrillo et al., 2002).  This mutant was 
reasoned to be unable to adopt the conformational change required to dissociate the G 
protein subunits.  It now therefore seems essential to conduct co-immunoprecipitation 
studies using the α1b-adrenoceptor-Gα11
G188S to quantify the amount of co-expressed β1 
associated with the mutant Gα subunit.  The results of this study would elucidate if indeed 
Gα11
G188S had a reduced ability to bind Gβγ or more likely, infer an inability of the mutant 
to dissociate Gβγ. 
Alternatively, the observed reduction of agonist-stimulated [Ca
2+]i following expression of 
the adrenoceptor-Gα11
G188S fusion protein or the TRHR-1R-Gα11
G188S fusion protein is      213 
perhaps due to an decreased availability of free Gβγ.  If RGS proteins and Gβγ cannot bind 
to the Gα subunit at the same time, then the RGS-insensitive mutation would presumably 
lead to less free Gβγ to elevate [Ca
2+]i .  Co-expression of the Gβγ complex with the 
mutant Gα11 containing-fusion protein would perhaps give sufficient Gβγ to allow [Ca
2+]i  
mobilisation in EF88 cells.  No increase in agonist-stimulated [Ca
2+]i would suggest that 
Gα11
G188S has good interactions with endogenous Gβγ and that the mutant fusion protein 
has lost the ability to dissociate the Gβγ complex.  However, a resultant increase in 
agonist-stimulated [Ca
2+]i would suggest that a reduction in available Gβγ is responsible 
for the observed reduction in agonist-stimulated [Ca
2+]i. 
PLCβ not only mediates agonist-stimulated [Ca
2+]i but is also a GAP for the Gαq subfamily 
of Gα subunits.  RGS4 can act as a receptor shield for Gαq (Hepler et al., 1997) and 
binding of RGS4 to Gα11 could interfere with the GAP activities of PLCβ, and have a 
positive effect on Gα protein activation.  If indeed RGS4 is endogenously expressed in 
EF88 cells, the transient expression of the α1b-adrenoceptor-Gα11
G188S fusion protein might 
have no interaction with RGS4 but allow PLCβ to interact with the fusion protein without 
restraint.  The Gα subunit would be subjected to maximal GAP activity from PLCβ and 
abolish second messenger signalling.  Indeed, biochemical characterisation demonstrated 
that Gαq
G188S responds to the GAP activity of PLCβ, but does not respond to the GAP 
activity of RGS4 (Clark and Lambert, 2006).   
Multifunctional protein complexes comprising of receptor, G protein and RGS protein 
have also been described (Ross and Wilkie, 2000).  Direct and specific binding of RGS 
proteins to Gα subunits and other components of the cellular signalling complex can 
contribute to signal transduction.  Preliminary research indicates that RGS proteins can act 
as scaffolds to assemble signalling complexes.  Perhaps the absence of RGS binding to the 
RGS-insensitive Gα subunits could abolish the scaffolding properties of RGS proteins and 
reduce signalling.  A specific interaction between RGS2 and the α1b-adrenoceptor has been 
shown to include the scaffold, spinophillin (Wang et al., 2005).  It is perhaps such an 
interaction which is prevented in RGS-insensitive Gα mutants and abolishes the rise in 
[Ca
2+]i. 
The PDZ domain of RGS12 has been found to selectively bind the chemokine receptor 
CXCR2 (Snow et al., 1998b).  A number of other RGS proteins contain this PDZ domain 
and are likely to show binding selectivity to other relevant receptors and it could be 
presumed that RGS proteins with multiple domains would provide the best scaffolding      214 
properties.  It has also been suggested that RGS proteins form stable complexes with 
inactive G proteins to form quaternary complex (Benians et al., 2005).  Although many 
RGS proteins show affinity for Gα11, the precise RGS proteins in EF88 cells remains 
unknown.  Total RNA prepared from cells was subject to reverse transcription-PCR using 
RGS specific primers that were tested by amplifying RGS cDNA plasmids as a positive 
control (data not shown).  Despite the presence of mRNA for the positive control 
(glyceraldehyde-3-phosphate dehydrogenase), available primers specific for RGS3, RGS4 
and RGS7 did not identify endogenous expression of any of these RGS proteins in EF88 
cells.  Despite these results, it is possible to assume that these RGS proteins, and others, are 
expressed in EF88 cells but at undetectable levels.   
The localisation of RGS4-eYFP in cells expressing the RGS-insensitive fusion proteins 
suggest that the mutation in Gα11, as previously predicted prevents RGS4 from binding to 
the Gα subunit and subsequently prevents RGS4 from translocating from the cytoplasm to 
the plasma membrane.  In this study, HEK293T cells are used because EF88 cells are 
difficult to transfect and yield minimal protein for determining the percentage fluorescence 
of RGS4-eYFP in the plasma membrane.  As mentioned previously, the RGS-insensitive 
Gα subunit mutations are under the control of receptors to enhance the overall efficacy of 
the G protein cycle.  Agonist-stimulation, therefore, promoted RGS4 to bind to the active 
conformation of the G protein at the plasma membrane.  Presence of the RGS-insensitive 
Gα subunit perhaps did not allow RGS4 to bind, reducing the presence of RGS4 at the 
plasma membrane.  Biochemical studies have shown that a Gαi1-RGS-insensitive mutant 
does not bind to RGS4 (Lan et al., 1998). The RGS-insensitive mutation is predicted to be 
in the switch region I of Gαi1 and provide a substantial contribution to the buried surface 
area between the Gα subuit and RGS4 (DiBello et al., 1998).  Introduction of the 
hydromethyl side chain of serine would sterically hinder the formation of a tight complex 
between Gαi1 and RGS4 (Lan et al., 1998) suggesting that RGS4 would not be translocated 
to the plasma membrane in the presence of agonist-activated RGS-insensitive Gαi1.   
The use of RGS-insensitive Gα subunits provide novel insights into subtype-selective 
signalling by Gα subunits.  Other approaches, such as expression of constitutively active 
Gα subunits, will not reveal key functions mediated by Gβγ release. In addition, any non-
GAP effects must consequently involve the 
G188S mutation site.  The results from this study 
suggest that introduction of serine at position 188 in Gα11 may well disrupt G protein 
activation, Gβγ binding or release, effector antagonism and/or RGS scaffolding properties.  
The inability to identify which RGS proteins are responsible for these differences is a      215 
limitation in this present study but RGS-insensitive mutants will prove useful tools in 
future investigations into the role of endogenous RGS proteins.    216 
7  Final Discussion 
RGS proteins modulate G protein mediated signalling pathways by acting as GAPs for Gαi, 
Gαq, and Gα12 heterotrimeric G proteins.  Often comprising of a diverse combination of 
signalling domains, RGS proteins are regulated by a variety of assorted mechanisms. 
Discovering how specific RGS proteins modulate signal transduction remains vitally 
important, as pathological conditions have been linked to abnormal RGS
 expression. 
Pharmaceutical intervention of RGS activity
 may therefore impact the treatment of these 
conditions (Mittmann et al., 2002).  The precise role of RGS4, one of the most extensively 
studied RGS proteins, is still uncertain in the face of complex biochemical activity and 
overlapping patterns of expression.   
In this study, the first objective was to investigate the subcellular localisation of RGS4. 
This was done using several techniques including microscopy, immunoblotting, and 
fluorescence analysis.  Each technique demonstrated that transiently expressed RGS4 is 
located within the cytosol of HEK293T cells.  Co-expression of Gαi1, or the α2A-
adrenoceptor, or agonist-activated α2A-adrenoceptor, clearly translocated transiently 
expressed RGS4 from the cytosol to the plasma membrane.  Previous studies investigating 
the cellular localisation of RGS4 proteins also demonstrated that RGS4 could be recruited 
to the plasma membrane by the incorporation of a specific Gαi- or Gαq-associated 
signalling partner (Druey et al., 1998;Roy et al., 2003).  Unlike other RGS proteins such as 
RGS9-2, which has been reported to be largely membrane associated (Song et al., 2006) 
and RGS2 which has been reported to localise in the nucleus (Heximer et al., 2001), the 
majority of transfected RGS4 was found in the cytoplasm of HEK293T cells.  
The transfection of RGS proteins is typically conducted in order to overcome the
 low 
natural abundance of endogenous RGS proteins.  However, substantial differences between 
endogenous RGS4 and heterologously over-expressed RGS4 have been suggested 
(Krumins et al., 2004).  An alternative start site for synthesis of RGS4 from methionine 19 
has previously been predicted (Davydov and Varshavsky, 2000).  RGS4 lacking the first
 18 
amino acids is typically produced
 by in vitro translation and in contrast, the longer full 
length form of RGS4 is expressed endogenously in tissue
 or cultured cells.  As previously 
mentioned, the N-terminal of RGS4 is particularly important to the subcellular localisation 
of RGS4.  Therefore, it is perhaps not surprising that Krumins et al., found endogenous full 
length RGS4 predominantly in the membrane fraction of cells. Endogenous RGS4 at the 
plasma membrane would seem reasonable to preclude the necessity for translocation in      217 
physiological systems.  The physiological relevance of the differences between the 
transcription and localisation of endogenous and transfected RGS proteins therefore needs 
to be carefully considered. 
In this study, it was noticed that a relatively small portion of RGS4-eYFP was membrane 
associated at any given time.  This most likely reflects the transient over-expression of 
RGS4.  Over-expression of RGS4 could flood the cell’s cytoplasm and subsequently 
transfected RGS4 is pushed to the plasma membrane. Alternatively, the RGS4 could 
perhaps be recruited to the plasma membrane by the endogenous pool of Gα subunits in 
HEK293T cells.  It was also noticed that on co-expression of Gαi, or indeed any of the 
other signalling proteins that were co-expressed, a proportion of RGS4 is always left 
residing in the cytosol.  Again, this is most likely due to the transient over-expression of 
RGS4 and possibly the saturation of RGS4 binding sites at the plasma membrane.     The 
amount of RGS4 cDNA transfected was initially optimised but perhaps re-visiting this area 
and modulating the level of expression of RGS4 and the relative co-expression levels of 
Gα subunits and GPCRs would now allow this concept to be further explored.  When Roy 
et al., (2003) decreased the amount of receptor cDNA co-transfected with
 RGS-GFP to a 
level at which RGS-GFP did not significantly localise
 to the plasma membrane, addition of 
agonist also failed to recruit RGS4-GFP to the plasma membrane (Roy et al., 2003).  This 
reinforces that a careful approach is needed to work out the precise transfection ratio of 
RGS and signalling proteins. 
RGS proteins have been reported to physically interact with the transition state 
conformation of Gα subunits (Tesmer et al., 1997).  Localisation of RGS4 by a protein 
partner has therefore been most clearly demonstrated by studies transiently expressing a 
constitutively active GTPase-deficient Gα subunit.  Constitutively active Gα subunits are 
locked in an active state and are transition state models of Gα subunits.  RGS proteins are 
therefore predicted to bind to these proteins but are unable to modulate intrinsic GTPase 
activity.  Over-expression of the constitutively active GTPase-deficient Gαi2 (Gαi2
Q205L) 
showed the recruitment of the majority of the cytosolic RGS4 to the membrane surface 
(Druey et al., 1998).  Data from the current study, using the constitutively active Gαi1 
(Gαi1
Q204L), was consistent with this hypothesis and indicated that RGS4 can be cytosolic 
and then be recruited to the plasma membrane in the presence of a constitutively active 
Gαi1 subunit.  RGS proteins must still bind to the constitutively active Gα subunit, moving 
between different signalling complexes on the plasma membrane depending on the 
availability of interaction sites.  RGS8 translocates to the plasma membrane from the      218 
nucleus on co-expression of Gαo. Co-expression with a constitutively active Gαo also 
resulted in the translocation of RGS8 protein to the plasma membrane (Masuho et al., 
2004). Thus, the expression of a GTPase deficient Gα subunit still recruits RGS proteins 
and furthermore, even the over-expression of a Gα subunit in the inactive state can 
translocate transfected RGS4 to the plasma membrane.  Gα subunits in the inactive state 
are perhaps momentarily activated, in constant transition between inactive and active 
conformation, thus in the active state able to irreversibly bind RGS4 and cause its 
translocation to the plasma membrane.   
The confirmation of an N-terminal GOF mutant in a mammalian RGS by Hill et al., 
(personal communication) was carried out using an in vitro high-affinity GTPase assay.  
RGS4
S30C enhanced the α2A-adrenoceptor-activated increase in high-affinity GTPase 
activity of Gαo1 despite equal expression and comparable subcellular localisation compared 
to wild type RGS4.  Serine
30 is conserved in many other members of the B/R4 family of 
RGS proteins and the conversion of this residue to cysteine in RGS16 also demonstrated a 
significant increase in high-affinity GTPase activity of Gαo1.  The conserved serine
30 
residue in the B/R4 subfamily of RGS proteins must be important for the GAP activity of 
these proteins. The N-terminus, and in particular, residue 30 may help correctly position 
RGS4 at the receptor where it can optimally inactivate the Gα subunit via the GAP activity 
of the RGS domain.  Mutation of this residue may serve to change the orientation of RGS4 
and subsequently the GAP activity of the RGS domain.  
The observed simultaneous significant decrease in potency of adrenaline to increase α2A-
adrenoceptor-activated high-affinity GTPase activity of Gαo1 in the presence of RGS4 or 
RGS16 demonstrated that these RGS proteins must interact with the α2A-adrenoceptor.  If 
the RGS proteins were to interact only with the G proteins the agonist binding site on the 
receptor would remain unchanged and no change would be expected in the potency of the 
agonist.  In accordance with other published results (Ward and Milligan, 1999;Cavalli et 
al., 2000), the potency of adrenaline to stimulate the α2A-adrenoceptor high-affinity 
GTPase activity of Gαo1 on addition of purified RGS16 was lower than on the addition of 
RGS4 .  This perhaps provides yet further evidence for the selective interactions between 
RGS proteins and GPCRs.  RGS4 and RGS16 must interact and alter the conformation of 
the α2A-adrenoceptor in a different way.  These closely related RGS proteins do not 
function equally and the specificity of the interaction is perhaps fundamental to the GAP 
activity of the RGS protein and the ability to control biological functions.      219 
The GOF enhancing GAP activity of RGS4
S30C and RGS16
S30C are selective for Gαo1 over 
Gαi1.  The addition of purified RGS4 or RGS16 did, however, decrease the potency for 
adrenaline to stimulate high-affinity GTPase activity of Gαi1, suggesting the validity of the 
assay and the ability of the RGS proteins to perform.  However, the potency for adrenaline 
to stimulate high-affinity GTPase activity of Gαi1 was not further decreased by RGS4
S30C 
or RGS16
S30C.  It has previously been established that the B/R4 subfamily of RGS proteins 
show selectivity for Gαo1 over Gαi1 (Cavalli et al., 2000;Riddle et al., 2005).  It is probable 
that both RGS4 and RGS16 interact with the α2A-adrenoceptor but are not able to act as 
efficient GAPs for Gαi1.   
The subcellular localisation of RGS4
S30C-eYFP in the presence of exogenous Gαi1, the α2A-
adrenoceptor or agonist-activated α2A-adrenoceptor was also investigated.  Despite similar 
expression levels when compared to wild type RGS4-eYFP, as monitored by 
immunological detection with an anti-GFP antibody, no difference in subcellular 
localisation was detected in this study.  The knowledge of the selectivity of RGS
S30C to 
enhance the GAP activity of Gαo1, indicates that an important next step would be to study 
the subcellular localisation of RGS4
S30C-eYFP in the presence of exogenous Gαo1. 
The subsequent mutation of residue 30 of RGS4 to a range of other amino acids revealed 
that RGS4
S30K and RGS4
S30F were the most active and RGS4
S30P was the least active of the 
mutants that were studied.  No consensus side chain was identified that conferred a specific 
enhancement or loss of GTPase activity.  Both RGS5 and RGS18 contain a proline at 
residue 30.  Preliminary results suggest that RGS5
P30S is also GOF (Hill et al., personal 
communication) and it would now be of great interest to investigate the GAP activity of 
RGS18
P30S.  Clearly, it is also now important to mutate residue 30 of RGS4 to threonine 
and tyrosine to identify if the hydroxyl side chain at position 30 in RGS4 is crucial to 
maintain wild type GAP activity.   
The N-terminal of RGS4 is particularly important for the membrane localisation of the 
protein.  Using a peptide corresponding to the first 33 residues of RGS4 in yeast provided 
direct evidence for the localisation of RGS4 to a signalling complex to be determined 
solely by the N-terminal domain (Bernstein et al., 2000).  Site-directed mutagenesis of 
hydrophobic
 and basic residues within the N-terminal domain of RGS4 also revealed
 that 
the GAP activity of RGS4 is strongly correlated with the ability of the protein to bind to 
anionic
 liposomes and the tendency of an N-terminal peptide to adopt
 an α-helical 
conformation (Bernstein et al., 2000). In addition, extensive mutational
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has demonstrated that the N-terminal of RGS16 plays a critical role in membrane 
association
 and also may be important for
 the biological function of RGS16 (Chen et al., 
1999). Secondary
 structure analysis suggested that there may be two putative α-helices
 in 
the N-terminal of RGS16.  The
 first α-helix (amino acids 1-6) was not relevant for 
biological activity, however, the rest
 of the N-terminus (amino acids 7-32), which consists 
of predominantly
 the second putative α-helix from amino acids 12-30, has been defined
 as 
the core membrane-association domain. This membrane-targeting domain for RGS16, is 
likely shared by RGS4 and circular dichroism spectroscopy data directly demonstrated that
 
amino acid substitutions within residues 12-30 profoundly affect
 α-helical structure 
(Bernstein et al., 2000).  However, in the current study it was demonstrated that the 
subcellular localisation of RGS4
S30X-eYFP was not different to wild type RGS4.  This 
suggests that residue 30 in RGS4, although important for modulating the GAP activity of 
the protein, is not important for targeting RGS4 to the plasma membrane. Perhaps 
gathering circular dichroism spectroscopy data for RGS4
S30X would reveal changes in 
secondary structure for different mutants and confirm that mutation of residue 30 of RGS4 
alters the helical structure of the protein serving to alter the orientation of the protein and 
subsequently the GAP activity of the RGS domain.   
It has previously been suggested that the receptor and not the G protein dictate the function 
of RGS proteins.  Indeed, the translocation of RGS4 and RGS4
S30X to the plasma 
membrane in the presence of the α2A-adrenoceptor would support this suggestion. The 
significant reduction in potency of adrenaline of RGS4 and RGS16 to enhance the high-
affinity GTPase activity of the activated α2A-adrenoceptor-Gαo1 would also agree with this 
hypothesis. It could be envisaged in live cells, endogenous RGS proteins would not be free 
to find any G proteins, but instead the receptors would orientate the RGS protein at the 
plasma membrane and dictate specificity.  However, the current findings suggest that 
RGS4 has selectivity for Gαo1 over Gαi1 on activation of the same receptor, the α2A-
adrenoceptor, perhaps against suggesting that the α2A-adrenoceptor orientates RGS4 in a 
more advantageous position to interact with Gαo1.   
Interaction of RGS proteins with receptors may occur within lipid rafts or caveolae, 
specialised microdomains that may well modulate signalling events.  Indeed, the pre-
treatment of cells with the detergent methyl-β-cyclodextrin to deplete the membrane of 
cholesterol and disrupt such lipid rafts, weakens the interactions with RGS4 (Ishii et al., 
2005).  Compartmentalisation of several signal transduction pathways and proteins occurs 
in lipid rafts (Shaul and Anderson, 1998;Simons and Toomre, 2000;Brown and London,      221 
2000) and disruption of these lipid rafts can prevent signalling in many of these pathways 
(Miura et al., 2001).  RGS9 in a complex with Gβ5 translocates to lipid rafts after 
activation of photoreceptor outer segments by illumination (Nair et al., 2002).  However, 
the lipid raft localisation was not critical for the GAP activity of RGS16 but may be 
necessary for palmitoylation of an internal residue (Hiol et al., 2003).  To investigate the 
potential interaction of RGS4 with the α2A-adrenoceptor, specific residues involved in the 
interaction would first have to become apparent, but would allow further investigation into 
the involvement of lipid rafts in the regulation of RGS proteins 
From functional data (Srinivasa et al., 1998) and structural data (Tesmer et al., 1997) the 
principle function of asparagine
128 of RGS4 is to bind and stabilise switch region I and II 
of Gα subunits and to contribute to the overall stability of the RGS-Gα transition state 
complex. Evidence showed that RGS4 stimulates GTP hydrolysis primarily, if not 
exclusively by binding and stabilising the transition state conformation of Gα subunits. 
Correspondingly, in the present study, RGS4
N128A had ablated GAP activity towards Gα11. 
RGS4
N88S also had ablated GAP activity towards Gα11, demonstrating that no single residue 
seemed to exclusively catalyse GTP hydrolysis.  The double mutant (RGS4
N88S,N128A) also 
had ablated GAP activity towards Gα11 and any additive effect of GAP ablation was 
concealed due to the complete ablation of GAP activity with each single mutation.  No 
further inhibition of [Ca
2+]i mobilisation with the disruption of two binding interactions 
along the RGS4-Gα11 binding interface was possible.  The complete ablation of GAP 
activity suggests that each single mutation was sufficient at causing a global conformation 
change and ablating GAP activity of the protein.  The lack of modulation of [Ca
2+]i 
signalling by these GAP impaired RGS4 mutants suggests that the catalysis of GTPase 
activity is the
 dominant mechanism by which RGS4 regulates Ca
2+ signalling. 
Single cells positively transfected with RGS4 were selected for use in the [Ca
2+]i 
mobilisation assays by using RGS4-eYFP fusion proteins.  Only fluorescent cells and thus 
those cells expressing RGS4 were selected.  The brightest fluorescent cells were selected 
for analysis but in this way over-expression of RGS protein may have obscured small 
differences in RGS GAP activity amongst the RGS4 mutants.  Perhaps employing a 
different strategy, selecting cells with the least fluorescence in a field of view and therefore 
a lower expression of RGS4, would reveal differences in the GAP activity of these 
mutants. It is also noteworthy
 that the GAP activity of the fluorescently-tagged RGS4 and 
untagged RGS4 were previously shown to be identical.  This is consistent with other      222 
studies in which
 RGS4 has been similarly tagged without consequence (Berman et al., 
1996a;Chen et al., 1997) 
It has previously been demonstrated that RGS4
N128A caused severe defects in binding to 
Gαi2 (Srinivasa et al., 1998). To this end, the subcellular localisation of these GAP 
defected mutants would also have been worthy of investigation.  Asparagine 128 is the 
only RGS4 residue that projects into the active site of Gαi1 and together with its location at 
the binding interface and interaction with three Gαi1 residues at the active site 
(glutamine
204, glutamate 
207 and lysine
180) further underlines the importance of 
asparagine
128 to the GAP activity of RGS4.  Co-immunoprecipitation studies may provide 
further evidence that these GAP defective mutants have reduced binding to the transition 
state of Gαi1.  In addition, co-immunoprecipitation studies could elucidate the binding of 
these GAP defective mutants to Gα11. 
The third and final objective of this study was to investigate a potential RGS-insensitive 
Gα11 mutant.  A point mutation originally identified in yeast, has been shown to be RGS-
insensitive in Gαq, Gαi1 and Gαo.  This mutation was introduced to Gα11 (Gα11
G188S) and 
receptor- Gα11
G188S fusion proteins failed to translocate RGS4 to the plasma membrane.  
Moreover, agonist-activation of the fusion proteins also failed to translocate RGS4 to the 
plasma membrane suggesting that indeed Gα11
G188S cannot bind and subsequently 
translocate RGS4 to the plasma membrane.  However, fusion proteins have been reported 
not to be localised in lipid rafts (Hiol et al., 2003).  As mentioned previously, association 
of RGS4 in lipid rafts might be involved in the physical regulation of the protein (Ishii et 
al., 2005). The inability of the fusion protein to associate with the lipid rafts may therefore 
affect the translocation of RGS4.  Future translocation studies using Gα11
G188S should 
perhaps consider the use of separate receptors and Gα subunits.   
Despite this shortcoming, the present results are consistent with the finding that, RGS-
insensitive Gα subunits do not
 promote RGS association with the plasma membrane.  
RGS7 belongs to a subfamily of RGS proteins that exist as dimers with the Gβ5 subunit. 
When expressed in HEK293 cells, Gβ5-RGS7 was found to be cytoplasmic and soluble. 
Expression of Gαo promoted a strong redistribution of Gβ5-RGS7 to the plasma 
membrane.  The constitutively active mutant Gαo
R179C, like wild type Gαo, strongly 
recruited Gβ5-RGS7 to plasma membrane, however, RGS-insensitive Gαo
G184S was 
defective in the ability to promote plasma membrane localization of Gβ5-RGS7 (Takida et 
al., 2005).  It has also been demonstrated that RGS-insensitive Gα subunits containing an      223 
additional point mutation that conferred constitutive activity to the G proteins did not
 
promote RGS4-GFP association with the plasma membrane 
 (Gαi2
Q205L/G184S,
 
Gαq
Q209L/G188S) (Roy et al., 2003).  It has been further implied that RGS4-GFP binds 
directly
 to G proteins in the plasma membrane and that the recruitment of RGS proteins to 
the plasma membrane
 is not caused by events that occur after G protein activation.
 Agents 
that promote events
 downstream of G protein activation did not alter RGS localization 
(Roy et al., 2003).
 The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (which mimic
 
events down-stream of Gαq), forskolin (which bypasses Gαs to
 directly activate AC), and 
the tyrosine
 phosphatase inhibitor vanadate failed to promote RGS4 translocation to the 
plasma membrane in HEK293T cells.  Further use of these agents may be informative 
about the signal transduction pathway following Gα11 activation and RGS4 translocation.  
RGS-insensitive mutations have been reported to only have an effect on RGS binding (Lan 
et al., 1998).  In the present study, however, Gα11
G188S had significantly reduced agonist-
stimulated [
35S]GTPγS binding compared to wild type Gα11.  A subsequent review of the 
literature uncovered two additional independent reports that the RGS-insensitive mutation 
attenuated [
35S]GTPγS binding (Boutet-Robinet et al., 2003;Shi et al., 2006).  Boutenet-
Robinet et al., reasoned that the reduction in [
35S]GTPγS binding by the RGS-insensitive 
Gα subunit was caused by RGS proteins increasing the pool of endogenous Gαo proteins 
available for interaction with the activated receptor.  An RGS-insensitive Gα subunit 
would not be able to bind RGS protein and subsequently not be able to increase the pool of 
endogenous Gα subunits and increase G protein signalling. However, this reasoning has 
been contradicted by the present study.  Using an equivalent number of the α1b-
adrenoceptor-Gα11 fusion protein and the α1b-adrenoceptor-Gα11
G188S fusion protein, as 
established by [
3H]prasozin binding, made it clear that the endogenous pool of Gα subunits 
in HEK293T cells would be having a the same effect with both the RGS-sensitive and -
insensitive Gα11.  The reduction in [
35S]GTPγS binding to the RGS-insensitive Gα subunit 
was therefore not caused by availability of action of endogenous G proteins. 
Shi and co-workers suggested that GTPγS-stimulated PLC activity was lower in rats over-
expressing the Gαq
G188S compared to its wild type counterpart because RGS proteins favour 
G protein cycling (Shi et al., 2006). The absence of RGS proteins may lead to a decrease in 
G protein signalling and a decrease in receptor mediated GTPγS loading (Ross and Wilkie, 
2000). This hypothesis may also be true for the present study but is difficult to prove and 
investigating other possibilities about the properties of Gα11
G188S would be less 
problematic.       224 
It has been well established that co-expression of RGS4 reduces agonist-stimulated 
mobilisation of [Ca
2+]i (Tovey and Willars, 2004).  In the present study, single-cell imaging 
techniques demonstrated that RGS4 inhibited both the magnitude and rate of the 
immediate,
 agonist-induced generation of [Ca
2+]i.  In EF88 cells expressing the α1b-
adrenoceptor-Gα11
G188S fusion protein or the TRHR-1-Gα11
G188S fusion protein, agonist-
induced generation of [Ca
2+]i was ablated.  In EF88 cells the agonist-mediated elevation of 
[Ca
2+]i is a measure of Gβγ release and function (Stevens et al., 2001).  The predicted 
RGS-insensitive mutation in Gα11 may therefore also have a deficiency in Gβγ release.  It 
could also be reasoned that the reduced binding of [
35S]GTPγS was also due to a reduced 
ability of the mutant Gα subunit to release Gβγ and subsequently bind [
35S]GTPγS.  The 
expression of α-transducin to sequester free Gβγ would investigate this new hypothesis. 
The ability of RGS4 to bind to Gα11
G188S is clearly an important future experiment.  Co-
immunoprecipitation studies using the predicted RGS-insensitive and –sensitive Gα11 
subunits would determine if RGS4 interacted with this mutant Gα subunit.  Future studies 
could also transfer the predicted RGS-insensitive mutation into Gαq.  Gαq and Gα11 share 
98% homology but RGS5 and RGS16 can discriminate between the two highly related Gαq 
family subunits (Ladds et al., 2007).   
When the N-terminal of RGS4 targets the protein to particular GPCRs, RGS4 can occupy a 
position that can prevent coupling between Gαq/11 and PLCβ (Zeng et al., 1998). RGS 
proteins could therefore act as negative regulators of Gαq/11 signalling by serving as 
effector antagonists, competing with PLCβ for binding to active G proteins (Hepler et al., 
1997).  Thus, it is not clear to what extent RGS proteins are essential for terminating 
transient Gαq/11-mediated signals and it is important to consider the possibility that the 
RGS-insensitive mutation introduced into Gαq/11 may have caused an altered kinetic 
response of PLCβ.  A recent study used over-expression of constitutively active Gαq 
protein to investigate the
 functional importance of GTPase activation to mediate
 the 
inhibitory effect of RGS proteins.  Cells were transiently transfected with either the M3 
muscarinic
 receptor or Gαq
Q209L
.  Comparing the inhibitory effect of RGS proteins 
demonstrated that RGS5 and RGS16 did
 not exert any inhibitory effect when they were 
unable to act
 as a GAP, whereas RGS2 and RGS3 markedly blunted Gαq-mediated
 
signalling even in the absence of GAP, suggesting that other
 mechanisms, such as effector 
antagonism, are sufficient to mediate
 their inhibitory effect (Anger et al., 2004).  Future 
Ca
2+ signalling experiments in EF88 could also use the over-expression of constitutively      225 
active Gαq/11.  Any observed differences in kinetics or amplitude of [Ca
2+]i could be 
attributed to the effector antagonism properties of endogenous RGS4.    
Alternatively, the observed reduction of agonist-stimulated [Ca
2+]i release following 
expression of the α1b-adrenoceptor-Gα11
G188S fusion protein or the TRHR-1-Gα11
G188S 
fusion protein is perhaps due to an decreased availability of free Gβγ.  If RGS proteins and 
Gβγ cannot bind to the Gα subunit at the same time, then the RGS-insensitive mutation 
would presumably lead to less free Gβγ to elevate [Ca
2+]i .  Co-expression of the Gβγ 
complex with the mutant Gα11 containing-fusion protein would perhaps give sufficient Gβγ 
to allow [Ca
2+]i  mobilisation in EF88 cells.   
The predicted RGS-insensitive mutant has great potential to more fully understand the 
specific functions of endogenous RGS proteins. However, the specific RGS proteins 
endogenously expressed in HEK293T cells and EF88 cells remain unclear, most likely due 
to very low expression.  Others too have also experienced difficulty in detecting 
endogenous RGS proteins. 
 Immunoblotting of COS, murine neuro-2A neuroblastoma, and
 
NG108 neuroblastoma/glioma cells, with a specific anti-RGS4 antiserum failed to identify 
endogenous RGS4.  A PCR-based
 screen was performed to "semi quantitatively" examine 
the level
 of RGS4 mRNA in various cell types. Strong signals were obtained
 for rat PC12M 
and human AtT-20 cells but little or no signal
 was produced from murine neuro-2A 
neuroblastoma, rat pituitary
 GH3, rat RBL-2H3, rat C6 glioma, CHO, or NG108
 
neuroblastoma/glioma cells (Krumins et al., 2004).  Perhaps future studies carrying out 
RGS RNA interference, the specific knock-down of mRNA, with rat PC12M or human 
AtT-20 cells would allow the role of endogenous RGS proteins to be determined in these 
cells. 
The current study has attempted to further elucidate the function of RGS4 in signal 
transduction.  Future studies will undoubtedly uncover as yet unidentified mechanisms of 
regulation and functions for this complex protein.  For example, the recent discovery of an 
Arabidopsis protein (AtRGS1) containing both a GPCR and a RGS domain within the 
same protein is an exciting breakthrough (McCudden et al., 2005).  Perhaps by having 
conjoined guanine nucleotide exchange factors and GAP capabilities, the AtRGS1 forms a 
precisely controlled signalling complex.  Alternatively, an agonist (or an inverse agonist) 
could regulate the activity of the RGS domain or the membrane spanning N-terminal 
GPCR domain may simply anchor the protein to the membrane.        226 
The translocation of RGS4 from the cytoplasm to the plasma membrane will always be of 
particular interest.  Electron microscopy has previously been used to study RGS 
localisation (Druey et al., 1998;Fischer et al., 1999;Hiol et al., 2003) but there have been 
no reports recording the real-time live images of  translocating RGS4.  Efforts to assess 
this are beyond the scope
 of the current study but new advances in high-resolution electron 
microscopy to visualise the macromolecular arrangements in cells and improved methods 
for rapid freezing to capture transient processes may improve the understanding of RGS4 
translocation.  The ability to dynamically define the 3-D locations of signalling 
components will be central to unravelling the function and regulation of RGS4.  
At the next level of investigation, a capillary electrophoresis assay could be employed to 
further compare the functional activity of RGS mutants.  Capillary electrophoresis using a 
fluorescent, hydrolysable GTP analogue to detect GPCR-stimulated G protein GTPase 
activity in cell membranes expressing the α2A adrenoreceptor-Gαo1 fusion protein has 
recently been described (Jameson et al., 2007). Separation of fluorescent GTP from 
fluorescent GDP by capillary electrophoresis can show the accumulation of product or 
substrate and hence, the relative GTPase activity of the G protein.  Addition of RGS 
mutants would allow the comparison of agonist-stimulated substrate levels and the 
development of a high throughput method of investigating the GAP activity of RGS 
mutants. 
Polymorphisms in RGS4 loci have been linked to schizophrenia in humans (Chowdari et 
al., 2002). Remarkably, RGS4 expression levels are also modulated by cocaine and 
morphine in brain regions known to be involved in drug behaviour (Bishop et al., 2002). It 
will be extremely interesting to determine whether small molecules designed to inhibit 
RGS4 from interacting with the Gα subunit (Jin et al., 2004) will be directly involved in 
regulating drug sensitivity and physiological processes in mammalian tissues.  If RGS 
proteins were unrestrictedly active, they would completely suppress G protein mediated 
cell signalling. Therefore, it is important to understand how the activity of RGS proteins 
are regulated.  RGS4 is considered the prototypical member of the B/R4 subfamily and 
therefore discoveries about candidate regions that could serve as targets for drugs to alter 
RGS function may be transferred to a number of related RGS proteins.  The GOF mutants 
in RGS4 could be used directly to decrease signalling and current small molecule 
inhibitors (Ingi et al., 1998) could be tested to examine their ability to inhibit the enhanced 
RGS activity of these mutants.        227 
It will be important in future investigations to determine whether
 conservation of distinct 
regulatory and
 functional properties exists in various RGS proteins.  The expression of 
RGS proteins is, in many
 cases, considerably more restricted than that of most G proteins
 
or GPCRs.  RGS proteins therefore represent novel and
 potentially exciting targets for the 
development of new pharmaceuticals. RGS proteins and
 the regulation of signal 
transduction will certainly remain an intensely studied area of investigation. 
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9  Additional Material 
The following paper was published as a result of the studies carried out for this thesis. 